Methods of isolating allergen-specific antibodies from humans and uses thereof

Abstract

In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

Claims

1. A monoclonal antibody, or an antigen-binding portion thereof, that specifically binds to a peanut allergen with a binding affinity (K.sub.D) of less than 100 nM, wherein the monoclonal antibody or the antigen binding portion thereof comprises: a heavy chain CDR1 comprising SEQ ID NO:10, a heavy chain CDR2 comprising SEQ ID NO:11, a heavy chain CDR3 comprising SEQ ID NO:12, a light chain CDR1 comprising SEQ ID NO:14, a light chain CDR2 comprising SEQ ID NO:15, and a light chain CDR3 comprising SEQ ID NO:8.

2. The monoclonal antibody, or the antigen binding portion thereof, of claim 1, wherein the antigen-binding portion is a Fab, a F(ab).sub.2, a Fv, a scFv, a bivalent scFv or a diabody.

3. A pharmaceutical composition comprising the monoclonal antibody, or the antigen binding portion thereof, of claim 1 and a pharmaceutically acceptable carrier.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1. Flowchart of exemplary workflow for method of generating allergen-specific monoclonal antibodies.

(2) FIGS. 2A-2G. Characterization of single B cells isolated from fresh human peripheral blood. (A) Principal component analysis (left) separates naive/memory (black dots) and plasmablast (PB, gray dots) B cell subsets identified by expression of established transcription factors and marker genes (right; non-striped for naive/memory B cells and striped for plasmablast (PB) B cells). (B) Isotype of B cells, black dots for IGHE and gray dots for other isotypes. (C) Number of cells belonging to each subtype in (A) by isotype (non-striped for naive/memory B cells and striped for plasmablast (PB) B cells). (D-G) Analysis of clonal families (CFs). (D) Distribution of the number of cells per CF. (E) Fraction of cells of each isotype that belong to a multi-member CF. (F) Isotype, B cell subtype, mutational frequency, and patient of origin of each cell within multi-member CFs. CFs referred to in the text are labeled. (G) Heavy (right) and light (left) chain CDR3 sequences and similarity heatmap for CFs in (F).

(3) FIGS. 3A-3G. Characterization of 89 IgE antibodies from single B cells. (A) Phylogenetic depiction of antibody heavy chains arranged by IGHV gene (background pattern), patient of origin (node pattern), and mutation frequency (node size). (B) Heatmap indicating number of cells with a given heavy and light chain CDR3 length. (C) Heavy and light chain mutation frequency of each cell. (D) Silent (S) and replacement (R) mutations by region within heavy and light chains. (E) Differential gene expression between IgE PBs and PBs of other isotypes. Positive log fold change indicates genes enriched in IgE PBs. (F) Heavy chain constant region coverage histograms for na?ve/memory B cells (top) and PBs (bottom) by isotype, with loci oriented in the 5 to 3 direction. Mean normalized read depth and 95% confidence interval are indicated by solid lines and shaded area, respectively, for the number of cells (n) inscribed. Membrane exons are the two most 3 exons of each isotype. (G) Summary of (F), but depicting the fraction of cells of each isotype with any membrane exon coverage.

(4) FIGS. 4A-4C. High affinity, cross-reactive IgE antibody convergence in two unrelated individuals (PA12 & PA13). Antibody patterns are conserved among panels. (A) Frequency of silent (S) and replacement (R) mutations by region. (B) Mutation frequency percentiles compared to all class-switched antibodies. (C) Dissociation constants (KDs) for major allergenic peanut proteins Ara h 2 and Ara h 3 for six convergent antibodies as well as eight variants of PA13P1H08. Shortened antibody variant names are designated as heavy-light, using the following abbreviations: N=native, R=reverted, FWRs=framework regions. An r prefix indicates only that region has been reverted.

(5) FIGS. 5A-5E. Germline transcription reveals class switch priming in single B cells. (A) Identity of CE germline transcript splice donors along with the number of cells, by isotype, expressing each. (B) Fraction of cells expressing EGLTs by isotype. (C) Example from individual PA11 where identification of phased variants within IgE constant region exons enables subsequent verification of biallelic GLT expression in other B cells from the same patient. (D) Global germline transcription state heatmap indicating the fraction of cells of a given isotype expressing a given GLT. Above: GLT isotype expression frequency relative to all GLT isotypes; excludes self-isotype GLT expression. (E) Histogram of the number of non-self GLT isotypes expressed in each cell.

(6) FIG. 6. Study overview. Plasma was extracted from fresh blood to measure circulating IgE levels, while the cellular fraction was enriched for B cells prior to FACS. Single cells were sorted into individual wells of a 96 well plate and processed with scRNA-seq, generating sequencing reads that were aligned to the genome to calculate gene expression and assess splicing as well as assembled in order to reconstruct heavy and light chain sequences. Specificity and affinity data were generated for recombinantly expressed antibodies.

(7) FIGS. 7A-7C. Plasma IgE levels. (A) Allergen-specific and allergen component (hazelnut, peanut) concentrations. (B) Total IgE concentration. (C) Positive correlation between total plasma IgE level and the number confirmed IgE+ B cells. Each point is an individual.

(8) FIGS. 8A-8C. FACS gating and analysis. (A) Gating strategy for sorting single B cells. IgE+ B cells have been overlaid as dark gray dots. (B) Isotype identity within the final IgE gate as determined by heavy chain transcript assembly. ND=not determined. (C) For reference, putative basophils (CD19?IgE+) display higher IgE surface expression than IgE+ B cells.

(9) FIGS. 9A-9G. Single cell RNA-seq data overview and quality control. (A) Cells were sequenced in 5 libraries to a depth of ?1-2 million reads/cell. (B) Genes per cell histogram. Cells expressing fewer than 950 genes were discarded. (C) Rarefaction curve depicting the number of genes detected as a function of sequencing depth for eight randomly selected cells in each B cell subtype. Solid lines and shaded area represent mean and 95% confidence interval for the gene count, respectively. (D) Read mapping distribution for retained cells. Most reads mapped uniquely (Ensembl reference annotation) and multimapped reads largely belonged to RNA18S5 repeats on chr21 and unplaced scaffolds. (E) Read mapping across gene bodies showed minimal 3 or 5 bias. (F) V gene assembly length histogram by chain. (G) PCA on the top 500 most variable genes before (top) and after (bottom) batch correction.

(10) FIGS. 10A-10D. Auxiliary data supporting B cell subtype classification. PBs (striped) have greater FACS forward and side scatter (A), more cDNA after SmartSeq2 preamplification (B), and have greater gene expression of antibody light and heavy chains (C) as compared to the naive/memory B cell subset (non-striped). (D) Top differentially expressed genes for each subset.

(11) FIGS. 11A-11K. B cell comparisons across isotypes. (A-I) Number of cells with a given V and J gene by isotype and chain. (A) IGHM. (B) IGHD. (C) IGHG3. (D) IGHG1. (E) IGHA1. (F) IGHG2. (G) IGHG4. (H) IGHE. (I) IGHA2. (J) Heavy chain mutation frequency by isotype. (K) Relative utilization of the lambda and kappa light chain by isotype.

(12) FIGS. 12A-12H. Antibody specificity and affinity characterizations. (A) Semi-quantitative indirect ELISAs of convergent antibodies, controls, PA13P1H08 variants, and antibodies from other clonal families. Human IgG isotype control (abcam #ab206195) served as a negative control, while positive controls included anti-Ara h mouse monoclonal antibodies purchased from Indoor Biotechnologies. (B-G) Kinetic characterization of antibody binding to Ara h 2 (B-D) and Ara h 3 (E-G) using biolayer interferometry. Antibodies are named and described herein. (H) Indirect ELISA showing binding of recombinant monoclonal antibodies from subjects PA11, PA12, PA13, PA14, PA15, and PA16 (rows) to allergen extracts, natural peanut allergen Ara h 2, and bovine serum albumin (BSA) (columns). The isotype of each antibody is shown to the left. Higher values indicate stronger binding. OD=optical density. Depicted values represent those after subtraction of human IgG isotype control. Only the tested antibodies with any OD value above 0.25 are shown.

(13) FIGS. 13A-13E. Sequences of heavy and light chains used in constructing PA13P1H08 antibody variants. (A) Derivation of the inferred na?ve heavy chain CDR3 and surrounding amino acids. (B) Native and reverted heavy chain sequences, in addition to sequences where region(s) of the heavy chain have been reverted to the inferred na?ve rearrangement. Labels with an r prefix indicate only that region has been reverted. FWRs=frameworks. (C) Derivation of the inferred na?ve light chain CDR3 and surrounding amino acids. (D) Native and reverted light chain sequences. (E) Sequence of a light chain taken from another antibody, PA12P4H03, which we confirmed did not to bind any peanut allergens by ELISA.

(14) FIG. 14. GLT splicing for all isotypes. Note that only the first three constant region exons are shown for each isotype for clarity.

(15) FIG. 15. IGV coverage histograms and splice junctions for the ighe constant region locus showing ?GLTs in single murine B cells stimulated with IL-4, LPS, and BAFF (Wu et al. 2017). Arrows indicate ighe GLT splice donors.

(16) FIG. 16. Pairwise CDR3 sequence identity of the heavy chain CDR3 sequences from clones PA12P3F10, PA12P3DO8, PA12P1C07, PA13P1E10, PA13P3G09, and PA13P1H08 (SEQ ID NOs: 19, 35, 42, 12, 27, 4) and three heavy chain CDR3 sequences derived from multiple patients in a separate peanut allergy immune repertoire sequencing study (62). Each sequence from this separate study has an identity of at least 70% with one or more sequences from the present study. All sequences share the IGHV3-30 and IGHJ6 gene segments and have CDR3s 17 amino acids in length.

(17) FIG. 17A. Microarray scan confirming the absence of background interactions of the secondary goat anti-human IgG and the control mouse monoclonal anti-HA antibody with antigen-derived peptides. The control antibody gave rise to the expected HA control spot pattern framing the peptide microarray (white dots).

(18) FIGS. 17B and 17C. Microarray epitope mapping of PA13P1H08 to Ara h 2 (Ah2) and Ara h 3 (Ah3) peptides. (B) Microarray scan illustrating antibody binding to antigen peptides (light gray) as well as the expected HA control spot pattern (white dots). (C) Microarray fluorescence intensity by antigen peptide. Ara h 2 motifs with high intensity are annotated.

(19) FIG. 18. Plasma IgE levels for milk allergic subject PA01 and Aspergillus study subject 10033201 against common food allergens as well as Aspergillus fumigatus and Aspergillus niger. NP=not performed. Total IgE was 353 kU/L and 3528 kU/L for PA01 and 10033201, respectively. The assay was performed by CLIA-licensed Johns Hopkins University Dermatology, Allergy, and Clinical Immunology Reference Laboratory using the ImmunoCAP system.

(20) FIG. 19. Indirect ELISA showing binding of recombinant monoclonal antibodies (columns) to antigens (rows). Antigens include extracts of Aspergillus fumigatus, Aspergillus niger, and Aspergillus nidulans, as well as a purified recombinant allergen Aspergillus fumigatus 1 (rAsp f 1). Bovine serum albumin (BSA) serves as a negative antigen control. A monoclonal antibody against Asp f 1 (anti-Asp f 1) serves as a positive control against this allergen. Higher values indicate stronger binding. OD=optical density. hIgG=human IgG isotype control.

(21) FIG. 20. Indirect ELISA showing binding of recombinant monoclonal antibodies from subject PA01 (rows) to allergen extracts, natural peanut allergen Ara h 2, and BSA (columns). The isotype of each antibody is shown to the left. Higher values indicate stronger binding. OD=optical density. Depicted values represent those after subtraction of human IgG isotype control.

TABLE 1

(22) Table 1 includes protein and nucleic acid sequences discussed herein. Polypeptide sequences are provided using the standard one-letter code. One of ordinary skill in the art provided with an amino acid sequence will understand that the amino acid sequence may be encoded by a defined set of nucleotide sequences such that the reader and inventors have possession of the nucleotide sequences encoding each amino acid sequence. A nucleic acid sequence encoding a polynucleotide may be a naturally occurring human sequence. In some embodiments a nucleic acid sequence encoding a polynucleotide is not a naturally occurring human sequence. A nucleic acid sequence encoding a polynucleotide may be a sequence that is codon optimized for expression in human cells or specific cell types, eukaryotic cells, bacteria cells, or otherwise. Codon optimization, which replaces one codon by another codon encoding the same amino acid and having a higher frequency of occurrence in the particular host cell, can be performed to improve the ability of the host to produce the polypeptide encoded by the nucleic acid (see, e.g., Mauro, BioDrugs 32(1):69-81, 2018 and Kato, Int J Mol Sci. 20(4), 2019).

(23) In certain embodiments it is contemplated that variant sequences may be used in methods and compositions disclosed herein. For example, in one aspect, an antibody with a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity to SEQ ID NO:1 and a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity to SEQ ID NO:5 is described. A degree of sequence identity or similarity can be determined using art-known methods. In one approach, the identity of two nucleotide or polypeptide sequences or subsequences is calculated as the percentage of positions that are identical or equivalent after the sequences have been aligned, introducing gaps, if necessary, to achieve maximum percent sequence identity. Methods of sequence alignment are art-known methods, and include, but are not limited to the Needleman-Wunsch global alignment algorithm (Needleman and Wunsch (1970) J. Mol. Biol. 48(3):443-453 (30)), the Smith and Waterman local homology search algorithm (Smith, Temple F. & Waterman, Michael S. (1981) J. Mol. Biol. 147 (1): 195-197.), manual alignment and inspection, or computerized implementations of these algorithms, such asthe needle program, distributed as part of the EMBOSS software package (Rice, P. et al., Trends in Genetics 16(6): 276-277 (31), versions 6.3.1 available from EMBnet at various sources).

(24) It is contemplated that, in certain embodiments, a method or composition described herein will differ from a polypeptide sequence provided herein (e.g., in Table 1) by one or more amino acid substitutions. In some embodiments a sequence will have at least 90% sequence identity (or other degree of sequence identity disclosed hereinbelow) to a sequence or combination of sequences described herein. In one embodiment the polypeptide sequence differs from a reference sequence (e.g., in Table 1) by one amino acid substitution. In one embodiment the polypeptide sequence differs from a reference sequence (e.g., in Table 1) by two amino acid substitutions. In one embodiment the polypeptide sequence differs from a reference sequence by two amino acid substitutions. In one embodiment the polypeptide sequence differs from a reference sequence by three amino acid substitutions. In one embodiment the polypeptide sequence differs from a reference sequence by four amino acid substitutions. In one embodiment the polypeptide sequence differs from a reference sequence by five amino acid substitutions. In one embodiment the polypeptide sequence differs from a reference sequence by six amino acid substitutions. In one embodiment the polypeptide sequence differs from a reference sequence by seven amino acid substitutions. In one embodiment the polypeptide sequence differs from a reference sequence by eight amino acid substitutions. In one embodiment the polypeptide sequence differs from a reference sequence by nine amino acid substitutions. In one embodiment the polypeptide sequence differs from a reference sequence by ten amino acid substitutions. In certain embodiments the polypeptide sequence differs from a reference sequence by 1-10 amino acid substitutions, sometimes 1-5 amino acid substitutions. In some cases, amino acid substitutions are selected that do not change a basic property (e.g., binding specificity) relative to the reference sequence. In some cases, amino acid substitutions are selected that change binding affinity but not binding specificity. In some cases substitutions are selected to change a property (e.g., substitutions that affect effector function or half-life) as known in the art or described herein below. In some embodiments the amino acid substitutions are conservative substitutions. A conservative amino acid substitution is recognized in the art as a substitution of one amino acid for another amino acid that has similar properties, such as polarity, charge, hydrophobicity, and aromaticity. A conservative amino acid substitution can also be made based on the side chain characteristics of the amino acid, such as containing sulfur, hydroxyl, or amide. Non-limiting examples of conservative amino acid substitutions are set out below.

(25) TABLE-US-00001 Amino acid property Amino acid Polar-uncharged Cys, Ser, Thr, Met, Asn, Gln Polar-charged Asp, Glu, Lys, Arg Non-polar Gly, Ala, Pro, Ile, Leu, Val Aromatic His, Phe, Trp, Tyr Aliphatic Ala, Leu, Ile, Val, Pro Positively charged Lys, Arg, His Negatively charged Asp, Glu Sulfur-containing Met Hydroxyl-containing Ser, Thr, Tyr Amide-containing Asn, Gln Sulfhydryl containing Cys

DETAILED DESCRIPTION OF THE INVENTION

I. Introduction

(26) In one aspect, the present disclosure provides human allergen-specific monoclonal antibodies and methods for generating human allergen-specific monoclonal antibodies from single IgE- or IgG4-expressing human B cells. IgE antibodies, the least abundant class of antibodies in humans, are known to cause the symptoms of allergic reactions. For example, food allergy symptoms ranging from urticaria to potentially fatal anaphylaxis result from the degranulation of mast cells and basophils induced by the recognition of allergic food proteins by surface-bound IgE antibodies. Despite this central role in immunity and allergic disease, human IgE antibodies remain poorly characterized due to their scarcity. Fitzsimmons et al., Front Immunol., 2014, 5:61. Similarly, there is a lack of knowledge, but growing interest, surrounding the IgG4 isotype due to its potential role in mediating the reduced clinical allergen reactivity that accompanies immunotherapy and early allergen exposure through antigen blocking. Tordesillas et al., Immunity, 2017, 47:32-50.

(27) The present disclosure provides therapeutic methods for treating a human subject having an allergy or reducing one or more allergy symptoms in a human subject with one or more of the allergen-specific monoclonal antibodies or antigen-binding portions thereof as disclosed herein. In some embodiments and without intending to be bound by a particular mechanism, the allergen-specific monoclonal antibodies disclosed herein are used therapeutically as blocking antibodies, which is often referred to as passive immunotherapy.

(28) As described herein, the methods of the disclosure can be used to generate, from a sample from a human subject having an allergy to an antigen of interest, a pool of genotype-confirmed IgE or IgG4 single B cells that are candidates for producing antibodies having high affinity for an allergen of interest. As described in the Examples section below, it has been found that analyzing the cDNA sequences of immunoglobulin heavy chain constant regions to identify the isotype of single B cells avoids the problem of isotype mischaracterization that is known to occur when B cell isotype is determined based on sorting cells by cell surface markers (e.g., as is typically done in FACS cell surface staining). This problem of isotype mischaracterization is known to be especially pervasive for IgE B cells because the marker CD23 is a low-affinity IgE receptor that captures IgE on the surface of non-IgE B cells. See, Berkowska et al., J Allergy Clin Immunol, 2014, 134:688-697. Thus, the methods of the present disclosure generate a pool of single B cells that are much more likely to produce antibodies having high affinity for the allergen. Furthermore, it has been found that antibodies generated according to the methods disclosed herein are among the highest affinity native human antibodies discovered to date and exhibit cross-reactivity to different antigens.

II. Definitions

(29) The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, because the scope of the present invention will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings unless a contrary intention is apparent. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not be construed as representing a substantial difference over the definition of the term as generally understood in the art.

(30) All numerical designations, e.g., pH, temperature, time, concentration, and molecular weight, including ranges, are approximations which are varied (+) or (?) by increments of 0.1 or 1.0, as appropriate. It is to be understood, although not always explicitly stated that all numerical designations are preceded by the term about.

(31) The singular forms a, an, and the include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a compound includes a plurality of compounds.

(32) The term comprising is intended to mean that the compounds, compositions and methods include the recited elements, but not excluding others. Consisting essentially of when used to define compounds, compositions and methods, shall mean excluding other elements that would materially affect the basic and novel characteristics of the claimed invention. Consisting of shall mean excluding any element, step, or ingredient not specified in the claim. Embodiments defined by each of these transition terms are within the scope of this invention.

(33) The term allergen refers to a substance that induces an immune response in a subject that results in an allergic reaction by the subject.

(34) As used herein, the term antibody refers to a polypeptide encoded by an immunoglobulin gene or functional fragments thereof that specifically binds and recognizes an antigen. The term antibody, as used herein, also includes antibody fragments that retain binding specificity, including but not limited to Fab, F(ab).sub.2, Fv, and scFv. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

(35) An exemplary immunoglobulin (antibody) structural unit comprises two identical pairs of polypeptide chains, each pair having one light chain (about 25 kDa) and one heavy chain (about 50-70 kDa). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. Thus, the terms variable heavy chain or VH refer to the variable region of an immunoglobulin heavy chain, including an Fv, scFv, dsFv or Fab; while the terms variable light chain or VL refer to the variable region of an immunoglobulin light chain, including an Fv, scFv, dsFv or Fab.

(36) The term variable region refers to a domain in an antibody heavy chain or light chain that gives an antibody its specificity for binding to an antigen. Typically, an antibody variable region comprises four conserved framework regions interspersed with three hypervariable complementarity determining regions.

(37) The term complementarity determining region or CDR refers to the three hypervariable regions in each chain that interrupt the four framework regions established by the light and heavy chain variable regions. The CDRs are primarily responsible for binding to an epitope of an antigen. The CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3, numbered sequentially starting from the N-terminus, and are also typically identified by the chain in which the particular CDR is located. Thus, a VH CDR3 is located in the variable domain of the heavy chain of the antibody in which it is found, whereas a VL CDR1 is the CDR1 from the variable domain of the light chain of the antibody in which it is found.

(38) As noted, the part of a variable region not contained in the CDRs is called the framework. The framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three-dimensional space. Framework sequences can be obtained from public DNA databases or published references that include germline antibody gene sequences. For example, germline DNA sequences for human heavy and light chain variable region genes can be found in the VBASE2 germline variable gene sequence database for human and mouse sequences.

(39) The amino acid sequences of the CDRs and framework regions can be determined using various well known definitions in the art. The position and length of the CDRs have been precisely defined by Kabat et al., Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, 1983, 1987, and others. See, e.g., Johnson and Wu, Nucleic Acids Res. 2000 Jan. 1; 28(1): 214-218; Johnson et al., Nucleic Acids Res., 29:205-206 (2001); Chothia & Lesk, (1987) J. Mol. Biol. 196, 901-917; Chothia et al. (1989) Nature 342, 877-883; Chothia et al. (1992) J. Mol. Biol. 227, 799-817; Al-Lazikani et al., J. Mol. Biol 1997, 273(4)); and MacCallum et al., J. Mol. Biol., 262:732-745 (1996). Also see international ImMunoGeneTics database (IMGT), AbM, and observed antigen contacts.

(40) The terms antigen-binding portion and antigen-binding fragment are used interchangeably herein and refer to one or more fragments of an antibody that retains the ability to specifically bind to an antigen (e.g., an allergen, e.g., Ara h 2 or Ara h 3). Examples of antibody-binding fragments include, but are not limited to, a Fab fragment (a monovalent fragment consisting of the VL, VH, CL, and CH1 domains), F(ab).sub.2 fragment (a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region), a single chain Fv (scFv), a disulfide-linked Fv (dsFv), complementarity determining regions (CDRs), VL (light chain variable region), VH (heavy chain variable region), nanobodies, and any combination of those or any other functional portion of an immunoglobulin peptide capable of binding to target antigen. Antibodies and antigen-binding portions thereof include domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g. monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains. Exemplary configurations of variable and constant domains that may be found within an antigen-binding fragment of an antibody of the present invention include: (a) VH-CH1; (b) VH-CH2; (c) VH-CH3; (d) VH-CH1-CH2; (e) VH-Ch1-Ch2-Ch3; (f) VH-Ch2-Ch3; (g) VH-CL; (h) VL-CH1; (i) VL-Ch2; (X) VL-Ch3; (j) VL-CH1-CH2; (k) VL-CH1-CH2-CH3; (l) VL-CH2-CH3; and (m) VL-CL (see, e.g., FUNDAMENTAL IMMUNOLOGY (Paul ed., 4th ed. 2001), Gruber et al. (1994) J Immunol. 152:5368-5374; McCartney, et al., 1995 Protein Eng. 8:301-314; Shukra et al., 2014, Production of recombinant antibodies using bacteriophages Eur J Microbial Immunol (Bp). 4(2): 91-98; Todorovska, 2001, Design and application of diabodies, triabodies and tetrabodies for cancer targeting J Immunol Methods; 248(1-2):47-66; Salvador et al., 2019, Nanobody: outstanding features for diagnostic and therapeutic applications Anal Bioanal Chem. 411(9):1703-1713; Gill et al., 2006, Biopharmaceutical drug discovery using novel protein scaffolds. Curr Opin Biotechnol., (6):653-8; and Ubah et al., 2016, Phage Display Derived IgNAR V Region Binding Domains for Therapeutic Development Curr Pharm Des. 22(43):6519-6526, each of which is incorporated by reference herein.

(41) The term epitope refers to the area or region of an antigen to which an antibody specifically binds, i.e., an area or region in physical contact with the antibody, and can include a few amino acids or portions of a few amino acids, e.g., 5 or 6, or more, e.g., 20 or more amino acids, or portions of those amino acids. In some cases, the epitope includes non-protein components, e.g., from a carbohydrate, nucleic acid, or lipid. In some cases, the epitope is a three-dimensional moiety. Thus, for example, where the target is a protein, the epitope can be comprised of consecutive amino acids, or amino acids from different parts of the protein that are brought into proximity by protein folding (e.g., a discontinuous epitope).

(42) A monoclonal antibody refers to antibodies produced by a single clone of cells or a single cell line and consisting of or consisting essentially of antibody molecules that are identical in their primary amino acid sequence. In some embodiments, a monoclonal antibody preparation comprises a population of antibodies that are identical and bind to the same epitope of an antigen, except for mutations that arise during monoclonal antibody production. Unless otherwise specified or clear from context, the term monoclonal antibody includes synthetic antibodies and antigen binding fragments thereof.

(43) A human antibody refers to an antibody having variable and constant regions derived from human germline immunoglobulin sequences. A human antibody of the present disclosure may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or by somatic mutations in vivo). The term human antibody is not intended to include chimeric or humanized antibodies in which CDR sequences derived from the germline or immune cells of a non-human species (e.g., mouse) have been grafted onto human framework sequences.

(44) The term specifically binds refers to a molecule (e.g., an antibody or antibody fragment) that binds to a target with greater affinity, avidity, more readily, and/or with greater duration to that target in a sample than it binds to a non-target compound. In some embodiments, an antibody or antigen-binding portion thereof that specifically binds a target (e.g., an allergen, e.g., Ara h 2 or Ara h 3) is an antibody or antigen-binding portion that binds to the target with at least 2-fold greater affinity than non-target compounds, e.g., at least 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 25-fold, 50-fold or greater affinity. For example, in some embodiments, an antibody that specifically binds to an allergen target, such as Ara h 2 or Ara h 3, will typically bind to the allergen target with at least a 2-fold greater affinity than to a non-allergen target. It will be understood by a person of ordinary skill in the art that an antibody that specifically or preferentially binds to a first target may or may not specifically or preferentially bind to a second target.

(45) The term binding affinity, as used herein, refers to the strength of a non-covalent interaction between two molecules, e.g., an antibody (or an antigen-binding fragment thereof) and an antigen. Thus, for example, the term may refer to 1:1 interactions between an antibody (or an antigen-binding fragment thereof) and an antigen, unless otherwise indicated or clear from context. Binding affinity may be quantified by measuring an equilibrium dissociation constant (K.sub.D), which refers to the dissociation rate constant (k.sub.d, time.sup.?1) divided by the association rate constant (k.sub.a, time.sup.?1 M.sup.?1). K.sub.D can be determined by measurement of the kinetics of complex formation and dissociation, e.g., using Surface Plasmon Resonance (SPR) methods, e.g., a Biacore? system; kinetic exclusion assays such as KinExA?; and BioLayer interferometry (e.g., using the ForteBio? Octet platform). As used herein, binding affinity includes not only formal binding affinities, such as those reflecting 1:1 interactions between an antibody (or an antigen-binding fragment thereof) and an antigen, but also apparent affinities for which K.sub.Ds are calculated that may reflect avid binding.

(46) The term cross-reacts, as used herein, refers to the ability of an antibody to bind to two or more antigens. As a non-limiting example, in some embodiments, an antibody that specifically binds to a first allergen target (e.g., a first peanut allergen, such as Ara h 2) can exhibit cross-reactivity with a second allergen target (e.g., a second peanut allergen, such as Ara h 3).

(47) The term isolated, as used with reference to a nucleic acid or protein (e.g., antibody), denotes that the nucleic acid or protein is essentially free of other cellular components with which it is associated in the natural state. It is preferably in a homogeneous state. Purity and homogeneity are typically determined using analytical chemistry techniques such as electrophoresis (e.g., polyacrylamide gel electrophoresis) or chromatography (e.g., high performance liquid chromatography). In some embodiments, an isolated nucleic acid or protein (e.g., antibody) is at least 85% pure, at least 90% pure, at least 95% pure, or at least 99% pure.

(48) The terms polypeptide, peptide, and protein are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. As used herein, the terms encompass amino acid chains of any length, including full length proteins, wherein the amino acid residues are linked by covalent peptide bonds.

(49) The term amino acid refers to refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ?-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

(50) Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

(51) As used herein, the terms nucleic acid and polynucleotide are used interchangeably. Use of the term polynucleotide includes oligonucleotides (i.e., short polynucleotides). This term also refers to deoxyribonucleotides, ribonucleotides, and naturally occurring variants, and can also refer to synthetic and/or non-naturally occurring nucleic acids (i.e., comprising nucleic acid analogues or modified backbone residues or linkages), such as, for example and without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs), and the like. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (see, e.g., Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al, J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al, Mol. Cell. Probes 8:91-98 (1994)).

(52) The term sample, as used herein, refers to a biological sample obtained from a human or non-human mammalian subject. In some embodiments, a sample comprises blood, blood fractions or blood products (e.g., serum, plasma, platelets, red blood cells, peripheral blood mononuclear cells and the like); sputum or saliva; stool, urine, other biological fluids (e.g., lymph, saliva, prostatic fluid, gastric fluid, intestinal fluid, renal fluid, lung fluid, cerebrospinal fluid, and the like), tissue (e.g., kidney, lung, liver, heart, brain, nervous tissue, thyroid, eye, skeletal muscle, cartilage, or bone tissue), cultured cells (e.g., primary cultures, explants, transformed cells, or stem cells), or a biopsy sample.

(53) The terms subject and patient, as used interchangeably herein, refer to a mammal, including but not limited to humans, non-human primates, rodents (e.g., rats, mice, and guinea pigs), rabbits, cows, pigs, horses, and other mammalian species. In one embodiment, the subject or patient is a human.

(54) The terms treat, treating, and treatment refer to any indicia of success in the treatment or amelioration of an injury, disease, or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, disease, or condition more tolerable to the subject; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; and/or improving a subject's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters. The effect of treatment can be compared to an individual or pool of individuals not receiving the treatment, or to the same patient prior to treatment or at a different time during treatment.

(55) The term pharmaceutical composition refers to a composition suitable for administration to a subject. In general, a pharmaceutical composition is sterile, and preferably free of contaminants that are capable of eliciting an undesirable response with the subject. Pharmaceutical compositions can be designed for administration to subjects in need thereof via a number of different routes of administration, including oral, intravenous, buccal, rectal, parenteral, intraperitoneal, intradermal, intratracheal, intramuscular, subcutaneous, inhalational, and the like.

(56) The term pharmaceutically acceptable excipient refers to a non-active pharmaceutical ingredient that is biologically or pharmacologically compatible for use in humans or animals, such as, but not limited to a buffer, carrier, or preservative.

(57) As used herein, a therapeutic amount or therapeutically effective amount of an agent (e.g., a monoclonal antibody as disclosed herein) is an amount of the agent that treats, ameliorates, abates, remits, improves patient survival, increases survival time or rate, diminishes symptoms, makes an injury, disease, or condition (e.g., an allergy) more tolerable, slows the rate of degeneration or decline, or improves a patient's physical or mental well-being. For example, for the given parameter, a therapeutically effective amount will show an increase or decrease of therapeutic effect at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or 100%. Therapeutic efficacy can also be expressed as -fold increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.

(58) The terms administer, administered, or administering refer to methods of delivering agents, compounds, or compositions to the desired site of biological action. These methods include, but are not limited to, topical delivery, parenteral delivery, intravenous delivery, intradermal delivery, intramuscular delivery, rectal delivery, or intraperitoneal delivery. Administration techniques that are optionally employed with the agents and methods described herein, include e.g., as discussed in Goodman and Gilman, The Pharmacological Basis of Therapeutics, current ed.; Pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, PA.

III. Methods of Generating Allergen-Specific Antibodies

(59) In one aspect, methods of generating allergen-specific monoclonal antibodies from a human sample are provided. In some embodiments, the method comprises: (a) isolating single B cells from a sample from a human subject, wherein the subject is allergic to the allergen; (b) generating cDNAs from the single B cells of step (a), wherein the cDNA sequences comprise a first sequence that encodes all or part of an immunoglobulin heavy chain and a second sequence that encodes all or part of an immunoglobulin light chain; (c) determining the sequences of the cDNAs from step (b); (d) analyzing the sequences determined in step (c) to identify single B cells comprising a first sequence that comprises an IgE constant region or an IgG4 constant region; (e) identifying, from the single B cells of step (d), (i) a heavy chain variable region sequence in the immunoglobulin heavy chain that comprises an IgE constant region or an IgG4 constant region, and (ii) a light chain variable region sequence in an immunoglobulin light chain that is co-expressed with the immunoglobulin heavy chain in the same single B cell; (f) expressing antibodies comprising the heavy chain variable region sequence and the light chain variable region sequence from step (e); and (g) identifying one or more antibodies from step (f) that specifically bind to the allergen.
Subject Populations and Samples

(60) In some embodiments, the method of generating allergen-specific monoclonal antibodies comprises isolating B cells from a biological sample from a human subject. In some embodiments, the sample comprises whole blood, peripheral blood, or a leukapheresis product. In some embodiments, the sample comprises peripheral blood mononuclear cells (PBMCs). In some embodiments, the sample comprises a tissue from the human subject, e.g., tonsil tissue, spleen, or bone marrow. Methods of isolating B cells from blood and tissue samples are described in the art. See, e.g., Heine et al., Curr Protoc. Immunol., 2011, 94:7.5.1-7.5.14; and Zuccolo et al., BMC Immunol, 2009, 10:30, doi:10.1186/1471-2172-10-30.

(61) In some embodiments, the allergen-specific antibodies are generated from a human subject having an allergy to the allergen. In some embodiments, the human subject having an allergy is an adult. In some embodiments, the human subject having an allergy is a juvenile. In some embodiments, the human subject has an allergy to a food allergen, a plant allergen, a fungal allergen, an animal allergen, a dust mite allergen, a drug allergen, a cosmetic allergen, or a latex allergen. In some embodiments, the human subject has allergies to two or more allergens, e.g., to two or more of a food allergen, a plant allergen, a fungal allergen, an animal allergen, a dust mite allergen, a drug allergen, a cosmetic allergen, or a latex allergen. In some embodiments, the human subject has allergies to 2, 3, 4, 5, 6, 7, 8, 9, 10 or more allergens. In some embodiments, the human subject has allergies to two or more different types of antigens (allergens) in a class of allergen, e.g., allergies to two or more different food allergens (e.g., allergies to two or more different peanut antigens, or allergies to a peanut allergen and a non-peanut allergen such as a tree nut, egg, or milk allergen), or allergies to two more different fungal allergens (e.g., allergies to two or more different species of Aspergillus). In some embodiments, the human subject has allergies to two more different classes of allergens (e.g., allergies to one or more food allergens and to one or more plant allergens). In some embodiments, the human subject has allergies to only one class of allergens (e.g., the subject has allergies to one or more food allergens but not to non-food allergens, or the subject has allergies to one or more fungal allergens but not to non-fungal allergens).

(62) In some embodiments, the human subject has an allergy to a food allergen. In some embodiments, the food allergen is a milk allergen, an egg allergen, a nut allergen, a tree nut allergen, a fish allergen, a shellfish allergen, a soy allergen, a legume allergen, a seed allergen, or a wheat allergen. In some embodiments, the food allergen is a peanut allergen.

(63) In some embodiments, the human subject has an allergy to a plant allergen or a fungal allergen. In some embodiments, the allergen is a fungal allergen (e.g., Aspergillus, e.g., Asp. fumigatus, Asp. niger, or Asp. nidulans). In some embodiments, the allergen is a pollen allergen (e.g., tree pollen, grass pollen, or weed pollen) or a mold allergen. In some embodiments, the human subject has an allergy to an animal allergen. In some embodiments, the allergen is a dander allergen or an insect sting.

(64) In some embodiments, the method of generating allergen-specific monoclonal antibodies does not comprise immunizing the human subject with the allergen or exposing the human subject to the allergen prior to obtaining the sample from the subject.

(65) B Cell Isolation and Screening

(66) In some embodiments, single B cells are isolated from the sample from the subject having an allergy to the allergen. In some embodiments, the single B cells are separated into separate partitions, e.g., separate wells of a multi-well plate, encapsulated into droplets, or dispersed into microwells. In some embodiments, at least 10, 50, 100, 500, 1,000, 5,000, or 10,000B cells or more are isolated from a sample and are separated into separate partitions.

(67) In some embodiments, the isolating step comprises sorting cells in the sample by fluorescent activated cell sorting (FACS). FACS sorting can be used to sort cells based on cell surface marker expression, cell size, and/or granularity and deliver cells individually to a well, e.g., a 96-well or 384-well tissue culture or PCR plate. Methods of isolating and purifying cell populations by FACS are described in the art. See, e.g., Basu et al., J Vis Exp, 2010, 41:1546, doi:10.3791/1546.

(68) In some embodiments, a droplet microfluidic platform can be used to dispense single B cells into separate droplets. In some embodiments, the nucleic acids (e.g., mRNA) of a single cell in a droplet is labeled with a nucleotide sequence that is unique to the droplet, e.g., a Unique Molecular Identifier barcode nucleotide sequence, thereby enabling downstream processing steps for the sequences from multiple B cells to be performed in a single reaction container. Methods of encapsulating single cells in droplets are described in the art. See, e.g., Macosko et al., Cell, 2015, 161: 1202-1214; Zhang et al., Scientific Reports, 2017, 7:41192, doi:10.1038/srep41192.

(69) In some embodiments, cells are dispersed into microwells designed to trap a single cell. Methods of single cell microwell trapping are described in the art. See, e.g. Han et al., Cell, 2018, 172:5, doi:10.1016/j.cell.2018.02.001.

(70) In some embodiments, cells from the sample are screened for the presence, absence, or level of expression of one or more markers and single B cells are isolated based on the presence or level of expression of the one or more B cell markers (e.g., one, two, three, four, five, six, seven, eight, or more markers). In some embodiments, cells are screened for the presence, absence, or level of expression of one or more cell surface B cell markers, such as but not limited to CD19, CD20, CD21, CD22, CD23, CD24, CD40, CD72, or CD79. In some embodiments, a cell is determined to be a B cell if the cell is positive for one or more of the B cell markers, e.g., is positive for one or more of CD19, CD20, CD21, CD22, CD23, CD24, CD40, CD72, or CD79. In some embodiments, single CD19.sup.+ B cells are isolated.

(71) In some embodiments, cells from the sample are screened for the presence, absence, or level of expression of one or more immunoglobulin isotypes, such as but not limited to IgE, IgG, IgM, IgA, or IgD or a subclass thereof. In some embodiments, the single B cells that are isolated are selected for expression of cell surface IgE and/or for expression of cell surface IgG4. In some embodiments, single B cells are isolated without selecting for expression of one or more immunoglobulin isotypes (e.g., without selecting for expression of cell surface IgE and/or for expression of cell surface IgG4).

(72) IgE Selection

(73) In some embodiments, the method comprises isolating single B cells that are selected for expression of cell surface IgE. In some embodiments, the isolating step comprises contacting cells of the sample with an anti-human IgE antibody and selecting for cells that express IgE on the cell surface. In some embodiments, the isolating step comprises contacting cells of the sample with antibody against a B cell marker (e.g., an antibody against CD19, CD20, CD21, CD22, CD23, CD24, CD40, CD72, or CD79) and an anti-human IgE antibody and selecting for cells that express the B cell marker and that express IgE on the cell surface. In some embodiments, the isolating step comprises contacting cells of the sample with an anti-human CD19 antibody and an anti-human IgE antibody and selecting for CD19.sup.+ IgE-expressing B cells.

(74) In some embodiments, the isolating step comprises contacting cells of the sample with antibody against a B cell marker (e.g., an antibody against CD19, CD20, CD21, CD22, CD23, CD24, CD40, CD72, or CD79), an anti-human IgE antibody, and an antibody against one or more immunoglobulin isotypes (e.g., an anti-human IgG antibody, an anti-human IgM antibody, an anti-human IgA antibody, and/or an anti-human IgD antibody) or subclass thereof and selecting for cells that express the B cell marker, that express IgE on the cell surface, and that do not express detectable levels of the one or more other immunoglobulin isotypes being screened for. In some embodiments, the isolating step comprises contacting cells of the sample with an anti-human CD19 antibody, an anti-human IgE antibody, and one or more of an anti-human IgG antibody, an anti-human IgM antibody, an anti-human IgA antibody, or an anti-human IgD antibody, and selecting for CD19 IgE-expressing B cells that are negative for IgG, IgM, IgA, or IgD cell surface expression.

(75) In some embodiments, the isolating step comprises contacting cells from the sample with an anti-human CD19 antibody, an anti-human IgE antibody, an anti-human IgM antibody, and an anti-human IgG antibody and selecting for CD19.sup.+ IgM.sup.?IgG.sup.?IgE-expressing B cells. In some embodiments, the isolating step comprises contacting cells from the sample with an anti human CD19 antibody, an anti-human IgE antibody, an anti-human IgM antibody, an anti human IgG antibody, an anti-human IgA antibody, and an anti-human IgD antibody and selecting for CD19.sup.+ IgM.sup.?IgG.sup.?IgA.sup.?IgD.sup.?IgE-expressing B cells.

(76) In some embodiments, the isolating step comprises contacting cells of the sample with antibody against a B cell marker (e.g., an antibody against CD19, CD20, CD21, CD22, CD23, CD24, CD40, CD72, or CD79) and antibodies against non-IgE isotypes (e.g., an anti-human IgG antibody, an anti-human IgM antibody, an anti-human IgA antibody, and an anti-human IgD antibody) or subclass thereof, and selecting for cells that express the B cell marker and that do not express detectable levels of the non-IgE isotypes. In some embodiments, the isolating step comprises contacting cells from the sample with an anti-human CD19 antibody, an anti-human IgM antibody, an anti-human IgG antibody, an anti-human IgA antibody, and an anti-human IgD antibody and selecting for CD19.sup.+ IgM.sup.?IgG.sup.?IgA.sup.?IgD.sup.? B cells.

(77) In some embodiments, the method comprises isolating IgE-expressing B cells that are antibody-secreting B cells (e.g., plasmablasts or plasma cells). In some embodiments, the method comprises isolating IgE-expressing B cells that are memory B cells. In some embodiments, the method comprises isolating IgE-expressing antibody-secreting B cells and IgE-expressing memory B cells.

(78) IgG4 Selection

(79) In some embodiments, the method comprises isolating single B cells that are selected for expression of cell surface IgG4. In some embodiments, the isolating step comprises contacting cells of the sample with an anti-human IgG4 antibody and selecting for cells that express IgG4 on the cell surface. In some embodiments, the isolating step comprises contacting cells of the sample with an antibody against a B cell marker (e.g., an antibody against CD19, CD20, CD21, CD22, CD23, CD24, CD40, CD72, or CD79) and an anti-human IgG4 antibody and selecting for cells that express the B cell marker and that express IgG4 on the cell surface. In some embodiments, the isolating step comprises contacting cells of the sample with an anti human CD19 antibody and an anti-human IgG4 antibody and selecting for CD19+ IgG4-expressing B cells.

(80) In some embodiments, the isolating step comprises contacting cells of the sample with an antibody against a B cell marker (e.g., an antibody against CD19, CD20, CD21, CD22, CD23, CD24, CD40, CD72, or CD79), an anti-human IgG4 antibody, and an antibody against one or more IgG subclasses (e.g., an anti-human IgG1 antibody, an anti-human IgG2 antibody, an anti-human IgG3 antibody) and selecting for cells that express the B cell marker, that express IgG4 on the cell surface, and that do not express detectable levels of the one or more other IgG subclasses being screened for. In some embodiments, the isolating step comprises contacting cells from the sample with an anti-human CD19 antibody, an anti-human IgG1 antibody, an anti-human IgG2 antibody, an anti-human IgG3 antibody, and an anti-human IgG4 antibody and selecting for CD19+ IgG1.sup.?IgG2.sup.?IgG3.sup.?IgG4-expressing B cells.

(81) In some embodiments, the isolating step comprises contacting cells of the sample with an antibody against a B cell marker (e.g., an antibody against CD19, CD20, CD21, CD22, CD23, CD24, CD40, CD72, or CD79), an anti-human IgG4 antibody, and an antibody against one or more immunoglobulin isotypes (e.g., an anti-human IgE antibody, an anti-human IgM antibody, an anti-human IgA antibody, and/or an anti-human IgD antibody) or subclass thereof and selecting for cells that express the B cell marker, that express IgG4 on the cell surface, and that do not express detectable levels of the one or more other immunoglobulin isotypes being screened for. In some embodiments, the isolating step comprises contacting cells of the sample with an anti-human CD19 antibody, an anti-human IgG4 antibody, and one or more of an anti human IgE antibody, an anti-human IgM antibody, an anti-human IgA antibody, or an anti human IgD antibody, and selecting for CD19+ IgG4-expressing B cells that are negative for IgE, IgM, IgA, or IgD cell surface expression.

(82) In some embodiments, the isolating step comprises contacting cells from the sample with an anti-human CD19 antibody, an anti-human IgG4 antibody, an anti-human IgM antibody, and an anti-human IgG antibody and selecting for CD19.sup.+ IgM.sup.?IgE.sup.?IgG4-expressing B cells. In some embodiments, the isolating step comprises contacting cells from the sample with an anti human CD19 antibody, an anti-human IgG4 antibody, an anti-human IgM antibody, an anti human IgE antibody, an anti-human IgA antibody, and an anti-human IgD antibody and selecting for CD19+ IgM.sup.?IgE.sup.?IgA.sup.?IgD.sup.?IgG4-expressing B cells.

(83) In some embodiments, the isolating step comprises contacting cells of the sample with an antibody against a B cell marker (e.g., an antibody against CD19, CD20, CD21, CD22, CD23, CD24, CD40, CD72, or CD79) and antibodies against non-IgG isotypes (e.g., an anti human IgE antibody, an anti-human IgM antibody, an anti-human IgA antibody, and an anti human IgD antibody) or non-IgG4 isotypes thereof, and selecting for cells that express the B cell marker and that do not express detectable levels of the non-IgG or non-IgG4 isotypes. In some embodiments, the isolating step comprises contacting cells from the sample with an anti human CD19 antibody, an anti-human IgM antibody, an anti-human IgE antibody, an anti human IgA antibody, and an anti-human IgD antibody and selecting for CD19.sup.+ IgM.sup.?IgE.sup.?IgA.sup.?IgD.sup.?B cells. In some embodiments, the isolating step comprises contacting cells from the sample with an anti-human CD19 antibody, an anti-human IgM antibody, an anti-human IgE antibody, an anti-human IgA antibody, an anti-human IgD antibody, an anti-human IgG1 antibody, an anti human IgG2 antibody, and an anti-human IgG3 antibody and selecting for CD19.sup.+ IgM.sup.?IgE.sup.?IgA.sup.?IgD.sup.?IgG1.sup.?IgG2.sup.?IgG3.sup.? B cells.

(84) In some embodiments, the method comprises isolating IgG4-expressing B cells that are antibody-secreting B cells. In some embodiments, the method comprises isolating IgG4-expressing B cells that are memory B cells. In some embodiments, the method comprises isolating IgG4-expressing antibody-secreting B cells and IgG4-expressing memory B cells.

(85) Generating and Sequencing cDNAs

(86) In some embodiments, cDNAs are generated from the isolated single B cells from the sample (e.g., from single B cells that have been screened for expression of an immunoglobulin isotype such as IgE or IgG4, or from single B cells that have not been screened for expression of an immunoglobulin isotype). In some embodiments, cDNA libraries are prepared from the single B cells. In some embodiments, for the cDNAs that are generated for each single B cell, the cDNA sequences comprise a sequence that encodes an immunoglobulin heavy chain and a sequence that encodes an immunoglobulin light chain.

(87) In some embodiments, cDNAs are generated by reverse transcribing cDNA sequences from RNA (e.g., total RNA or mRNA) from the single B cell and amplifying the cDNA sequences. For generating cDNAs, in some embodiments, the single B cells are lysed and cDNA sequences are reverse transcribed from mRNA present in the cell lysate. In some embodiments, RNA is isolated from the single B cell and cDNAs are reverse transcribed from the isolated RNA.

(88) In some embodiments, the method comprises amplifying the transcriptome of the single B cell. For example, in some embodiments, the method comprises reverse transcribing RNA (e.g., polyadenylated mRNA) to synthesize cDNAs, then amplifying the cDNA, e.g., by PCR. Exemplary methods for reverse transcribing polyadenylated mRNA and amplifying the transcriptome of a single cell are described in Darmanis et al., Cell Reports, 2017, 21:1399-1410, and in Picelli et al., Nature Protocols, 9, 2014, 171-181.

(89) In some embodiments, the method comprises amplifying immunoglobulin heavy chain and light chain sequences from the single B cells. For example, in some embodiments, the method comprises reverse transcribing RNA (e.g., total RNA) to synthesize cDNAs, then amplifying the cDNAs, e.g., by PCR, using primers for immunoglobulin heavy chain variable regions and constant regions. In some embodiments, the method comprises reverse transcribing RNA using immunoglobulin-specific primers (e.g., constant region-specific primers) to synthesize cDNAs comprising immunoglobulin sequences, then amplifying the cDNAs using primers for immunoglobulin heavy chain variable regions and constant regions. An exemplary method for amplifying immunoglobulin heavy chain and light chain sequences from a single cell is described in Tiller et al., J. Immunol. Methods, 2008, 329:112-124.

(90) After the cDNAs are generated, in some embodiments, the method comprises determining the sequences of the cDNAs. In some embodiments, the cDNAs are subjected to sequencing. In some embodiments, the method comprises sequencing the transcriptomes of the single B cells. In some embodiments, the method comprises sequencing target genes (e.g., immunoglobulin genes, e.g., immunoglobulin heavy chain variable regions and constant regions and immunoglobulin light chain variable regions and constant regions).

(91) Sequencing methods, including methods for high-throughput sequencing, are known in the art. For example, such sequencing technologies include, but are not limited to, pyrosequencing, sequencing-by-ligation, single molecule sequencing, sequence-by-synthesis (SBS), massive parallel clonal, massive parallel single molecule SBS, massive parallel single molecule real-time, massive parallel single molecule real-time nanopore technology, etc. Morozova and Marra provide a review of some such technologies in Genomics, 92: 255 (2008), herein incorporated by reference in its entirety.

(92) In some embodiments, sequencing comprises high-throughput sequencing. In high-throughput sequencing, parallel sequencing reactions using multiple templates and multiple primers allows rapid sequencing of genomes or large portions of genomes. High throughput sequencing methods include methods that typically use template amplification and those that do not. Sequencing methods that utilize amplification include pyrosequencing commercialized by Roche as the 454 technology platforms (e.g., GS 20 and GS FLX), clonal array formation and sequencing by synthesis (SBS) chemistry commercialized by Illumina with systems such as the NextSeq, and the Supported Oligonucleotide Ligation and Detection (SOLID) platform commercialized by Applied Biosystems. Non-amplification approaches, also known as single-molecule sequencing, are exemplified by the HeliScope platform commercialized by Helicos BioSciences, and platforms commercialized by VisiGen, Oxford Nanopore Technologies Ltd., Life Technologies/Ion Torrent, and Pacific Biosciences, respectively.

(93) In some embodiments, an Illumina sequencing platform, such as NextSeq, is used. This sequencing technology utilizes clonal array formation and sequencing by synthesis to produce sequences on a large scale. In this method, sequencing templates are immobilized on a flow cell surface, then solid-phase amplification creates copies of each template molecule (up to 1,000 identical copies) in close proximity, forming dense clusters of polynucleotide sequences. For sequencing the clusters, fluorescently-labeled nucleotides are used to sequences the clusters on the flow cell surface in parallel. For each sequencing cycle, a single labeled reversible terminator-bound dNTP is added to the nucleic acid chain. The sequence of incorporated nucleotides is determined by detection of post-incorporation fluorescence, then the fluorescent dye is removed prior to the next cycle of dNTP addition, resulting in base-by-base sequencing. Typically sequence read length ranges from about 30 nucleotides to over 150 nucleotides. For a target cDNA of interest having a longer length, the sequence can be bioinformatically reassembled based on overlaps between the short sequencing reads to determine the sequence of the full-length target cDNA.

(94) Identifying B Cells Having an IgE or IgG4 Isotype

(95) In some embodiments, after the sequences of cDNAs have been determined for the single B cells, the method comprises analyzing the sequences of the cDNAs to identify single B cells that express an immunoglobulin heavy chain having a constant region that is of the IgE isotype and/or of the IgG4 isotype. As described herein, it has been found that determining the isotype of the B cell based on the sequence of the heavy chain transcript, rather than FACS immunoglobulin surface staining, substantially reduces the number of false positive IgE cells in the B cell population, and thus results in a population of B cells that is much more likely to yield antibodies that specifically bind to the allergen to which the human subject who is the source of the B cells is allergic.

(96) In some embodiments, the method comprises identifying a sequence encoding an immunoglobulin heavy chain that comprises an IgE constant region. In some embodiments, the method comprises identifying a sequence encoding an immunoglobulin heavy chain that comprises an IgG4 constant region. In some embodiments, the cDNA sequence is analyzed by comparing the sequence to a known IgE constant region sequence or to a known IgG4 constant region sequence. For example, a comparison of a cDNA sequence of interest (e.g., a test sequence from a B cell) can be compared to a known IgE or IgG4 constant region sequence (e.g., a reference sequence) by aligning the sequences. Methods of alignment of sequences for comparison are known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. App. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection. Algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1990) J. Mol. Biol. 215: 403-410 and Altschul et al. (1977) Nucleic Acids Res. 25: 3389-3402, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (NCBI) web site.

(97) For comparing a test sequence to an IgE or IgG4 constant region reference sequence, in some embodiments, the reference sequence is published sequence such as an IgE or IgG4 constant region sequence that is publicly available in the ImMunoGeneTics (IMGT) database. See, e.g., Camacho et al., BMC Bioinformatics, 2009, 10:421; Lefranc et al., Nucleic Acids Res, 2009, 37:D1006-1012. Methods of analyzing test sequences to identify sequences comprising an immunoglobulin heavy chain constant region that is of the IgE isotype and/or of the IgG4 isotype are also described in Table 1 below.

(98) In some embodiments, in addition to analyzing sequences to identify and select single B cells comprising an immunoglobulin heavy chain sequence that comprises an IgE constant region or an IgG4 constant region, the method further comprises determining the sequences and/or levels of expression of one or more other genes in the single B cell. For example, in some embodiments, the method comprises determining the sequences and/or levels of expression of a set of genes that are a signature for a particular type of B cell.

(99) In some embodiments, for a B cell that is identified as having an immunoglobulin heavy chain that comprises an IgE constant region or an IgG4 constant region, the method further comprises identifying, from the same B cell, the heavy chain variable region sequence that is expressed by the cell and the light chain variable region sequence that is expressed by the cell.

(100) Antibody Expression

(101) Typically, for a single B cell that is identified as having a cDNA that comprises an IgE or IgG4 constant region sequence, the heavy chain variable region and light chain variable region sequences from the single B cell are candidate antibody sequences for having specificity to the allergen of interest. Thus, in some embodiments, the method comprises expressing antibodies comprising the heavy chain variable region and light chain variable region sequences from the single B cell and identifying whether the expressed antibody specifically binds to the allergen of interest. Methods for the expression and purification of recombinant antibodies are described in the art. See, e.g., Frenzel et al., Front Immunol., 2013, 4:217, doi:10.3389/fimmu.2013.00217; Siegemund et al., Methods Mol Biol., 2014, 1131:273-295.

(102) In some embodiments, the heavy chain variable region and light chain variable region sequences from the single B cell are amplified from the single B cell and cloned into an expression vector. In some embodiments, the heavy chain variable region and light chain variable region sequences from the single B cell are synthesized. In some embodiments, the heavy chain variable region sequence and/or light chain variable region sequence is codon-optimized, e.g., to increase antibody expression by the expression system. See, e.g., Ayyar et al., Methods, 2017, 116:51-62.

(103) The heavy chain variable region and light chain variable region sequences from the single B cell can be expressed using any number of expression systems, including prokaryotic and eukaryotic expression systems. In some embodiments, the expression system is a mammalian cell expression, such as a hybridoma, or a CHO or HEK293 cell expression system. Many such systems are widely available from commercial suppliers. Cell expression systems are also described in the art. See, e.g., Kunert and Reinhart, 2016, Advances in recombinant antibody manufacturing Appl Microbial Biotechnol. 100:3451-61; Jager et al., BMC Proc., 2015, 9:P40, doi:10.1186/1753-6561-9-S9-P40; and references cited therein. In some embodiments, the heavy chain and light chain are expressed using a single vector, e.g., in a di-cistronic expression unit, or under the control of different promoters. In other embodiments, the heavy chain and light chain are be expressed using separate vectors. In some embodiments, an expression vector for expressing heavy chain variable region sequence and/or light chain variable region sequence as disclosed herein is a vector that comprises a constant region of a desired heavy chain isotype or light chain subclass. For example, a heavy chain variable region sequence as disclosed herein can be cloned into a vector that comprises a human IgG (e.g., IgG1, IgG2, IgG3, or IgG4) heavy chain constant region, and a light chain variable region sequence as disclosed herein can be cloned into a vector that comprises a human lambda or kappa light chain constant region.

(104) After an antibody comprising a heavy chain variable region sequence and a light chain variable region sequence from the single B cell as disclosed herein is expressed and purified, in some embodiments, the method comprises determining whether the antibody specifically binds to the allergen. Methods for analyzing binding affinity and binding kinetics are known in the art. See, e.g., Ernst et al., Determination of Equilibrium Dissociation Constants, Therapeutic Monoclonal Antibodies (Wiley & Sons ed. 2009). These methods include, but are not limited to, solid-phase binding assays (e.g., ELISA assay), immunoprecipitation, surface plasmon resonance (SPR, e.g., Biacore? (GE Healthcare, Piscataway, NJ)), kinetic exclusion assays (e.g. KinExA?), flow cytometry, fluorescence-activated cell sorting (FACS), BioLayer interferometry (e.g., Octet (Fort?Bio, Inc., Menlo Park, CA)), and Western blot analysis. SPR techniques are reviewed, e.g., in Hahnfeld et al. Determination of Kinetic Data Using SPR Biosensors, Molecular Diagnosis of Infectious Diseases (2004). In a typical SPR experiment, one interactant (target or targeting agent) is immobilized on an SPR-active, gold-coated glass slide in a flow cell, and a sample containing the other interactant is introduced to flow across the surface. When light of a given wavelength is shined on the surface, the changes to the optical reflectivity of the gold indicate binding, and the kinetics of binding. In some embodiments, kinetic exclusion assays are used to determine affinity. This technique is described, e.g., in Darling et al., Assay and Drug Development Technologies Vol. 2, number 6 647-657 (2004). In some embodiments, BioLayer interferometry assays are used to determine affinity. This technique is described, e.g., in Wilson et al., Biochemistry and Molecular Biology Education, 38:400-407 (2010); Dysinger et al., J. Immunol. Methods, 379:30-41 (2012).

(105) In some embodiments, the expressed antibody specifically binds to the allergen with high affinity. In some embodiments, the antibody has a binding affinity (K.sub.D) for the allergen that is less than 250 nM, less than 100 nM, less than 50 nM, less than 10 nM, less than 5 nM, less than 1 nM, less than 500 pM, less than 250 pM, less than 150 pM, less than 100 pM, less than 50 pM, less than 40 pM, less than 30 pM, less than 20 pM, less than about 10 pM, or less than 1 pM. In some embodiments, the antibody binds to the allergen with a binding affinity (KD) from 1 nM to 250 nM.

(106) Nucleic Acids, Vectors, and Host Cells

(107) In some embodiments, the allergen-specific monoclonal antibodies as described herein are prepared using recombinant methods. Accordingly, in some aspects, the invention provides isolated nucleic acids comprising a nucleic acid sequence encoding any of the allergen-specific monoclonal antibodies as described herein (e.g., any one or more of the CDRs described herein); vectors comprising such nucleic acids; and host cells into which the nucleic acids are introduced that are used to replicate the antibody-encoding nucleic acids and/or to express the antibodies. In some embodiments, the host cell is eukaryotic, e.g., a human cell such as HEK-293.

(108) In some embodiments, a polynucleotide (e.g., an isolated polynucleotide) comprises a nucleotide sequence encoding an antibody or antigen-binding portion thereof as described herein (e.g., as described in Section IV below). In some embodiments, the polynucleotide comprises a nucleotide sequence encoding one or more amino acid sequences (e.g., CDR, heavy chain variable region, or light chain variable region) disclosed in Table 1 below.

(109) In a further aspect, methods of making an allergen-specific monoclonal antibody as described herein are provided. In some embodiments, the method includes culturing a host cell as described herein (e.g., a host cell expressing a polynucleotide or vector as described herein) under conditions suitable for expression of the antibody. In some embodiments, the antibody is subsequently recovered from the host cell (or host cell culture medium).

(110) Suitable vectors containing polynucleotides encoding antibodies of the present disclosure, or fragments thereof, include cloning vectors and expression vectors. While the cloning vector selected may vary according to the host cell intended to be used, useful cloning vectors generally have the ability to self-replicate, may possess a single target for a particular restriction endonuclease, and/or may carry genes for a marker that can be used in selecting clones containing the vector. Examples include plasmids and bacterial viruses, e.g., pUC18, pUC19, Bluescript (e.g., pBS SK+) and its derivatives, mpl8, mpl9, pBR322, pMB9, ColE1, pCR1, RP4, phage DNAs, and shuttle vectors such as pSA3 and pAT28. Cloning vectors are available from commercial vendors such as BioRad, Stratagene, and Invitrogen.

(111) Expression vectors generally are replicable polynucleotide constructs that contain a nucleic acid of the present disclosure. The expression vector may replicate in the host cells either as episomes or as an integral part of the chromosomal DNA. Suitable expression vectors include but are not limited to plasmids, viral vectors, including adenoviruses, adeno-associated viruses, retroviruses, and any other vector.

IV. Monoclonal Antibodies that Specifically Bind to Allergens

(112) In another aspect, allergen-specific monoclonal antibodies, and antigen-binding portions thereof, that are generated from a human sample according to a method disclosed herein are provided. In some embodiments, the monoclonal antibody is an antibody that is generated according to the methods disclosed in Section III above. In some embodiments, the monoclonal antibody is an antibody that is generated from a sample from a human subject having an allergy to a food allergen, a plant allergen, a fungal allergen, an animal allergen, a dust mite allergen, a drug allergen, a cosmetic allergen, or a latex allergen, and the monoclonal antibody specifically binds to the food allergen, plant allergen, fungal allergen, animal allergen, dust mite allergen, drug allergen, cosmetic allergen, or latex allergen.

(113) In some embodiments, an antibody described herein is a full-length antibody, a Fab, a Fab, a F(ab).sub.2, a Fab-SH, an Fv, a single-chain antibody, or a single chain Fv (scFv) antibody. In some embodiments, an antibody described herein comprises an IgG4 constant region. In some embodiments, an antibody described herein is a monospecific antibody. In some embodiments, an antibody described herein is a multispecific antibody. In particular, an antibody described herein can be a bispecific antibody that binds to two different allergens. For example, in some embodiments, an antibody described herein can bind to a peanut allergen and a tree nut allergen. In some embodiments, an antibody described herein can bind to a peanut allergen and a milk allergen. In some embodiments, an antibody described herein can bind to a peanut allergen and a fungal allergen. In some embodiments, an antibody described herein can bind to a tree nut allergen and a milk allergen. In some embodiments, an antibody described herein can bind to a tree nut allergen and a fungal allergen. In some embodiments, an antibody described herein can bind to a milk allergen and a fungal allergen.

(114) In some embodiments, the monoclonal antibody or antigen-binding portion thereof is an allergen-specific antibody that comprises a heavy chain variable region sequence and a light chain variable region sequence that are identified according to a process comprising: (a) isolating single B cells from a sample from a human subject, wherein the subject is allergic to the allergen; (b) generating cDNAs from the single B cells of step (a), wherein the cDNA sequences comprise a first sequence that encodes all or part of an immunoglobulin heavy chain and a second sequence that encodes all or part of an immunoglobulin light chain; (c) determining the sequences of the cDNAs from step (b); (d) analyzing the sequences determined in step (c) to identify single B cells comprising a first sequence that comprises an IgE constant region or an IgG4 constant region; (e) identifying, from the single B cells of step (d), (i) a heavy chain variable region sequence in the immunoglobulin heavy chain that comprises an IgE constant region or an IgG4 constant region, and (ii) a light chain variable region sequence in an immunoglobulin light chain that is co-expressed with the immunoglobulin heavy chain in the same single B cell.

(115) In some embodiments, the heavy chain variable region and the light chain variable region are from a B cell comprising an immunoglobulin that comprises an IgE constant region. In some embodiments, the heavy chain variable region and the light chain variable region are from a B cell comprising an immunoglobulin that comprises an IgG4 constant region.

(116) In some embodiments, the monoclonal antibody or antigen-binding portion thereof is an allergen-specific antibody that comprises: (a) a heavy chain variable region sequence that is derived from an immunoglobulin heavy chain from an IgE- or IgG4-producing single B cell from a human subject who is allergic to the allergen; (b) a heavy chain IgG constant region sequence; (c) a light chain variable region sequence that is derived from an immunoglobulin light chain from the IgE- or IgG4-producing single B cell from a human subject; (d) a light chain constant region sequence that is of the same class as the immunoglobulin light chain of (c).

(117) In some embodiments, the monoclonal antibody comprises a heavy chain variable region sequence and a light chain variable region sequence that are derived from an IgE-producing human B cell. In some embodiments, the monoclonal antibody comprises a heavy chain variable region sequence and a light chain variable region sequence that are derived from an IgG4-producing human B cell.

(118) Characteristics of Allergen-Specific Monoclonal Antibodies

(119) In some embodiments, the monoclonal antibody is an antibody that specifically binds to a food allergen, a plant allergen, a fungal allergen, an animal allergen, a dust mite allergen, a drug allergen, a cosmetic allergen, or a latex allergen. In some embodiments, the monoclonal antibody is an antibody that specifically binds to a food allergen, such as a milk allergen, an egg allergen, a nut allergen, a fish allergen, a shellfish allergen, a soy allergen, a legume allergen, a seed allergen, or a wheat allergen. In some embodiments, the monoclonal antibody specifically binds to a peanut allergen. In some embodiments, the monoclonal antibody specifically binds to a milk allergen. In some embodiments, the monoclonal antibody specifically binds to an egg allergen.

(120) In some embodiments, the monoclonal antibody specifically binds to the allergen (e.g., a food allergen, a plant allergen, a fungal allergen, an animal allergen, a dust mite allergen, a drug allergen, a cosmetic allergen, or a latex allergen) with a binding affinity (K.sub.D) of less than 100 nM, less than 50 nM, less than 10 nM, less than 5 nM, less than 1 nM, less than 500 pM, less than 250 pM, less than 150 pM, less than 100 pM, less than 50 pM, less than 40 pM, less than 30 pM, less than 20 pM, less than about 10 pM, or less than 1 pM. In some embodiments, the antibody binds to the allergen with a binding affinity (K.sub.D) from 1 nM to 250 nM.

(121) In some embodiments, the monoclonal antibody exhibits cross-reactivity with at least two different antigens (e.g., allergens), e.g., at least two food allergens, at least two plant allergens, at least two fungal allergens, at least two animal allergens, at least two dust mite allergens, at least two drug allergens, at least two cosmetic allergens, or at least two latex allergens. In some embodiments, the monoclonal antibody exhibits cross-reactivity with at least two milk allergens, at least two egg allergens, at least two nut allergens, at least two fish allergens, at least two shellfish allergens, at least two soy allergens, at least two legume allergens, at least two seed allergens, or at least two wheat allergens. It will be appreciated by a person of ordinary skill in the art that many different allergens, such as many plant food allergens, can be grouped within a small number of protein families. For example, more than half of all plant food allergens can be categorized into one of the following four structural protein families: the prolamin superfamily, the cupin superfamily, profilins, and Bet v-1-related proteins. It will also be appreciated by a person of ordinary skill in the art that for a particular type of allergen (e.g., a peanut allergen), there can be more than one peptide or protein that is an allergen. As a non-limiting example, there are 12 known peanut allergens. See, Mueller et al., Curr Allergy Asthma Rep, 2014, 14:429. In some embodiments, the monoclonal antibody exhibits cross-reactivity with two or more different antigens that are different types or classes of antigens. As a non-limiting example, in some embodiments, a monoclonal antibody exhibits cross-reactivity with an antigen that is a peanut allergen and an antigen that is a nut (e.g., tree nut) allergen.

(122) In embodiments in which the monoclonal antibody exhibits cross-reactivity with at least two different antigens (e.g., allergens), in some embodiments the monoclonal antibody specifically binds to at least one of the allergens with a K.sub.D of less than 100 nM, less than 50 nM, less than 10 nM, less than 5 nM, less than 1 nM, less than 500 pM, less than 250 pM, less than 150 pM, less than 100 pM, less than 50 pM, less than 40 pM, less than 30 pM, less than 20 pM, less than about 10 pM, or less than 1 pM. In some embodiments, the monoclonal antibody specifically binds to the first antigen (e.g., first allergen) with a K.sub.D of less than 100 nM, less than 50 nM, less than 10 nM, less than 5 nM, less than 1 nM, less than 500 pM, less than 250 pM, less than 150 pM, less than 100 pM, less than 50 pM, less than 40 pM, less than 30 pM, less than 20 pM, less than about 10 pM, or less than 1 pM. In some embodiments, the monoclonal antibody specifically binds to the second antigen (e.g., second allergen) with a K.sub.D of less than 1 ?M, less than 500 nM, less than 100 nM, less than 10 nM, or less than 1 nM.

(123) Engineered Variations in Variable Regions

(124) In some embodiments, the heavy chain variable region and/or the light chain variable region of the monoclonal antibody has an identical sequence to the heavy chain variable region and/or the light chain variable region encoded by the IgE-producing or IgG4-producing single B cell from the human subject having an allergy to the allergen. In some embodiments, the heavy chain variable region and/or the light chain variable region of the monoclonal antibody comprises one or more modifications, e.g., amino acid substitutions, deletions, or insertions.

(125) As described in the Examples section below, the heavy chain variable region sequence and/or light chain variable region sequence of an antibody described herein (e.g., a peanut allergen-specific monoclonal antibody such as Clone PA13P1H08, Clone PA13P1E10, Clone PA12P3F10, Clone PA13P3G09, Clone PA12P3DO8, Clone PA12P1C07, Clone PA15P1D12, Clone PA15P1D05, or a Clone PA13P1H08 variant) can be engineered to comprise one or more variations in the heavy chain variable region sequence and/or light chain variable region sequence. In some embodiments, the engineered variation(s) improves the binding affinity of the antibody for the allergen. In some embodiments, the engineered variation(s) improves the cross-reactivity of the antibody for a second allergen.

(126) In some embodiments, the engineered variation is a variation in one or more CDRs, e.g., an amino acid substitution in a heavy chain CDR and/or a light chain CDR as described herein. In some embodiments, the engineered variation is a variation in one or more framework regions, e.g., an amino acid substitution in a heavy chain framework region and/or a light chain framework region. In some embodiments, the engineered variation is a reversion of a region of the heavy chain and/or light chain sequence to the inferred na?ve sequence. Methods for determining an inferred na?ve immunoglobulin sequence are described in the art. See, e.g., Magnani et al., PLoS Negl Trop Dis, 2017, 11:e0005655, doi:10.1371/journal.pntd.0005655.

(127) In some embodiments, affinity maturation is used to engineer further mutations that enhance the binding affinity of the antibody for the allergen or enhance the cross-reactivity of the antibody for a second allergen. Methods for performing affinity maturation are known in the art. See, e.g., Renaut et al., Methods Mol Biol, 2012, 907:451-461.

(128) Constant Regions and Isotype Switching

(129) In some embodiments, the monoclonal antibody comprises a heavy chain variable region sequence and a light chain variable region sequence that are derived from an IgE-producing human B cell or from an IgG4-producing human B cell, and further comprises a kappa or lambda light chain constant region. In some embodiments, the light chain constant region (kappa or lambda) is from the same type of light chain (i.e., kappa or lambda) as the light chain variable region that was derived from the IgE-producing human B cell or from an IgG4-producing human B cell; as a non-limiting example, if an IgE-producing human B cell comprises a kappa light chain, then the monoclonal antibody that is produced comprises the light chain variable region from the IgE-producing B cell and further comprises a kappa light chain constant region.

(130) In some embodiments, the monoclonal antibody comprises a heavy chain variable region sequence and a light chain variable region sequence that are derived from an IgE-producing human B cell or from an IgG4-producing human B cell, and further comprises a heavy chain constant region having an IgG isotype (e.g., IgG4), an IgA isotype (e.g., IgA1), an IgM isotype, an IgD isotype, or that is derived from an IgG, IgA, IgM, or IgD isotype (e.g., is a modified IgG4 constant region). It will be appreciated by a person of ordinary skill in the art that the different heavy chain isotypes (IgA, IgD, IgE, IgG, and IgM) have different effector functions that are mediated by the heavy chain constant region, and that for certain uses it may be desirable to have an antibody that has the effector function of a particular isotype (e.g., IgG).

(131) In some embodiments, the monoclonal antibody comprises a native (i.e., wild-type) human IgG, IgA, IgM, or IgD constant region. In some embodiments, the monoclonal antibody comprises a native human IgG1 constant region, a native human IgG2 constant region, a native human IgG3 constant region, a native human IgG4 constant region, a native human IgA1 constant region, a native human IgA2 constant region, a native human IgM constant region, or a native human IgD constant region. In some embodiments, the monoclonal antibody comprises a heavy chain constant region that comprises one or more modifications. It will be appreciated by a person of ordinary skill in the art that modifications such as amino acid substitutions can be made at one or more residues within the heavy chain constant region that modulate effector function. In some embodiments, the modification reduces effector function, e.g., results in a reduced ability to induce certain biological functions upon binding to an Fc receptor expressed on an effector cell that mediates the effector function. In some embodiments, the modification (e.g., amino acid substitution) prevents in vivo Fab arm exchange, which can introduce undesirable effects and reduce the therapeutic efficacy of the antibody. See, e.g., Silva et al., J Biol Chem, 2015, 280:5462-5469.

(132) In some embodiments, the monoclonal antibody comprises a native (i.e., wild-type) human IgM constant region, human IgD constant region, human IgG constant region that is derived from IgG1, IgG2, IgG3, or IgG4, or human IgA constant region that is derived from IgA1 or IgA2 and comprises one or more modifications that modulate effector function. In some embodiments the monoclonal antibody comprises a human IgM constant region, human IgD constant region, human IgG constant region that is derived from IgG1, IgG2, IgG3, or IgG4, or human IgA constant region that is derived from IgA1 or IgA2. In some embodiments, the monoclonal antibody comprises a native (i.e., wild-type) human IgM constant region, human IgD constant region, human IgG constant region that is derived from IgG1, IgG2, IgG3, or IgG4, or human IgA constant region that is derived from IgA1 or IgA2 and comprises one, two, three, four, five, six, seven, eight, nine, ten or more modifications (e.g., amino acid substitutions). In some embodiments the constant regions includes variations (e.g., one, two, three, four, five, six, seven, eight, nine, ten or more amino acid substitutions) that reduce effector function.

(133) In some embodiments, a monoclonal antibody comprises CDR sequences, a heavy chain variable region, and/or a light chain variable region from an antibody from an IgE or IgG4 B cell as described herein (e.g., as disclosed in Table 1 below) and further comprises a heavy chain constant region and/or a light chain constant region that is heterologous to the antibody from the IgE or IgG4 B cell from which the CDR sequences and/or variable region sequences are derived. For example, in some embodiments, the monoclonal antibody comprises the CDR sequences and/or variable region sequences of an antibody from an IgE B cell, and further comprises a heavy chain constant region and a light chain constant region that is heterologous to the antibody from the IgE B cell (e.g., the heavy chain constant region and/or light chain constant region is a wild-type or modified IgG1, IgG2, IgG3, or IgG4 constant region, or the heavy chain constant region and/or light chain constant region comprises one or more modifications (e.g., amino acid substitutions) relative to the native constant region of the antibody from the IgE B cell).

(134) Antibodies that Specifically Bind to Peanut and/or Tree Nut Allergens

(135) In some embodiments, a monoclonal antibody or antigen-binding portion thereof as disclosed herein specifically binds to a peanut allergen and/or a tree nut allergen. In some embodiments, the monoclonal antibody specifically binds to a peanut allergen. In some embodiments, the monoclonal antibody specifically binds to a peanut allergen that is Ara h 1, Ara h 2, Ara h 3, or Ara h 6.

(136) In some embodiments, the monoclonal antibody exhibits cross-reactivity with at least two peanut allergens. In some embodiments, the monoclonal antibody exhibits cross-reactivity with two or more of the peanut allergens Ara h 1, Ara h 2, Ara h 3, and Ara h 6. In some embodiments, the monoclonal antibody specifically binds to at least one of the peanut allergens with a K.sub.D of less than 100 nM, less than 50 nM, less than 10 nM, less than 5 nM, less than 1 nM, less than 500 pM, less than 250 pM, less than 150 pM, less than 100 pM, less than 50 pM, less than 40 pM, less than 30 pM, less than 20 pM, less than about 10 pM, or less than 1 pM. In some embodiments, the monoclonal antibody specifically binds to a first peanut allergen with a K.sub.D of less than 100 nM (e.g., less than 50 nM, less than 10 nM, less than 5 nM, or less than 1 nM) and specifically binds to a second peanut allergen with a K.sub.D of less than 1 ?M (e.g., less than 500 nM, less than 100 nM, less than 10 nM, or less than 1 nM). In some embodiments, the monoclonal antibody specifically binds to Ara h 2 with a K.sub.D of less than 100 nM (e.g., less than 50 nM, less than 10 nM, less than 5 nM, or less than 1 nM) and specifically binds to Ara h 1, Ara h 3, or Ara h 6 with a K.sub.D of less than 1 ?M (e.g., less than 500 nM, less than 100 nM, less than 10 nM, or less than 1 nM).

(137) In some embodiments, the monoclonal antibody recognizes an epitope that comprises or consists of the amino acid motif DPYSPS (SEQ ID NO:704). In some embodiments, the monoclonal antibody recognizes an epitope that comprises or consists of the amino acid sequence DSYGRDPYSPS (SEQ ID NO:705), YSPSQDPYSPS (SEQ ID NO:706), or PDRRDPYSPS (SEQ ID NO:707).

(138) In some embodiments, the monoclonal antibody or antigen-binding portion thereof specifically binds to a tree nut allergen. In some embodiments, the tree nut allergen is a cashew, pistachio, almond, pine nut, pecan, walnut, hazelnut, or macadamia nut allergen. In some embodiments, the monoclonal antibody exhibits cross-reactivity with at least two tree nut allergens. In some embodiments, the monoclonal antibody exhibits cross-reactivity with both cashew and pistachio allergens. In some embodiments, the monoclonal antibody exhibits cross-reactivity with both pecan and walnut allergens. In some embodiments, the monoclonal antibody exhibits cross-reactivity with two or more of pecan, walnut, hazelnut, and macadamia nut allergens. In some embodiments, the monoclonal antibody specifically binds to at least one of the tree nut allergens with a K.sub.D of less than 100 nM, less than 50 nM, less than 10 nM, less than 5 nM, less than 1 nM, less than 500 pM, less than 250 pM, less than 150 pM, less than 100 pM, less than 50 pM, less than 40 pM, less than 30 pM, less than 20 pM, less than about 10 pM, or less than 1 pM.

(139) In some embodiments, the monoclonal antibody or antigen-binding portion thereof specifically binds to a peanut allergen and to a tree nut allergen. In some embodiments, the monoclonal antibody specifically binds to a peanut allergen and to one or more (e.g., 1, 2, 3, 4, or more) of a cashew, pistachio, almond, pine nut, pecan, walnut, hazelnut, or macadamia nut allergen.

(140) Peanut-Specific Antibody Sequences

(141) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen (e.g., that specifically binds to Ara h 1, Ara h 2, Ara h 3, or Ara h 6) comprises heavy chain CDRs and/or light chain CDRs that are disclosed in Table 1 below. In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a light chain variable region sequence and/or a heavy chain variable region sequence that is disclosed in Table 1 below. In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises: a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a heavy chain variable region sequence disclosed in Table 1 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that heavy chain variable region sequence, and a light chain variable region comprising an amino acid sequence that has at least 70% sequence identity (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a light chain variable region sequence disclosed in Table 1 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that light chain variable region sequence.

(142) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen (e.g., that specifically binds to Ara h 1, Ara h 2, Ara h 3, or Ara h 6) comprises a light chain sequence, or a portion thereof, and/or a heavy chain sequence, or a portion thereof, derived from any of the following antibodies described herein: Clone PA13P1H08, Clone PA13P1E10, Clone PA12P3F10, Clone PA13P3G09, Clone PA12P3DO8, Clone PA12P1CO7, Clone PA15P1D12, Clone PA15P1D05, a variant of Clone PA13P1H08 (e.g., an R-R variant, an R-N variant, an N-R variant, an rCDR1-N variant, an rCDR2-N variant, an rCDR3-N variant, or an rFWRs-N variant of Clone PA13P1H08), Clone PA12P4DO2, Clone PA12P3E09, Clone PA12P3E11, Clone PA12P1D02, Clone PA12P1G11, Clone PA13P1H03, Clone PA12P3CO1, or Clone PA12P3EO4. The amino acid sequences of the CDR, light chain variable domain (VL), and heavy chain variable domain (VH) of Clone PA13P1H08, Clone PA13P1E10, Clone PA12P3F10, Clone PA13P3G09, Clone PA12P3DO8, Clone PA12P1C07, Clone PA15P1D12, Clone PA15P1D05, Clone PA13P1H08 variants, Clone PA12P4DO2, Clone PA12P3E09, Clone PA12P3E11, Clone PA12P1D02, Clone PA12P1G11, Clone PA13P1H03, Clone PA12P3CO1, and Clone PA12P3EO4 are set forth in Table 1 below.

(143) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises one or more (e.g., one, two, three, four, five, or all six) of: (a) a heavy chain CDR1 comprising the amino acid sequence of any one of SEQ ID NOs:2, 10, 17, 25, 33, 41, 47, 58, 113, 129, 199, 341, 348, 409, 459, or 593; (b) a heavy chain CDR2 comprising the amino acid sequence of any one of SEQ ID NOs:3, 11, 18, 26, 34, 48, 59, 130, 200, 342, 349, 410, 460, 539, or 594; (c) a heavy chain CDR3 comprising the amino acid sequence of any one of SEQ ID NOs:4, 12, 19, 27, 35, 42, 49, 55, 60, 131, 201, 350, 411, 461, 540, or 595; (d) a light chain CDR1 comprising the amino acid sequence of any one of SEQ ID NOs:6, 14, 21, 29, 37, 44, 51, 62, 133, 203, 343, 352, 413, 463, 542, or 597; (e) a light chain CDR2 comprising the amino acid sequence of any one of SEQ ID NOs:7, 15, 22, 30, 38, 52, 78, 86, 126, 149, 196, 345, 353, or 598; and (f) a light chain CDR3 comprising the amino acid sequence of any one of SEQ ID NOs:8, 23, 31, 39, 45, 53, 63, 134, 204, 346, 354, 414, 464, 543, or 599.

(144) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of: (a) SEQ ID NOs: 2, 3, 4, 6, 7, and 8, respectively; or (b) SEQ ID NOs: 10, 11, 12, 14, 15, and 8, respectively; or (c) SEQ ID NOs: 17, 18, 19, 21, 22, and 23, respectively; or (d) SEQ ID NOs: 25, 26, 27, 29, 30, and 31, respectively; or (e) SEQ ID NOs: 33, 34, 35, 37, 38, and 39, respectively; or (f) SEQ ID NOs: 41, 34, 35, 37, 38, and 39, respectively; or (g) SEQ ID NOs: 47, 48, 49, 51, 52, and 53, respectively; or (h) SEQ ID NOs: 47, 48, 55, 51, 52, and 53, respectively; or (i) SEQ ID NOs: 58, 59, 60, 62, 30, and 63, respectively; or (j) SEQ ID NOs: 58, 59, 60, 6, 7, and 8, respectively; or (k) SEQ ID NOs: 2, 3, 4, 62, 30, and 63, respectively; or (l) SEQ ID NOs: 58, 3, 4, 6, 7, and 8, respectively; or (m) SEQ ID NOs: 2, 59, 4, 6, 7, and 8, respectively; or (n) SEQ ID NOs: 2, 3, 60, 6, 7, and 8, respectively; or (o) SEQ ID NOs:129, 130, 131, 133, 126, and 134, respectively; or (p) SEQ ID NOs:341, 342, 343, 345, 78, and 346, respectively; or (q) SEQ ID NOs:348, 349, 350, 352, 353, and 354, respectively; or (r) SEQ ID NOs:199, 200, 201, 203, 149, and 204, respectively; or (s) SEQ ID NOs:409, 410, 411, 413, 86, and 414, respectively; or (t) SEQ ID NOs:459, 460, 461, 463, 196, and 464, respectively; or (u) SEQ ID NOs:113, 539, 540, 542, 196, and 543, respectively; or (v) SEQ ID NOs:593, 594, 595, 597, 598, and 599, respectively.

(145) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs:1, 9, 16, 24, 32, 40, 46, 54, 57, 64, 65, 66, 67, 128, 340, 347, 406, 408, 458, 538, or 592. In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a light chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs:5, 13, 20, 28, 36, 43, 50, 56, 61, 132, 344, 351, 407, 412, 462, 541, or 596. In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs:1, 9, 16, 24, 32, 40, 46, 54, 57, 64, 65, 66, 67, 128, 340, 347, 406, 408, 458, 538, or 592, and comprises a light chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs: 5, 13, 20, 28, 36, 43, 50, 56, 61, 132, 344, 351, 407, 412, 462, 541, or 596.

(146) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85% 90%, 91%, 92% 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs: 1, 9, 16, 24, 32, 40, 46, 54, 57, 64, 65, 66, 67, 128, 340, 347, 406, 408, 458, 538, or 592 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that SEQ ID NO. In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a light chain variable region comprising an amino acid sequence that has at least 70% sequence identity (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93% 94%, 95%, 96% 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs: 5, 13, 20, 28, 36, 43, 50, 56, 61, 132, 344, 351, 407, 412, 462, 541, or 596 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that SEQ ID NO. In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises: (a) a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs: 1, 9, 16, 24, 32, 40, 46, 54, 57, 64, 65, 66, 67, 128, 340, 347, 406, 408, 458, 538, or 592 and that comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that SEQ ID NO; and (b) a light chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs: 5, 13, 20, 28, 36, 43, 50, 56, 61, 132, 344, 351, 407, 412, 462, 541, or 596 and that comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that SEQ ID NO.
Clone PA13P1H08

(147) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:3, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:4, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:6, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:8.

(148) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:1, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:2, 3, and 4, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:5, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:6, 7, and 8, respectively.

(149) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:1, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:5. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:1 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:5.

(150) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:2, 3, 4, 6, 7, and 8, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:1 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:5).

(151) Clone PA13P1E10

(152) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:10, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:11, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:12, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:14, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:15, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:8.

(153) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:9, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:10, 11, and 12, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:13, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:14, 15, and 8, respectively.

(154) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:9, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:13. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:9 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:13.

(155) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:10, 11, 12, 14, 15, and 8 respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:9 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:13).

(156) Clone PA12P3F10

(157) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:17, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:18, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:19, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:21, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:22, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:23.

(158) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:16, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:17, 18, and 19, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:20, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:21, 22, and 23, respectively.

(159) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:16, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:20. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:16 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:20.

(160) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:17, 18, 19, 21, 22, and 23, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:16 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:20).

(161) Clone PA13P3G09

(162) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:25, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:26, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:27, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:29, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:31.

(163) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:24, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:25, 26, and 27, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:28, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:29, 30, and 31, respectively.

(164) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:24, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:28. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:24 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:28.

(165) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:25, 26, 27, 29, 30, and 31, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:24 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:28).

(166) Clone PA12P3DO8

(167) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:33, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:34, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:35, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:37, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:38, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:39.

(168) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:32, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:33, 34, and 35, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:36, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:37, 38, and 39, respectively.

(169) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:32, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:36. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:32 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:36.

(170) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:33, 34, 35, 37, 38, and 39, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:32 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:36).

(171) Clone PA12P1CO7

(172) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:41, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:34, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:42, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:44, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:45.

(173) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:40, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:41, 34, and 42, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:43, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:44, 30, and 45, respectively.

(174) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:40, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:43. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:40 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:43.

(175) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:41, 34, 42, 44, 30, and 45, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:40 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:43).

(176) Clone PA15P1D12

(177) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:47, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:48, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:49, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:51, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:52, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:53.

(178) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:46, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:47, 48, and 49, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:50, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:51, 52, and 53, respectively.

(179) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:46, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:50. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:46 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:50.

(180) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:41, 34, 42, 44, 30, and 45, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:46 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:50).

(181) Clone PA15P1D05

(182) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:47, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:48, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:55, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:51, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:52, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:53.

(183) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:54, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:47, 48, and 55, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:56, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:51, 52, and 53, respectively.

(184) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:54, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:56. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:54 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:56.

(185) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:47, 48, 55, 51, 52, and 53, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:54 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:56).

(186) Variant Sequences

(187) In some embodiments, the allergen-specific monoclonal antibody comprises one or more variations (e.g., amino acid substitutions) in one or more CDR, heavy chain, and/or light chain sequences as disclosed herein (e.g., one or more mutations in one or more CDR, heavy chain, and/or light chain sequences of Clone PA13P1H08, Clone PA13P1E10, Clone PA12P3F10, Clone PA13P3G09, Clone PA12P3DO8, Clone PA12P1CO7, Clone PA15P1D12, Clone PA15P1DO5). In some embodiments, one or more substitutions are made in a CDR, heavy chain, or light chain sequence of Clone PA13P1H08. As described in the Examples section below, variants were made of Clone PA13P1H08, in which one or more regions in the heavy chain and/or light chain were reverted to the inferred na?ve rearrangement. It was found that antibody sequences comprising a na?ve light chain or heavy chain sequence were capable of binding to the peanut allergen Ara h 2. It was also surprisingly found that a variant of Clone PA13P1H08 comprising a reverted CDR-H2 sequence exhibited significantly improved cross-reactivity to a second peanut allergen (Ara h 3) in addition to having sub-nanomolar affinity for the Ara h 2 peanut allergen. Thus, in some embodiments, the mutation is an amino acid substitution that reverts at least a portion of the sequence of the clone from its native form (i.e., the CDR, heavy chain variable region, or light chain variable region sequence of the clone as disclosed in Table 1) to the inferred na?ve immunoglobulin sequence.

(188) In some embodiments, an allergen-specific monoclonal antibody comprises one or more variant sequences of a Clone PA13P1H08 variant as disclosed herein. In some embodiments, the antibody comprises one of the sequences of Clone PA13P1H08 variant R-R, in which both the heavy chain variable region and the light chain variable region of Clone PA13P1H08 are reverted back to the inferred na?ve rearrangement. In some embodiments, the antibody comprises a reverted heavy chain variable region sequence comprising SEQ ID NO:57. In some embodiments, the antibody comprises a reverted light chain variable region sequence comprising SEQ ID NO:61.

(189) In some embodiments, the antibody comprises one of the sequences of Clone PA13P1H08 variant R-N, in which the heavy chain variable region of Clone PA13P1H08 is reverted back to the inferred na?ve rearrangement and the light chain variable region retains the native sequence of Clone PA13P1H08 (i.e., SEQ ID NO:5). In some embodiments, the antibody comprises one of the sequences of Clone PA13P1H08 variant N-R, in which the heavy chain variable region retains the native sequence of Clone PA13P1H08 (i.e., SEQ ID NO:1), and the light chain variable region is reverted back to the inferred na?ve rearrangement of Clone PA13P1H08.

(190) In some embodiments, the antibody comprises one or more reverted CDR sequences, e.g., one or more reverted heavy chain CDR sequences, and/or one or more reverted light chain CDR sequences. In some embodiments, the antibody comprises one or more of a reverted CDR-H1 comprising SEQ ID NO:58, a reverted CDR-H2 comprising SEQ ID NO:59, or a reverted CDR-H3 comprising SEQ ID NO:60. In some embodiments, the antibody comprises one or more of a reverted CDR-L1 comprising SEQ ID NO:62, a reverted CDR-L2 comprising SEQ ID NO:30, or a reverted CDR-L3 comprising SEQ ID NO:63. In some embodiments, the antibody comprises one or more reverted framework regions, e.g., the heavy chain variable region comprising reverted framework regions of SEQ ID NO:67.

(191) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:58, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:59, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:60, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:62, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:30, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:63.

(192) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:1, SEQ ID NO:57, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, or SEQ ID NO:67, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:5 or SEQ ID NO:61. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:57 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:61. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:57 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:5. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:1 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:61. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:64 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:5. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:65 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:5. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:66 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:5. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:67 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:5.

(193) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:65, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:2, 59, and 4, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90% 91%, 92%, 93%, 94%, 95%, 96% 97%, 98%, or 99% sequence identity) to SEQ ID NO:5, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:6, 7, and 8, respectively.
Tree Nut-Specific Antibody Sequences

(194) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen (e.g., that specifically binds to a cashew, pistachio, almond, pine nut, pecan, walnut, hazelnut, or macadamia nut allergen) comprises heavy chain CDRs and/or light chain CDRs that are disclosed in Table 1 below. In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a light chain variable region sequence and/or a heavy chain variable region sequence that is disclosed in Table 1 below. In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises: a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a heavy chain variable region sequence disclosed in Table 1 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that heavy chain variable region sequence, and a light chain variable region comprising an amino acid sequence that has at least 70% sequence identity (e.g., at least 75%, 80%, 85%, 90%, 91% 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a light chain variable region sequence disclosed in Table 1 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that light chain variable region sequence.

(195) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a light chain sequence, or a portion thereof, and/or a heavy chain sequence, or a portion thereof, derived from any of the following antibodies described herein: Clone PA14P3H08, Clone PA11P1D11, Clone PA11P1G10, Clone PA12P4DO2, Clone PA11P1D12, Clone PA11P1F03, Clone PA11P1C04, Clone PA11P1G04, Clone PA11P1E01, Clone PA11P1C11, or Clone PA11P1CO3. The amino acid sequences of the CDR, light chain variable domain (VL), and heavy chain variable domain (VH) of Clone PA14P3H08, Clone PA11P1D11, Clone PA11P1G10, Clone PA12P4D02, Clone PA11P1D12, Clone PA11P1F03, Clone PA11P1CO4, Clone PA11P1G04, Clone PA11P1E01, Clone PA11P1C11, and Clone PA11P1CO3 are set forth in Table 1 below.

(196) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises one or more (e.g., one, two, three, four, five, or all six) of: (a) a heavy chain CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 113, 167, 175, 227, 311, 318, 438, 466, 621, 665, or 692; (b) a heavy chain CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 168, 176, 200, 312, 319, 439, 539, 666, or 693; (c) a heavy chain CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 169, 177, 228, 313, 320, 440, 467, 540, 667, or 694; (d) a light chain CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 171, 179, 230, 315, 322, 442, 469, 542, 623, 669, or 696; (e) a light chain CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 30, 94, 149, 172, 180, 196, 323, or 670; and (f) a light chain CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 173, 181, 231, 316, 324, 443, 470, 543, 624, 671, or 697.

(197) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a heavy chain variable region comprising an amino acid sequence that comprises the sequence of, or has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, any one of SEQ ID NOs:166, 174, 226, 310, 317, 437, 465, 538, 620, 664, or 691. In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a light chain variable region comprising an amino acid sequence that comprises the sequence of, or has at least 75% sequence identity (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, any one of SEQ ID NOs:170, 178, 229, 314, 321, 441, 468, 541, 622, 668, or 695. In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises a heavy chain variable region comprising an amino acid sequence that comprises the sequence of, or has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to, any one of SEQ ID NOs:166, 174, 226, 310, 317, 437, 465, 538, 620, 664, or 691, and comprises a light chain variable region comprising an amino acid sequence that comprises the sequence of, or has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92% 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, any one of SEQ ID NOs:170, 178, 229, 314, 321, 441, 468, 541, 622, 668, or 695.

(198) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises: (a) a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs:166, 174, 226, 310, 317, 437, 465, 538, 620, 664, or 691 and that comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that SEQ ID NO; and (b) a light chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs:170, 178, 229, 314, 321, 441, 468, 541, 622, 668, or 695 and that comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that SEQ ID NO.

(199) In some embodiments, the monoclonal antibody specifically binds to a pecan, walnut, hazelnut, and/or macadamia nut allergen and comprises one or more (e.g., one, two, three, four, five, or all six) of: (a) a heavy chain CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 113, 227, 311, 318, 665, or 692; (b) a heavy chain CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 200, 312, 319, 539, 666, or 693; (c) a heavy chain CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 228, 313, 320, 540, 667, or 694; (d) a light chain CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 230, 315, 322, 542, 669, or 696; (e) a light chain CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 94, 149, 196, 323, or 670; and (f) a light chain CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 231, 316, 324, 543, 671, or 697.

(200) In some embodiments, a monoclonal antibody that specifically binds to a pecan, walnut, hazelnut, and/or macadamia nut allergen comprises a heavy chain variable region comprising an amino acid sequence that comprises the sequence of, or has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, any one of SEQ ID NOs: 226, 310, 317, 538, 664, or 691. In some embodiments, a monoclonal antibody that specifically binds to a pecan, walnut, hazelnut, and/or macadamia nut allergen comprises a light chain variable region comprising an amino acid sequence that comprises the sequence of, or has at least 75% sequence identity (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, or 99% sequence identity) to, any one of SEQ ID NOs: 229, 314, 321, 541, 668, or 695. In some embodiments, a monoclonal antibody that specifically binds to a pecan, walnut, hazelnut, and/or macadamia nut allergen comprises a heavy chain variable region comprising an amino acid sequence that comprises the sequence of, or has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to, any one of SEQ ID NOs: 226, 310, 317, 437, 538, 664, or 691, and comprises a light chain variable region comprising an amino acid sequence that comprises the sequence of, or has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, any one of SEQ ID NOs: 229, 314, 321, 541, 668, or 695.

(201) In some embodiments, the monoclonal antibody specifically binds to a cashew and/or pistachio allergen and comprises one or more (e.g., one, two, three, four, five, or all six) of: (a) a heavy chain CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 167, 175, 227, 438, 466, or 621; (b) a heavy chain CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 168, 176, 200, or 439; (c) a heavy chain CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 169, 177, 440, or 467; (d) a light chain CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 171, 179, 442, 469, or 623; (e) a light chain CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 30, 149, 172, or 180; and (f) a light chain CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 173, 181, 443, 470, or 624.

(202) In some embodiments, a monoclonal antibody that specifically binds to a cashew and/or pistachio allergen comprises a heavy chain variable region comprising an amino acid sequence that comprises the sequence of, or has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, any one of SEQ ID NOs:166, 174, 437, 465, or 620. In some embodiments, a monoclonal antibody that specifically binds to a cashew and/or pistachio allergen comprises a light chain variable region comprising an amino acid sequence that comprises the sequence of, or has at least 75% sequence identity (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, any one of SEQ ID NOs:170, 178, 441, 468, or 622. In some embodiments, a monoclonal antibody that specifically binds to a cashew and/or pistachio allergen comprises a heavy chain variable region comprising an amino acid sequence that comprises the sequence of, or has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to, any one of SEQ ID NOs:166, 174, 437, 465, or 620, and comprises a light chain variable region comprising an amino acid sequence that comprises the sequence of, or has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, any one of SEQ ID NOs:170, 178, 441, 468, or 622.

(203) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of: (a) SEQ ID NOs:692, 693, 694, 696, 94, and 697, respectively; or (b) SEQ ID NOs:318, 319, 320, 322, 323, and 324, respectively; or (c) SEQ ID NOs:227, 200, 228, 230, 149, and 231, respectively; or (d) SEQ ID NOs:113, 539, 540, 542, 196, and 543, respectively; or (e) SEQ ID NOs:311, 312, 313, 315, 94, and 316, respectively; or (f) SEQ ID NOs:665, 666, 667, 669, 670, and 671, respectively; or (g) SEQ ID NOs:466, 200, 467, 469, 149, and 470, respectively; or (h) SEQ ID NOs:167, 168, 169, 171, 172, and 173, respectively; or (i) SEQ ID NOs:621, 176, 177, 623, 180, and 624, respectively; or (j) SEQ ID NOs:175, 176, 177, 179, 180, and 181, respectively; or (k) SEQ ID NOs:438, 439, 440, 442, 30, and 443, respectively.
Clone PA14P3H08

(204) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:692, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:693, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:694, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:696, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:94, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:697. In some embodiments, the monoclonal antibody binds to two or more tree nut allergens. In some embodiments, the monoclonal antibody binds to a pecan, walnut, hazelnut, and/or macadamia nut allergen.

(205) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:691, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:692, 693, and 694, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:695, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:696, 94, and 697, respectively.

(206) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:691, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:695. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:691 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:695.

(207) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:692, 693, 694, 696, 95, and 697, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:691 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:695).

(208) Clone PA11P1D11

(209) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:318, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:319, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:320, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:322, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:323, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:324. In some embodiments, the monoclonal antibody binds to two or more tree nut allergens. In some embodiments, the monoclonal antibody binds to a pecan, walnut, hazelnut, and/or macadamia nut allergen.

(210) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:317, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:318, 319, and 320, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:321, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:322, 323, and 324, respectively.

(211) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:317, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:321. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:317 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:321.

(212) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:318, 319, 320, 322, 323, and 324, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:317 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:321).

(213) Clone PA11P1G10

(214) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:227, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:200, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:228, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:230, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:149, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:231. In some embodiments, the monoclonal antibody binds to two or more tree nut allergens. In some embodiments, the monoclonal antibody binds to a pecan, walnut, hazelnut, and/or macadamia nut allergen.

(215) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:226, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:227, 200, and 228, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:229, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:230, 149, and 231, respectively.

(216) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:226, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:229. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:226 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:229.

(217) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:227, 200, 228, 230, 149, and 231, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:226 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:229).

(218) Clone PA12P4DO2

(219) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:113, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:539, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:540, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:542, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:196, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:543. In some embodiments, the monoclonal antibody binds to two or more tree nut allergens. In some embodiments, the monoclonal antibody binds to a pecan, walnut, hazelnut, and/or macadamia nut allergen.

(220) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:538, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:113, 539, and 540, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:541, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:542, 196, and 543, respectively.

(221) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:538, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:541. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:538 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:541.

(222) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:113, 539, 540, 542, 196, and 543, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:538 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:541).

(223) Clone PA11P1D12

(224) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:692, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:693, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:694, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:696, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:94, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:697. In some embodiments, the monoclonal antibody binds to two or more tree nut allergens. In some embodiments, the monoclonal antibody binds to a pecan, walnut, hazelnut, and/or macadamia nut allergen.

(225) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:310, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:311, 312, and 313, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:314, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:315, 94, and 316, respectively.

(226) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:310, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:314. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:310 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:314.

(227) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:311, 312, 313, 315, 94, and 316, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:310 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:314).

(228) Clone PA11P1F03

(229) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:665, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:666, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:667, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:669, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:670, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:671. In some embodiments, the monoclonal antibody binds to two or more tree nut allergens. In some embodiments, the monoclonal antibody binds to a pecan, walnut, hazelnut, and/or macadamia nut allergen.

(230) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:664, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:665, 666, and 667, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:668, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:669, 670, and 671, respectively.

(231) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:664, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:668. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:664 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:668.

(232) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:665, 666, 667, 669, 670, and 671, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:664 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:668).

(233) Clone PA11P1CO4

(234) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:466, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:200, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:467, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:469, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:149, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:470. In some embodiments, the monoclonal antibody binds to two or more tree nut allergens. In some embodiments, the monoclonal antibody binds to a cashew and/or a pistachio allergen.

(235) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:465, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:466, 200, and 467, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:468, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:469, 149, and 470, respectively.

(236) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:465, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:468. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:465 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:468.

(237) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:466, 200, 467, 469, 149, and 470, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:465 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:468).

(238) Clone PA11P1G04

(239) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:167, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:168, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:169, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:171, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:172, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:173. In some embodiments, the monoclonal antibody binds to two or more tree nut allergens. In some embodiments, the monoclonal antibody binds to a cashew and/or a pistachio allergen.

(240) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:166, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:167, 168, and 169, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:170, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:171, 172, and 173, respectively.

(241) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity) to SEQ ID NO:166, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:170. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:166 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:170.

(242) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:167, 168, 169, 171, 172, and 173, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:166 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:170).

(243) Clone PA11P1EO1

(244) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:621, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:176, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:177, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:623, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:180, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:624. In some embodiments, the monoclonal antibody binds to two or more tree nut allergens. In some embodiments, the monoclonal antibody binds to a cashew and/or a pistachio allergen.

(245) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:620, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:621, 176, and 177, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:622, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:623, 180, and 624, respectively.

(246) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:620, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:622. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:620 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:622.

(247) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:621, 176, 177, 623, 180, and 624, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:620 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:622).

(248) Clone PA11P1C11

(249) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:175, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:176, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:177, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:179, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:180, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:181. In some embodiments, the monoclonal antibody binds to two or more tree nut allergens. In some embodiments, the monoclonal antibody binds to a cashew and/or a pistachio allergen.

(250) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:174, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:175, 176, and 177, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:178, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:179, 180, and 181, respectively.

(251) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:174, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:178. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:174 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:178.

(252) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:175, 176, 177, 179, 180, and 181, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:174 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:178).

(253) Clone PA11P1CO3

(254) In some embodiments, a monoclonal antibody that specifically binds to a tree nut allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:438, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:439, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:440, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:442, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:443. In some embodiments, the monoclonal antibody binds to two or more tree nut allergens. In some embodiments, the monoclonal antibody binds to a cashew and/or a pistachio allergen.

(255) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:437, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:438, 439, and 440, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:441, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:442, 30, and 443, respectively.

(256) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:437, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:441. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:437 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:441.

(257) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:438, 439, 440, 442, 30, and 443, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:437 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:441).

(258) Antibodies that Specifically Bind to Milk Allergens

(259) In some embodiments, the monoclonal antibody or antigen-binding portion thereof specifically binds to a milk allergen (e.g., cow's milk allergen). In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises heavy chain CDRs and/or light chain CDRs that are disclosed in Table 1 below. In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a light chain variable region sequence and/or a heavy chain variable region sequence that is disclosed in Table 1 below. In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises: a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93% 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a heavy chain variable region sequence disclosed in Table 1 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that heavy chain variable region sequence, and a light chain variable region comprising an amino acid sequence that has at least 70% sequence identity (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a light chain variable region sequence disclosed in Table 1 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that light chain variable region sequence.

(260) In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a light chain sequence, or a portion thereof, and/or a heavy chain sequence, or a portion thereof, derived from any of the following antibodies described herein: Clone PA01P2C05, Clone PA01P2B03, Clone PA01P2A12, Clone PA01P2C12, Clone PA01P2E10, Clone PA01P2CO9, Clone PA01P2DO6, Clone PA01P2E08, Clone PA01P2A05, Clone PA01P2B04, Clone PA01P2EO5, Clone PA01P2DO4, Clone PA01P2B12, Clone PA01P2D11, Clone PA01P2B10, Clone PA01P2D10, Clone PA01P2DO9, Clone PA01P2B05, Clone PA01P4C11, Clone PA01P3E08, Clone PA01P2E06, Clone PA01P2E07, Clone PA01P2G07, Clone PA01P2B09, Clone PA01P2CO4, or Clone PA01P2H08. The amino acid sequences of the CDR, light chain variable domain (VL), and heavy chain variable domain (VH) of Clone PA01P2C05, Clone PA01P2B03, Clone PA01P2A12, Clone PA01P2C12, Clone PA01P2E10, Clone PA01P2CO9, Clone PA01P2DO6, Clone PA01P2EO8, Clone PA01P2A05, Clone PA01P2B04, Clone PA01P2E05, Clone PA01P2DO4, Clone PA01P2B12, Clone PA01P2D11, Clone PA01P2B10, Clone PA01P2D10, Clone PA01P2DO9, Clone PA01P2B05, Clone PA01P4C11, Clone PA01P3EO8, Clone PA01P2E06, Clone PA01P2EO7, Clone PA01P2G07, Clone PA01P2B09, Clone PA01P2CO4, and Clone PA01P2H08 are set forth in Table 1 below.

(261) In some embodiments, a monoclonal antibody that specifically binds to a peanut allergen comprises one or more (e.g., one, two, three, four, five, or all six) of: (a) a heavy chain CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 121, 750, 757, 765, 772, 779, 785, 793, 800, 807, 814, 821, 833, 838, 846, 853, 860, 868, 874, 881, 889, 895, 903, 911, 918, or 926; (b) a heavy chain CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 378, 532, 751, 758, 766, 773, 786, 794, 801, 808, 815, 822, 826, 839, 847, 854, 861, 875, 882, 890, 896, 904, 912, 919, or 927; (c) a heavy chain CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 752, 759, 767, 774, 780, 787, 795, 802, 809, 816, 827, 840, 848, 855, 862, 869, 876, 883, 891, 897, 905, 913, 920, or 928; (d) a light chain CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 523, 754, 761, 769, 776, 782, 789, 797, 804, 811, 818, 829, 835, 842, 850, 857, 864, 871, 878, 885, 899, 907, 915, 922, or 930; (e) a light chain CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 22, 30, 94, 110, 149, 186, 196, 389, 404, 509, 662, 682, 762, 790, 830, 843, 865, 886, 900, 908, 923, or 931; and (f) a light chain CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 755, 763, 770, 777, 783, 791, 798, 805, 812, 819, 824, 831, 836, 844, 851, 858, 866, 872, 879, 887, 893, 901, 909, 916, 924, or 932.

(262) In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of: (a) SEQ ID NOs:750, 751, 752, 754, 196, and 755, respectively; or (b) SEQ ID NOs:757, 758, 759, 761, 762, and 763, respectively; or (c) SEQ ID NOs:765, 766, 767, 769, 30, and 770, respectively; or (d) SEQ ID NOs:772, 773, 774, 776, 389, and 777, respectively; or (e) SEQ ID NOs:779, 532, 780, 782, 404, and 783, respectively; or (f) SEQ ID NOs:785, 786, 787, 789, 790, and 791, respectively; or (g) SEQ ID NOs:793, 794, 795, 797, 30, and 798, respectively; or (h) SEQ ID NOs:800, 801, 802, 804, 110, and 805, respectively; or (i) SEQ ID NOs:807, 808, 809, 811, 509, and 812, respectively; or (j) SEQ ID NOs:814, 815, 816, 818, 94, and 819, respectively; or (k) SEQ ID NOs:821, 822, 787, 776, 790, and 824, respectively; or (l) SEQ ID NOs:121, 826, 827, 829, 830, and 831, respectively; or (m) SEQ ID NOs:833, 826, 827, 835, 149, and 836, respectively; or (n) SEQ ID NOs:838, 839, 840, 842, 843, and 844, respectively; or (o) SEQ ID NOs:846, 847, 848, 850, 196, and 851, respectively; or (p) SEQ ID NOs:853, 854, 855, 857, 662, and 858, respectively; or (q) SEQ ID NOs:860, 861, 862, 864, 865, and 866, respectively; or (r) SEQ ID NOs:868, 378, 869, 871, 682, and 872, respectively; or (s) SEQ ID NOs:874, 875, 876, 878, 22, and 879, respectively; or (t) SEQ ID NOs:881, 882, 883, 885, 886, and 887, respectively; or (u) SEQ ID NOs:889, 890, 891, 523, 762, and 893, respectively; or (v) SEQ ID NOs:895, 896, 897, 899, 900, and 901, respectively; or (w) SEQ ID NOs:903, 904, 905, 907, 908, and 909, respectively; or (x) SEQ ID NOs:911, 912, 913, 915, 149, and 916, respectively; or (y) SEQ ID NOs:918, 919, 920, 922, 923, and 924, respectively; or (z) SEQ ID NOs:926, 927, 928, 930, 931, and 932, respectively.

(263) In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs:749, 756, 764, 771, 778, 784, 792, 799, 806, 813, 820, 825, 832, 837, 845, 852, 859, 867, 873, 880, 888, 894, 902, 910, 917, or 925. In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a light chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs:753, 760, 768, 775, 781, 788, 796, 803, 810, 817, 823, 828, 834, 841, 849, 856, 863, 870, 877, 884, 892, 898, 906, 914, 921, or 929. In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs:749, 756, 764, 771, 778, 784, 792, 799, 806, 813, 820, 825, 832, 837, 845, 852, 859, 867, 873, 880, 888, 894, 902, 910, 917, or 925, and comprises a light chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs:753, 760, 768, 775, 781, 788, 796, 803, 810, 817, 823, 828, 834, 841, 849, 856, 863, 870, 877, 884, 892, 898, 906, 914, 921, or 929.

(264) In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs:749, 756, 764, 771, 778, 784, 792, 799, 806, 813, 820, 825, 832, 837, 845, 852, 859, 867, 873, 880, 888, 894, 902, 910, 917, or 925 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that SEQ ID NO. In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a light chain variable region comprising an amino acid sequence that has at least 70% sequence identity (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to any one of SEQ ID NOs:753, 760, 768, 775, 781, 788, 796, 803, 810, 817, 823, 828, 834, 841, 849, 856, 863, 870, 877, 884, 892, 898, 906, 914, 921, or 929 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that SEQ ID NO.

(265) In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises: (a) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93% 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:749 or that has the sequence of SEQ ID NO:749, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:753 or that has the sequence of SEQ ID NO:753; or (b) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:756 or that has the sequence of SEQ ID NO:756, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:760 or that has the sequence of SEQ ID NO:760; or (c) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75% 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:764 or that has the sequence of SEQ ID NO:764, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:768 or that has the sequence of SEQ ID NO:768; or (d) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:771 or that has the sequence of SEQ ID NO:771, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:775 or that has the sequence of SEQ ID NO:775; or (e) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:778 or that has the sequence of SEQ ID NO:778, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:781 or that has the sequence of SEQ ID NO:781; or (f) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93% 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:784 or that has the sequence of SEQ ID NO:784, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:788 or that has the sequence of SEQ ID NO:788; or (g) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93% 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:792 or that has the sequence of SEQ ID NO:792, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:796 or that has the sequence of SEQ ID NO:796; or (h) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:799 or that has the sequence of SEQ ID NO:799, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:803 or that has the sequence of SEQ ID NO:803; or (i) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:806 or that has the sequence of SEQ ID NO:806, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:810 or that has the sequence of SEQ ID NO:810; or (j) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75% 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:813 or that has the sequence of SEQ ID NO:813, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:817 or that has the sequence of SEQ ID NO:817; or (k) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:820 or that has the sequence of SEQ ID NO:820, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92% 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:823 or that has the sequence of SEQ ID NO:823; or (l) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93% 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:825 or that has the sequence of SEQ ID NO:825, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:828 or that has the sequence of SEQ ID NO:828; or (m) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:832 or that has the sequence of SEQ ID NO:832, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92% 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:834 or that has the sequence of SEQ ID NO:834; or (n) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93% 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:837 or that has the sequence of SEQ ID NO:837, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:841 or that has the sequence of SEQ ID NO:841; or (o) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:845 or that has the sequence of SEQ ID NO:845, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:849 or that has the sequence of SEQ ID NO:849; or (p) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75% 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:852 or that has the sequence of SEQ ID NO:852, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:856 or that has the sequence of SEQ ID NO:856; or (q) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:859 or that has the sequence of SEQ ID NO:859, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:863 or that has the sequence of SEQ ID NO:863; or (r) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75% 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:867 or that has the sequence of SEQ ID NO:867, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:870 or that has the sequence of SEQ ID NO:870; or (s) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:873 or that has the sequence of SEQ ID NO:873, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92% 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:877 or that has the sequence of SEQ ID NO:877; or (t) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93% 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:880 or that has the sequence of SEQ ID NO:880, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:884 or that has the sequence of SEQ ID NO:884; or (u) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:888 or that has the sequence of SEQ ID NO:888, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:892 or that has the sequence of SEQ ID NO:892; or (v) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:894 or that has the sequence of SEQ ID NO:894, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:898 or that has the sequence of SEQ ID NO:898; or (w) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:902 or that has the sequence of SEQ ID NO:902, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:906 or that has the sequence of SEQ ID NO:906; or (x) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:910 or that has the sequence of SEQ ID NO:910, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:914 or that has the sequence of SEQ ID NO:914; or (y) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93% 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:917 or that has the sequence of SEQ ID NO:917, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:921 or that has the sequence of SEQ ID NO:921; or (z) a heavy chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93% 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:925 or that has the sequence of SEQ ID NO:925, and a light chain variable region comprising an amino acid sequence that has at least 90% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO:929 or that has the sequence of SEQ ID NO:929.
Clone PA01P2D09

(266) In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:860, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:861, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:862, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:864, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:865, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:866.

(267) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:859, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:860, 861, and 862, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:863, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:864, 865, and 866, respectively.

(268) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity) to SEQ ID NO:859, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:863. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:859 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:863.

(269) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:860, 861, 862, 864, 865, and 866, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:859 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:863).

(270) Clone PA01P2D04

(271) In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:121, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:826, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:827, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:829, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:830, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:831.

(272) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:825, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:121, 826, and 827, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:828, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:829, 830, and 831, respectively.

(273) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:825, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:828. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:825 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:828.

(274) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:121, 826, 827, 829, 830, and 831, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:825 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:828).

(275) Clone PA01P2B12

(276) In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:833, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:826, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:827, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:835, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:149, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:836.

(277) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:832, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:833, 826, and 827, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:834, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:835, 149, and 836, respectively.

(278) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:832, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:834. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:832 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:834.

(279) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:833, 826, 827, 835, 149, and 836, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:832 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:834).

(280) Clone PA01P2805

(281) In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:868, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:378, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:869, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:871, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:682, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:872.

(282) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:867, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:868, 378, and 869, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:870, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:871, 682, and 872, respectively.

(283) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:867, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:870. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:867 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:870.

(284) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:868, 378, 869, 871, 682, and 872, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:867 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:870).

(285) Clone PA01P2D10

(286) In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:853, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:854, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:855, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:857, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:662, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:858.

(287) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:852, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:853, 854, and 855, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:856, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:857, 662, and 858, respectively.

(288) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:852, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:856. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:852 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:856.

(289) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:853, 854, 855, 857, 662, and 858, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:852 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:856).

(290) Clone PA01P2E08

(291) In some embodiments, a monoclonal antibody that specifically binds to a milk allergen comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:800, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:801, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:802, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:804, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:110, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:805.

(292) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:799, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:800, 801, and 802, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:803, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:804, 110, and 805, respectively.

(293) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity) to SEQ ID NO:799, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:803. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:799 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:803

(294) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:800, 801, 802, 804, 110, and 805, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:799 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:803).

(295) Antibodies that Specifically Bind to Fungal Allergens

(296) In some embodiments, the monoclonal antibody or antigen-binding portion thereof specifically binds to a fungal allergen. In some embodiments, the monoclonal antibody specifically binds to a fungal allergen that is an Aspergillus fumigatus, Aspergillus niger, or Aspergillus nidulans allergen (e.g., an extract of Aspergillus fumigatus, Aspergillus niger, or Aspergillus nidulans). In some embodiments, the fungal allergen is Aspergillus fumigatus 1 (Asp f 1), e.g., a purified recombinant allergen Aspergillus fumigatus 1 (rAsp f 1).

(297) In some embodiments, the monoclonal antibody exhibits cross-reactivity with at least two fungal allergens. In some embodiments, the monoclonal antibody exhibits cross-reactivity with two or more Aspergillus allergens (e.g., two or more species of Aspergillus). In some embodiments, the monoclonal antibody exhibits cross-reactivity with two or more of the fungal allergens Aspergillus fumigatus, Aspergillus niger, and Aspergillus nidulans. In some embodiments, the monoclonal antibody specifically binds to at least one of the fungal allergens with a K.sub.D of less than 100 nM, less than 50 nM, less than 10 nM, less than 5 nM, less than 1 nM, less than 500 pM, less than 250 pM, less than 150 pM, less than 100 pM, less than 50 pM, less than 40 pM, less than 30 pM, less than 20 pM, less than about 10 pM, or less than 1 pM.

(298) Antibody Sequences

(299) In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen (e.g., that specifically binds to an Aspergillus allergen) comprises heavy chain CDRs and/or light chain CDRs that are disclosed in Table 1 below. In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen (e.g., an Aspergillus allergen) comprises a light chain variable region sequence and/or a heavy chain variable region sequence that is disclosed in Table 1 below. In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen (e.g., an Aspergillus allergen) comprises: a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a heavy chain variable region sequence disclosed in Table 1 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that heavy chain variable region sequence, and a light chain variable region comprising an amino acid sequence that has at least 70% sequence identity (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity to a light chain variable region sequence disclosed in Table 1 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that light chain variable region sequence.

(300) In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen (e.g., that specifically binds to an Aspergillus allergen) comprises a light chain sequence, or a portion thereof, and/or a heavy chain sequence, or a portion thereof, derived from any of the following antibodies described herein: Clone 1003320101D6, Clone 1003320105_D6, Clone 1003320107_C5, Clone 1003320107_F3, or Clone 1003320107_F8. The amino acid sequences of the CDR, light chain variable domain (VL), and heavy chain variable domain (VH) of Clone 1003320101_D6, Clone 1003320105_D6, Clone 1003320107_C5, Clone 1003320107_F3, and Clone 1003320107_F8 are set forth in Table 1 below.

(301) In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen comprises one or more (e.g., one, two, three, four, five, or all six) of: (a) a heavy chain CDR1 comprising the amino acid sequence of any one of SEQ ID NOs:710, 718, 726, 734, or 742; a heavy chain CDR2 comprising the amino acid sequence of any one of SEQ ID NOs:711, 719, 727, 735, or 743; a heavy chain CDR3 comprising the amino acid sequence of any one of SEQ ID NOs:712, 720, 728, 736, or 744; a light chain CDR1 comprising the amino acid sequence of any one of SEQ ID NOs:714, 722, 730, 738, or 746; a light chain CDR2 comprising the amino acid sequence of any one of SEQ ID NOs:715, 723, 731, 739, or 747; and a light chain CDR3 comprising the amino acid sequence of any one of SEQ ID NOs:716, 724, 732, 740, or 748.

(302) In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen comprises a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of: (a) SEQ ID NOs: 710, 711, 712, 714, 715, and 716, respectively; or (b) SEQ ID NOs:718, 719, 720, 722, 723, and 724, respectively; or (c) SEQ ID NOs:726, 7272, 728, 730, 731, and 732, respectively; or (d) SEQ ID NOs:734, 735, 736, 738, 739, and 740, respectively; or (e) SEQ ID NOs:742, 743, 744, 746, 747, and 748, respectively.

(303) In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen comprises a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85% 90%, 91%, 92% 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs:709, 717, 725, 733, or 741. In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen comprises a light chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs:713, 721, 729, 737, or 745. In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen comprises a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs:709, 717, 725, 733, or 741, and comprises a light chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs:713, 721, 729, 737, or 745.

(304) In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen comprises a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs:709, 717, 725, 733, or 741 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that SEQ ID NO. In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen comprises a light chain variable region comprising an amino acid sequence that has at least 70% sequence identity (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs:713, 721, 729, 737, or 745 and comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that SEQ ID NO. In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen comprises: (a) a heavy chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs:709, 717, 725, 733, or 741 and that comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that SEQ ID NO; and (b) a light chain variable region comprising an amino acid sequence that has at least 75% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs:713, 721, 729, 737, or 745 and that comprises a CDR1, a CDR2, and a CDR3 that is identical to the CDRs of that SEQ ID NO.
Clone 1003320101 D6

(305) In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen (e.g., Aspergillus allergen) comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:710, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:711, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:712, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:714, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:715, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:716. In some embodiments, the antibody specifically binds to the fungal allergen Aspergillus fumigatus.

(306) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:709, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:710, 711, and 712, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:713, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:714, 715, and 716, respectively.

(307) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:709, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:713. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:709 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:713.

(308) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:710, 711, 712, 714, 715, and 716, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:709 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:713).

(309) Clone 1003320105 D6

(310) In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen (e.g., Aspergillus allergen) comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:718, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:719, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:720, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:722, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:723, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:724. In some embodiments, the antibody specifically binds to the fungal allergen Aspergillus fumigatus.

(311) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:717, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:718, 719, and 720, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:721, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:722, 723, and 724, respectively.

(312) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity) to SEQ ID NO:717, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:721. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:717 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:721.

(313) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:718, 719, 720, 722, 723, and 724, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:717 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:721).

(314) Clone 1003320107 C5

(315) In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen (e.g., Aspergillus allergen) comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:726, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:727, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:728, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:730, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:731, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:732. In some embodiments, the antibody specifically binds to the fungal allergen Aspergillus fumigatus. In some embodiments, the antibody specifically binds to the fungal allergen Aspergillus niger. In some embodiments, the antibody specifically binds to the fungal allergen Aspergillus nidulans. In some embodiments, the antibody specifically binds to a recombinant Aspergillus antigen (e.g., rAsp f 1). In some embodiments, the antibody specifically binds cross-reactively to more than one of Aspergillus fumigatus, Aspergillus niger, Aspergillus nidulans, or a recombinant Aspergillus antigen (e.g., rAsp f 1).

(316) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:725, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:726, 727, and 728, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:729, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:730, 731, and 732, respectively.

(317) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:725, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:729. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:725 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:729.

(318) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:726, 727, 728, 730, 731, and 732, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:725 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:729).

(319) Clone 1003320107 F3

(320) In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen (e.g., Aspergillus allergen) comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:734, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:735, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:736, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:738, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:739, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:740. In some embodiments, the antibody specifically binds to a recombinant Aspergillus antigen (e.g., rAsp f 1).

(321) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:733, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:734, 735, and 736, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% sequence identity) to SEQ ID NO:737, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:738, 739, and 740, respectively.

(322) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:733, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:737. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:733 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:737.

(323) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:734, 735, 736, 738, 739, and 740, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:733 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:737).

(324) Clone 1003320107 F8

(325) In some embodiments, a monoclonal antibody that specifically binds to a fungal allergen (e.g., Aspergillus allergen) comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:742, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:743, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:744, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:746, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:747, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:748. In some embodiments, the antibody specifically binds to the fungal allergen Aspergillus fumigatus.

(326) In some embodiments, the antibody comprises: (a) a heavy chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:741, and that comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:74222, 743, and 744, respectively; and (b) a light chain variable region that comprises an amino acid sequence that has at least 70% sequence identity (e.g., at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:745, and that comprises the light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:746, 747, and 748, respectively.

(327) In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:741, and comprises a light chain variable region comprising an amino acid sequence that has at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:745. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:741 and comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:745.

(328) In some embodiments, the antibody is an antibody that competes for binding with an antibody as described herein (e.g., an antibody comprising a heavy chain CDR1-3 and a light chain CDR1-3 comprising the amino acid sequences of SEQ ID NOs:742, 743, 744, 746, 747, and 748, respectively, or an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:741 and further comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:745).

(329) Antigen-Binding Fragments

(330) In some embodiments, an antibody as disclosed herein (e.g., an antibody as disclosed in Section IV that binds to a food allergen, plant allergen, fungal allergen, animal allergen, dust mite allergen, drug allergen, cosmetic allergen, or latex allergen) is an antigen-binding portion (also referred to herein as an antigen-binding fragment). Examples of antigen-binding fragments include, but are not limited to, a Fab, a F(ab).sub.2, a Fv, a scFv, a bivalent scFv, a single domain antibody, or a diabody. Various techniques have been developed for the production of antigen-binding fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., J. Biochem. Biophys. Meth., 24:107-117 (1992); and Brennan et al., Science, 229:81 (1985)). However, these fragments can now be produced directly using recombinant host cells. For example, antigen-binding fragments can be isolated from antibody phage libraries. Alternatively, Fab-SH fragments can be directly recovered from E. coli cells and chemically coupled to form F(ab)2 fragments (see, e.g., Carter et al., BioTechnology, 10:163-167 (1992)). According to another approach, F(ab).sub.2 fragments can be isolated directly from recombinant host cell culture. Other techniques for the production of antigen-binding fragments are known in the art.

(331) Antibody Conjugates

(332) In some embodiments, the antibody or antigen-binding fragment can be conjugated to another molecule, e.g., polyethylene glycol (PEGylation) or serum albumin, to provide an extended half-life in vivo. Examples of PEGylation of antigen-binding fragments are provided in Knight et al. Platelets 15:409, 2004 (for abciximab); Pedley et al., Br. J. Cancer 70:1126, 1994 (for an anti-CEA antibody); Chapman et al., Nature Biotech. 17:780, 1999; and Humphreys, et al., Protein Eng. Des. 20: 227, 2007).

(333) In some embodiments, antibody-drug conjugates comprising a monoclonal antibody or antigen-binding fragment as described herein are provided. In some embodiments, a monoclonal antibody or antigen-binding fragment (e.g., an antibody or antigen-binding fragment that specifically binds to a food allergen or a fungal allergen) is covalently linked to a cytotoxic drug. In some embodiments, the antibody or antigen-binding fragment is an antibody that specifically binds to a fungal allergen and the drug is an anti-fungal drug. Suitable anti-fungal drugs include, but are not limited to, Amphotericin B, azole anti-fungals (e.g., ketoconazole, fluconazole, isavuconazole, itraconazole, posaconazole, or voriconazole), echinocandins (e.g., anidulafungin, caspofungin, or micafungin), and flucytosine. Methods for making antibody-drug conjugates are described, e.g., in Chudasama et al., Nature Chemistry, 2016, 8:114-119; WO 2013/068874; and U.S. Pat. No. 8,535,678.

(334) Synthetic Antibodies, Antibody Compositions, and Antibody-Producing Cells

(335) Certain antibodies described herein are derived from B cells isolated from human subjects who have been exposed to allergen(s). In certain embodiments, antibodies, antibody compositions, and cells of the invention are distinguishable from naturally occurring antibodies, compositions and cells in one or more respects. The distinguishable antibodies, compositions, and cells may be referred to as synthetic, or may be identified by the proviso that the antibody or composition is not naturally occurring or affirmatively as non-naturally occurring. As used herein the terms corresponding antibody, and corresponding to describes the relationship between (1) an antibody characterized by six specific CDR sequences and produced by immune cells of a study subject described in the Examples below and (2) a synthetic antibody comprising the same six CDR sequences.

(336) Synthetic Antibodies

(337) Synthetic antibodies of the invention may differ in structure from naturally occurring antibodies with the same CDRs. That is, synthetic antibodies identified by specified CDRs may be structurally different from antibodies comprising the specified CDRs that are produced by cells of the study subject described in the Examples below. Possible differences include:

(338) Variable Region Sequences that Differ Corresponding Naturally Occurring Antibodies

(339) In one approach, an antibody heavy chain comprises the CDRs of a clone described herein (e.g., PA13P1E10) with the proviso that the antibody heavy chain does not comprise the heavy chain variable region sequence associated with the clone described herein. For illustration, in one embodiment an antibody that comprises the CDRs of Clone PA13P1E10 does not have a heavy chain variable region that comprises SEQ ID NO:9. In another approach, an antibody light chain comprises the CDRs of a clone described herein (e.g., PA13P1E10) with the proviso that the antibody light chain does not comprise the light chain variable region sequence associated with the clone described herein. For illustration, in one embodiment an antibody that comprises the CDRs of Clone PA13P1E10 does not have a light chain variable region that comprises SEQ ID NO:13). In one approach both the heavy chain and the light chain variable region of an antibody of the invention have an amino acid sequence other than the sequence disclosed herein.

(340) Lambda and Kappa Light Chains

(341) In some embodiments the synthetic antibody comprises lambda type light chains. In some embodiments the synthetic antibody comprises kappa type light chains.

(342) Isotypes

(343) In some embodiments the synthetic antibody with specified CDRs is an isotype other the isotype(s) found associated with the study subject from which B cells with the specified CDRs was derived. In some embodiments the antibody disclosed herein is an isotype other than IgG1. In some embodiments the antibody disclosed herein is an isotype other than IgG2. In some embodiments the antibody disclosed herein is an isotype other than IgG3. In some embodiments the antibody disclosed herein is an isotype other than IgG4. In some embodiments the antibody disclosed herein is an isotype other than IgM. In some embodiments the antibody disclosed herein is an isotype other than IgA.

(344) Allotypes

(345) In some embodiments the synthetic antibody with specified CDRs is an allotype other the allotype(s) found associated with the study subject from which B cells with the specified CDRs was derived. In some embodiments, the synthetic antibody of the invention comprises an allotype selected from those listed in Table 2, below, which is different from an allotype of antibodies from the corresponding study subject. In some embodiments the synthetic antibody of the invention comprises any individual allotype selected from those listed in Table 2, with the proviso that the allotype differs from the corresponding allotype of antibodies from a study subject.

(346) TABLE-US-00002 TABLE 2 Human immunoglobulin allotypes Heavy chains Light Isotype/type IgG1 IgG2 IgG3 IgA chains Allotypes G1m G2m G3m A2m Km 1 (a) 23 (n) 21 (g1) 1 1 2 (x) 28 (g5) 2 2 3 (f) 11 (b0) 3 17 (z) 5 (b1) 13 (b3) 14 (b4) 10 (b5) 15 (s) 16 (t) 6 (c3) 24 (c5) 26 (u) 27 (v) NB: Alphabetical notation given within brackets. From: Jefferis and Marie-Paule Lefranc, 2009, Human immunoglobulin allotypes: Possible implications for immunogenicity mAbs 1(4): 332-338, incorporated herein by reference.
Constant Domain Variants

(347) Synthetic antibodies of the invention may comprise variations in heavy chain constant regions to change the properties of the synthetic antibody relative to the corresponding naturally occurring antibody. Exemplary changes include mutations to modulate antibody effector function (e.g., complement-based effector function or Fc?R-based effector function), alter half-like, modulate coengagement of antigen and Fc?Rs, introduce or remove glycosylation motifs (glyco-engineering). See Fonseca et al., 2018, Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review Int J Biol Macromol. 19:306-311; Wang et al., 2018, IgG Fc engineering to modulate antibody effector functions Protein Cell 2018, 9(1):63-73; Schlothauer, 2016, Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions, Protein Engineering, Design and Selection 29(10):457-466; Tam et al., 2017, Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality Antibodies 6, 12, each incorporated herein by reference for all purposes.

(348) Synthetic Antibody Compositions

(349) Synthetic antibody compositions of the invention may differ from naturally occurring compositions in at least one or more of the following respects: (i) composition comprises antibodies that are purified, i.e., separated from tissue or cellular material with which they are associated in the human body, and optionally in an manufactured excipient or medium; and/or (ii) antibody compositions of the invention contain a single species of antibody (are monoclonal) such that all antibodies in the composition have the same structure and specificity;

(350) Synthetic Antibody-Producing Cells

(351) Antibodies described herein may be produced by recombinant expression in a human or non-human cell. Synthetic antibody-producing cells include non-human cells expressing heavy chains, light chains, or both heavy and light chains; human cells that are not immune cells heavy chains, light chains, or both heavy and light chains; and human B cells that produce heavy chains or light chains, but not both heavy and light chains. Synthetic antibodies of the invention may be are heterologously expressed, in vitro or in vivo, in cells other than human B cells, such as non-human cells and human cells other than B cells, optionally other than immune cells, and optionally in cells other than cells in a B cell lineage.

V. Methods of Use

(352) In another aspect, the present disclosure provides therapeutic methods for treating a human subject with one or more of the allergen-specific monoclonal antibodies or antigen-binding portions thereof as disclosed herein. In some embodiments, methods of treating an allergy are provided. In some embodiments, methods of reducing one or more allergy symptoms in a subject are provided. In some embodiments, the allergen-specific monoclonal antibodies disclosed herein are used therapeutically as blocking antibodies, which is often referred to as passive immunotherapy. Without being bound to a particular theory, it is hypothesized that the allergen-specific monoclonal antibodies disclosed herein block allergen binding to IgE or outcompete endogenous IgE for allergen binding, which in turns prevents or reduces initiation of the allergic cascade. Without intending to be bound by a particular mechanism in some embodiments antibodies of the invention provide therapeutic benefit by binding inhibitory receptors on mast cells and/or basophils.

(353) In some embodiments, the method comprises administering to the subject a therapeutically effective amount of one or more allergen-specific monoclonal antibodies as disclosed herein (e.g., one or more allergen-specific monoclonal antibodies as disclosed in Section IV above). In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising one or more allergen-specific monoclonal antibodies as disclosed herein (e.g., a pharmaceutical composition as disclosed in Section VI below).

(354) In some embodiments, the method comprises administering to the subject a therapeutically effective amount of an allergen-specific monoclonal antibody that is a human IgG isotype, such as a human IgG4 isotype, or antigen-binding portion thereof comprising at least a portion of a human IgG or IgG4 isotype constant region sequence.

(355) In some embodiments, the method comprises administering to the subject a therapeutically effective amount of an allergen-specific monoclonal antibody or antigen-binding portion thereof. In some embodiments, the method comprises administering to the subject two or more allergen-specific monoclonal antibodies (e.g., in a pharmaceutical composition comprising the two or more allergen-specific monoclonal antibodies). In some embodiments, the method comprises administering two or more antibodies that specifically bind to the same allergen. In some embodiments, the method comprises administering two or more antibodies that specifically bind to different epitopes of the same allergen. In some embodiments, the method comprises administering two or more antibodies that specifically bind to two or more different allergens.

(356) In some embodiments, the therapeutic antibody is an antibody that comprises CDR sequences, a heavy chain variable region, and/or a light chain variable region as described herein (e.g., as disclosed in Table 1 below) and further comprises a native or modified IgM, IgD, IgG3, IgG1, IgA1, IgG2, IgG4, or IgA2 heavy chain constant region.

(357) In some embodiments, the therapeutic antibody is conjugated to a drug, e.g., as described in Section IV above.

(358) In some embodiments, the human subject to be treated is an adult. In some embodiments, the human subject is a juvenile.

(359) In some embodiments, a human subject to be treated has an allergy to a food allergen, a plant allergen, a fungal allergen, an animal allergen, a dust mite allergen, a drug allergen, a cosmetic allergen, or a latex allergen. In some embodiments, the human subject has an allergy to a food allergen. In some embodiments, the food allergen is a milk allergen, an egg allergen, a nut allergen, a fish allergen, a shellfish allergen, a soy allergen, a legume allergen, a seed allergen, or a wheat allergen. In some embodiments, the food allergen is a peanut allergen. In some embodiments, the food allergen is a milk allergen. In some embodiments, the food allergen is an egg allergen. In some embodiments, the human subject has an allergy to a plant allergen or a fungal allergen (e.g., an Aspergillus allergen). In some embodiments, the allergen is a pollen allergen (e.g., tree pollen, grass pollen, or weed pollen) or a mold allergen. In some embodiments, the human subject has an allergy to an animal allergen. In some embodiments, the allergen is a dander allergen or an insect sting.

(360) In some embodiments, the human subject to be treated has allergies to two or more allergens, e.g., to two or more of a food allergen, a plant allergen, a fungal allergen, an animal allergen, a dust mite allergen, a drug allergen, a cosmetic allergen, or a latex allergen. In some embodiments, the human subject has allergies to 2, 3, 4, 5, 6, 7, 8, 9, 10 or more allergens. In some embodiments, the human subject has allergies to two or more different types of antigens (allergens) in a class of allergen, e.g., allergies to two or more different food allergens (e.g., allergies to two or more different peanut antigens, or allergies to a peanut allergen and a non-peanut allergen such as an egg or milk allergen). In some embodiments, the human subject has allergies to two more different classes of allergens (e.g., allergies to one or more food allergens and to one or more plant allergens). In some embodiments, a human subject has an allergy to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more allergens in the same class of allergen but does not have any known allergies to allergens in other classes of allergens. For example, in some embodiments, a human subject has an allergy to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more food allergens but does not have any known allergies to non-food allergens. In some embodiments, a human subject has an allergy to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fungal allergens but does not have any known allergies to non-fungal allergens.

(361) In some embodiments, the therapeutic methods disclosed herein reduce one or more symptoms of the allergy in the subject. It will be appreciated by a person of ordinary skill in the art that the symptom(s) associated with an allergic reaction can vary depending upon the type of allergen that induces the allergic reaction. Examples of allergic reaction symptoms include, but are not limited to, hives, rashes, eczema flare, redness of skin, itchy mouth, itchy eyes, nausea, vomiting, diarrhea, stomach pain, nasal congestion, runny nose, stuffy nose, sneezing, cough, fatigue, sore throat, swelling of the lips, tongue, or throat, headaches, trouble swallowing, shortness of breath, wheezing, drop in blood pressure, or weak pulse. In some embodiments, the therapeutic methods disclosed herein reduce the severity of one or more symptoms of the allergy. In some embodiments of the therapeutic methods described herein, the allergy symptoms in the subject comprise one or more of runny nose, skin hives, skin redness, skin swelling, itching or tingling in or around the mouth and/or throat, difficulty swallowing, watery eyes, diarrhea, stomach cramps, nausea, vomiting, tightening of the throat, shortness of breath or wheezing, shortness of breath, and anaphylaxis. In some embodiments, the therapeutic methods disclosed herein reduce the length of duration of one or more symptoms of the allergy.

(362) In some embodiments, the therapeutic methods disclosed herein reduce one or more symptoms of allergic reaction to an allergen such as a food allergen (e.g., a peanut allergen), such as but not limited to hives, rashes, eczema flare, redness of skin, itchy mouth, nausea, vomiting, diarrhea, stomach pain, nasal congestion, runny nose, sneezing, dry cough, swelling of the lips, tongue, or throat, trouble swallowing, shortness of breath, wheezing, drop in blood pressure, or weak pulse. In some embodiments, administration of one or more allergen-specific monoclonal antibodies as disclosed herein reduces the severity of one or more of the symptoms and/or reduces the length of duration of one or more of the symptoms.

(363) In some embodiments, an allergen-specific monoclonal antibody as disclosed herein is administered to a human subject at a therapeutically effective amount or dose. In some embodiments, a daily dose range of about 0.01 mg/kg to about 500 mg/kg, or about 0.1 mg/kg to about 200 mg/kg, or about 1 mg/kg to about 100 mg/kg, or about 10 mg/kg to about 50 mg/kg, can be used. The dosages, however, may be varied according to several factors, including the chosen route of administration, the formulation of the composition, patient response, the severity of the condition, the subject's weight, and the judgment of the prescribing physician. The dosage can be increased or decreased over time, as required by an individual patient. In certain instances, a patient initially is given a low dose, which is then increased to an efficacious dosage tolerable to the patient. Determination of an effective amount is well within the capability of those skilled in the art.

(364) The route of administration of an antibody or composition comprising an antibody as described herein can be dermal or transdermal, inhalational, intestinal, intravenous, intramuscular, intraperitoneal, intrathecal, intralesional, intrabronchial, nasal, ocular or otic delivery, oral, rectal, subcutaneous, topical, transmucosal, or any other methods known in the art. In some embodiments, the antibody or composition is administered by infusion (e.g., intravenously) or by injection (e.g., subcutaneously). In some embodiments, the route of administration of an antibody or composition comprising an antibody in any of the methods described herein is subcutaneous, intravenous, or intranasal.

(365) In some embodiments, administration of a single dose of an antibody or composition comprising an antibody as described herein is effective to treat the allergy or reduce one or more symptoms of the allergy. In some embodiments, multiple doses of the antibody or composition are administered. In some embodiments, a second dose is administered at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days or longer, e.g., at least 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, or longer, after administration of the first dose. In some embodiments, an antibody or composition comprising an antibody as described herein is administered to a subject about every 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 week(s). In some embodiments, an antibody or composition comprising an antibody as described herein is administered to a subject over an extended period of time, e.g., for at least 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350 days or longer.

(366) In some embodiments, in any of the methods described herein, the subject is further administered an additional agent, e.g., an antihistamine, an epinephrine, a decongestant, a bronchial dilator, or a corticosteroid. In some embodiments, the monoclonal antibody and the additional agent are administered substantially simultaneously, i.e., in the same pharmaceutical composition or in separation pharmaceutical compositions that are administered at substantially the same time (e.g., administered within seconds of each other). In some embodiments, the monoclonal antibody and the additional agent are administered separately. In some embodiments, the monoclonal antibody is administered first, followed by administering of the additional agent. In some embodiments, the additional agent is administered first, followed by administering of the monoclonal antibody.

(367) In some embodiments, in any of the methods described herein, the methods can further comprise a step of assessing the reduction of the allergy symptoms (e.g., allergy symptoms related to a peanut allergy, a tree nut allergy, a milk allergy, or a fungal allergy) in the subject. In some embodiments, the reduction of the allergy symptoms can be measured by a Total Nasal Symptom Score (TNSS), which is made from patient assessment of four symptoms graded on a 0 (none) to 3 (severe) scale for congestion, itching, and rhinorrhea, and 0 (none) to 3 (5 or more sneezes) for sneezing. Each of the four symptoms is evaluated using the following scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. The TNSS has a possible score of 0-12. In other embodiments, the reduction of the allergy symptoms can be measured by a Visual Analog Scale (VAS) nasal symptoms score, which is often used to classify allergy burden into mild, moderate, and severe. A VAS nasal symptoms score ranging from 0 (no nasal symptoms) to 100 (maximal nasal symptoms) can be used to assess the severity of combined nasal symptoms. In other embodiments, the reduction of the allergy symptoms can be measured by peak nasal inspiratory flow (PNIF), which uses a nasal spirometer to measure the nasal airflow (measured as 1/min) in a patient. In yet other embodiments, the reduction of the allergy symptoms can be measured by an allergen skin test, such as a skin prick test (SPT), which uses the presence and degree of cutaneous reactivity as a marker for sensitization within target organs, such as eyes, nose, lung, gut and skin. When relevant allergens (e.g., a peanut allergen, a tree nut allergen, a milk allergen, or a fungal allergen) are introduced into the skin, allergic reactions on the skin produce a wheal and flare response that can be quantitated, for example, using the diameter of the wheal. In yet other embodiments, the reduction of the allergy symptoms can be measured by basophil activation test, which utilizes flow cytometry to quantify the expression of markers of activation on the surface of basophils following allergen stimulation. In yet other embodiments, the reduction of the allergy symptoms can be measured by oral food challenge, which involves administering escalating doses of an allergen to an allergic individual under the supervision of a trained allergist or immunologist. An oral food challenge may be conducted according to an open, single-blind, or double-blind format, with the gold-standard being both double-blind and placebo-controlled.

(368) In yet another aspect, the present disclosure provides diagnostic and detection methods using one or more of the allergen-specific monoclonal antibodies or antigen-binding portions thereof as disclosed herein. In some embodiments, an allergen-specific monoclonal antibody or antigen-binding portion thereof is used to detect whether a sample from a subject has allergic reactivity to an allergen (e.g., a food allergen such as a peanut allergen, tree nut allergen, or milk allergen), a plant allergen, a fungal allergen, an animal allergen, a dust mite allergen, a drug allergen, a cosmetic allergen, or a latex allergen. In some embodiments, the allergen-specific monoclonal antibody or antigen-binding portion thereof is used to detect whether a sample from a subject has allergic reactivity to a specific epitope of the allergen (e.g., using an antibody that is known to bind to a specific epitope of the allergen). In some embodiments, the method comprises contacting a sample from the subject (e.g., a blood or plasma sample) with an allergen-specific monoclonal antibody or antigen-binding portion as disclosed herein.

VI. Compositions and Kits

(369) In another aspect, compositions and kits comprising one or more allergen-specific monoclonal antibodies or antigen-binding portions thereof that are generated from human B cells are provided.

(370) Pharmaceutical Compositions

(371) In some embodiments, pharmaceutical compositions comprising one or more allergen-specific monoclonal antibodies or antigen-binding portions thereof are provided. In some embodiments, the pharmaceutical composition comprises a monoclonal antibody as described herein, e.g., as disclosed in Section IV above. In some embodiments, the pharmaceutical composition is for use in a method of reducing one or more allergy symptoms in a subject (e.g., allergy symptoms due to an allergy to a food allergen, a plant allergen, a fungal allergen, an animal allergen, a dust mite allergen, a drug allergen, a cosmetic allergen, or a latex allergen). In some embodiments, the pharmaceutical composition is for use in a method of reducing one or more allergy symptoms in a subject having a food allergy, e.g., a peanut allergy. In some embodiments, the pharmaceutical composition is for use in a method of reducing one or more allergy symptoms in a subject having an allergy to two more allergens (e.g., two or more food allergens, e.g., peanut allergy and tree nut allergy). In some embodiments, the pharmaceutical composition is for use in a method of reducing one or more allergy symptoms in a subject having a fungal allergy.

(372) In some embodiments, the pharmaceutical composition comprises two or more monoclonal antibodies or antigen-binding portions thereof as described herein (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more antibodies or antigen-binding portions thereof). In some embodiments, the composition comprises two or more monoclonal antibodies that specifically bind to the same allergen. In some embodiments, the composition comprises two or more monoclonal antibodies that specifically bind to different epitopes of the same allergen. In some embodiments, the composition comprises two or more monoclonal antibodies that specifically bind to two or more different allergens. It will also be appreciated by a person of ordinary skill in the art that for a particular type or class of allergen, e.g., a type of food allergen such as a peanut allergen, there can be more than one substance (e.g., peptide or protein) within that type or class of allergen that induces an allergic response. In some embodiments, a composition comprises two or more monoclonal antibodies that specifically bind to different allergens within a particular type or class of allergen, e.g., two or more different peptides or proteins that are allergens of the same type or class (e.g., two or more different proteins that are peanut allergens). In some embodiments, the composition comprises two or more monoclonal antibodies that specifically bind to the same first allergen and further comprises one or more monoclonal antibodies that specifically bind to a second allergen.

(373) Guidance for preparing formulations can be found in any number of handbooks for pharmaceutical preparation and formulation that are known to those of skill in the art. See, e.g., Remington: The Science and Practice of Pharmacy, 21st Edition, Philadelphia, PA. Lippincott Williams & Wilkins, 2005.

(374) In some embodiments, the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers, adjuvants, and/or vehicles appropriate for the particular route of administration for which the composition is to be employed. In some embodiments, the carrier, adjuvant, and/or vehicle is suitable for intravenous, intramuscular, oral, intraperitoneal, transdermal, topical, or subcutaneous administration. In some embodiments, the pharmaceutical composition is formulated for intravenous or subcutaneous administration. Methods of formulating antibodies for injection or infusion (e.g., subcutaneous or intramuscular injection or by intravenous infusion) are also described in the art. See, e.g., US 2013/0209465,

(375) Pharmaceutically acceptable carriers are well-known in the art. See, e.g., Handbook of Pharmaceutical Excipients (5.sup.th ed., Ed. Rowe et al., Pharmaceutical Press, Washington, D.C.). Examples of pharmaceutically acceptable carriers include, but are not limited to, aqueous solutions, e.g., water or physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.

(376) Typically, a pharmaceutical composition for use in in vivo administration is sterile. Sterilization can be accomplished according to methods known in the art, e.g., heat sterilization, steam sterilization, sterile filtration, or irradiation.

(377) Dosages and desired drug concentration of pharmaceutical compositions of the disclosure may vary depending on the particular use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of one in the art. Suitable dosages are also described in Section V above.

(378) In some embodiments, an antibody formulation comprising one or more allergen-specific monoclonal antibodies or antigen-binding portions thereof as disclosed herein are provided. In some embodiments, the antibody formulation comprises an antibody or antigen-binding portion thereof; and a buffer.

(379) In some embodiments, the buffer is an acetate, citrate, histidine, succinate, phosphate, or hydroxymethylaminomethane buffer. In some embodiments, the antibody formulation further comprises one or more additional excipients such as a salt, a surfactant, polyol/disaccharide/polysaccharides, amino acids, and/or an antioxidant. In some embodiments, the antibody formulation comprises a surfactant such as polysorbate 80 (Tween 80), polysorbate 20 (Tween 20), or poloxamer 188. In some embodiments, the antibody formulation comprises a polyol/disaccharide/polysaccharide such as mannitol, sorbitol, sucrose, trehalose, or dextran 40. In some embodiments, the antibody formulation comprises a salt such as sodium chloride. In some embodiments, the antibody formulation comprises an amino acid such as glycine or arginine. In some embodiments, the antibody formulation comprises an antioxidant such as ascorbic acid, methionine, or ethylenediaminetetraacetic acid (EDTA). In some embodiments, the antibody formulation is a lyophilized formulation. In some embodiments, the antibody formulation is a liquid formulation.

(380) Kits

(381) In some embodiments, kits comprising one or more allergen-specific monoclonal antibodies or antigen-binding portions thereof as disclosed herein, or a pharmaceutical composition comprising one or more allergen-specific monoclonal antibodies or antigen-binding portions thereof as disclosed herein, are provided. In some embodiments, the kit comprises a monoclonal antibody as described herein, e.g., as disclosed in Section IV above. In some embodiments, the kit comprises two or more monoclonal antibodies or antigen-binding portions thereof (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more antibodies or antigen-binding portions thereof) as described herein. In some embodiments, the kit is for use in a method of reducing one or more allergy symptoms in a subject (e.g., allergy symptoms due to an allergy to a food allergen, a plant allergen, a fungal allergen, an animal allergen, a dust mite allergen, a drug allergen, a cosmetic allergen, or a latex allergen). In some embodiments, the kit is for use in a method of reducing one or more allergy symptoms in a subject having a food allergy, e.g., a peanut allergy. In some embodiments, the kit is for use in a method of reducing one or more allergy symptoms in a subject having a fungal allergy. In some embodiments, the kit is for use in a method of reducing one or more allergy symptoms in a subject having an allergy to two or more allergens (e.g., two or more food allergens, e.g., a peanut allergen and a tree nut allergen).

(382) In some embodiments, the kits can further comprise instructional materials containing directions (i.e., protocols) for the practice of the methods of this invention (e.g., instructions for using the kit for treating an allergy). While the instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. Such media may include addresses to internet sites that provide such instructional materials.

VII. EXAMPLES

(383) The following examples are offered to illustrate, but not to limit, the claimed invention.

Example 1Single Cell Transcriptomic Analysis of Human IgE Producing Cells and Their Antibodies from Allergic Individuals

Abstract

(384) IgE antibodies provide immunity from helminth infections, but also can cause life-threatening allergic reactions. Despite their importance to human health, these antibodies and the cells that produce them remain enigmatic due to their scarcity in humans; much of our knowledge of their properties is derived from model organisms. Herein the isolation of IgE producing B cells from the blood of individuals with food allergies is described, followed by a detailed study of their properties by single cell RNA sequencing (scRNAseq). It has been discovered that IgE B cells are deficient in membrane immunoglobulin expression and that the IgE plasmablast state is more immature than that of other antibody producing cells. Through recombinant expression of monoclonal antibodies derived from single cells, cross-reactive IgE antibodies specific for both major peanut allergens Ara h 2 and Ara h 3 were discovered and characterized; these are among the highest affinity native human antibodies discovered to date. Surprisingly, an example of convergent evolution in unrelated individuals who independently evolved nearly identical antibodies to peanut allergens was found. Finally, it was discovered that splicing within B cells of all isotypes reveals polarized germline transcription of the IgE, but not IgG4, isotype as well as several examples of biallelic expression of germline transcripts. These results offer insights into IgE B cell transcriptomics, clonality and regulation, provide a striking example of adaptive immune convergence, and offer an approach for accelerating mechanistic disease understanding by characterizing a rare B cell population underlying IgE-mediated disease at single cell resolution.

Introduction

(385) The IgE antibody class is the least abundant of all isotypes in humans and plays an important role in host defense against parasitic worm infections (1), but it can also become misdirected towards otherwise harmless antigens. Food allergies are one example of this misdirection, where symptoms ranging from urticaria to potentially fatal anaphylaxis result from the degranulation of mast cells and basophils induced by the recognition of allergic food proteins by surface-bound IgE antibodies. Despite this central role in immunity and allergic disease, human IgE antibodies remain poorly characterized due to their scarcity (2). Bulk epitope mapping experiments have revealed that IgE antibodies are polyclonal and epitopes are heterogeneous (3); however, individuals with the same allergy tend to recognize a core set of one or a few allergenic proteins (4). Recent studies applying bulk fluorescence activated cell sorting (FACS) immunophenotyping (5, 6) and immune repertoire deep sequencing (7) have inferred IgE B cell origins, while studies performing peanut allergen specific single cell sorting (8, 9) have described clonal families to which IgE antibodies belong. However, none have successfully isolated single IgE producing cells or the paired heavy and light chain sequences that comprise individual IgE antibodies, leaving unanswered questions as to the functional properties of such antibodies, transcriptional programs of these cells, and the degree to which any of these features are shared across individuals. Similarly, there is a lack of knowledge, but growing interest, surrounding the IgG4 isotype due to its potential role in mediating the reduced clinical allergen reactivity that accompanies immunotherapy and early allergen exposure through antigen blocking (10). Here we report the first successful isolation and transcriptomic characterization of single IgE and IgG4 producing B cells from humans. We combined single cell RNA sequencing (scRNA-seq) with functional antibody assays to elucidate mechanisms underlying the regulation of IgE and to discover high affinity, cross-reactive peanut specific antibodies in unrelated individuals.

(386) Characterization of Single B Cells from Peripheral Blood

(387) We performed scRNA-seq on B cells isolated from the peripheral blood of food allergic individuals, which enabled us to characterize each cell's gene expression, splice variants, and heavy and light chain antibody sequences (FIG. 6). Fresh peripheral blood from six peanut allergic individuals was first separated into plasma and cellular fractions; plasma was stored and later used for allergen-specific IgE concentration measurements (FIGS. 7A-7C), while the cellular fraction was enriched for B cells prior to FACS (see Materials and Methods). CD19+ B cells of all isotypes were sorted exclusively based on immunoglobulin surface expression, but with an emphasis on maximizing IgE B cell capture (FIGS. 8A-8C). Because cellular identity was determined from scRNA-seq rather than a complex, many-color gating scheme, we were able to sort and capture cells with high sensitivity. This approach makes the prospect of IgE B cell capture accessible for many laboratories without stringent requirements on FACS gate purity.

(388) Single cells were sorted into 96 well plates, processed using a modified version of the SmartSeq2 protocol (11) and sequenced on an Illumina NextSeq with 2?150 bp reads to an average depth of 1-2 million reads per cell (FIGS. 9A-9G). Sequencing reads were independently aligned and assembled to produce a gene expression count table and reconstruct antibody heavy and light chains, respectively (FIG. 6, Materials and Methods). Using STAR (12) for alignment also facilitated the assessment of splicing within single cells. Cells were stringently filtered to remove those of low quality, putative basophils, and those lacking a single productive heavy and light chain, yielding a total of 973 cells for further analysis (Materials and Methods). The isotype identity of each cell was determined by its productive heavy chain assembly, which avoids misclassification of isotype based on FACS immunoglobulin surface staining (FIG. 8B), a problem which is especially pervasive for IgE B cells due to CD23, the low-affinity IgE receptor that captures IgE on the surface of non-IgE B cells (6).

(389) Principal component analysis of normalized gene expression following batch effect correction (FIGS. 9A-9G and Materials and Methods) separated cells into two distinct clusters (FIG. 2A) identifiable as plasmablasts (PBs) and naive/memory B cells. PBs expressed the triad of transcription factors BLIMP1 (PRDM1), XBP1, and IRF4 that drive plasma cell differentiation (13), as well as genes associated with antibody secretion, such as the J chain, while naive and memory cells expressed the canonical mature B cell surface marker CD20 (MS4A1), as well as transcription factor IRF8, which antagonizes the PB fate and instead promotes a germinal center response (14). Additional data corroborated this cell subtype assignment; PBs had greater FACS forward and side scatter in agreement with their larger size and increased granularity, PB cDNA concentrations were higher following preamplification, and PBs expressed more antibody heavy and light chain transcripts (FIGS. 10A-10D).

(390) We assessed isotype distribution within each B cell subtype and found that, in stark contrast to other isotypes, IgE B cells overwhelmingly belonged to the PB subtype (FIG. 2B-2C). This discovery is consistent with observations of preferential differentiation of IgE B cells into PBs in mice (15). Subtype proportions for other isotypes followed expectations: IgM B cells, which are primarily naive, had the lowest PB percentages, while IgA B cells had the highest in accordance with their secretory role in maintaining mucosal homeostasis. Interestingly, we found that the number of circulating IgE B cells for each individual correlated with total plasma IgE levels (FIG. 7C); a similar phenomenon has been noted in cases of hyper-IgE syndrome (16).

(391) By clustering antibodies into clonal families (CFs) we were able to observe elements of classical germinal center phenomenon such as somatic hypermutation, class switching, and fate determination in our data. Antibody heavy chain sequences were first divided by V and J genes and were clustered if their amino acid CDR3 sequences shared at least 75% similarity. Only 49 heavy chains formed CFs with multiple members, although this was not surprising given the vast diversity of potential immunoglobulin gene rearrangements (FIG. 2D). We found that in contrast to other isotypes, IgE and IgG4 were surprisingly clonal as over 20% of IgE and IgG4 antibodies belonged to such multi-member CFs (FIG. 2E). Multi-member CFs were diverse; they contained between two and six sequences, had variable isotype membership (node pattern), and had a comprehensive distribution of mutational frequency (node size). CFs were specific to an individual (node shape), with the exception of one CF (CF1) that contained six heavily mutated IgE PB sequences: three each from individuals PA12 and PA13, as discussed in depth later. Four CFs illustrated the two possible terminal differentiation pathways of germinal centers in that they contained both PBs and memory B cells. Other CFs contained cells belonging to multiple isotypes, with one of particular interest (CF3), discussed later, that contained an IgE PB and an IgG4 PB. Validating the premise of CFs as a collection of cells with similar origin, we found light chain CDR3 sequences were often comparable within families (FIG. 2G).

(392) IgE antibodies varied widely in gene usage, CDR3 lengths, and mutation frequency (FIGS. 3A-3C). There was moderate correlation between the mutation frequency of heavy and light chains within single cells (FIG. 3C), with evidence of selection via an enrichment of replacement mutations relative to silent mutations in the heavy chain CDR1 and CDR2 that was absent in framework (FWR) regions. Light chains were similarly enriched for replacement mutations in the CDR1 and, to a lesser degree, FWR1 (FIG. 3D). Compared to other isotypes, IgE B cells had a similar distribution of heavy chain mutation frequency, relative utilization of the lambda versus kappa light chains, and heavy chain V and J gene usage (FIGS. 11A-11K).

(393) B Cell Intrinsic Factors Define IgE Cell State

(394) To elucidate B cell intrinsic factors affecting PB activation, survival, and differentiation, we assessed genes differentially expressed between IgE PBs and PBs of other isotypes (FIG. 3E). A host of MHC genes were robustly upregulated in IgE PBs, suggesting a more immature transcriptional program given the established loss of MHC-II during the maturation of PBs to plasma cells (17) (18) (19). FCER2 (CD23), the low-affinity IgE receptor was also highly upregulated, although its precise role within IgE PBs is unclear; autoinhibition of IgE production could result from membrane CD23-mediated co-ligation of membrane IgE (mIgE) and CD21 (20). IgE production could also be upregulated through antagonistic effects of soluble CD23 (21), which is produced following cleavage by ADAM10 (22), a disintegrin and metalloproteinase domain-containing protein that we find is co-expressed in a subset of IgE PBs. LAPTM5, a negative regulator of B cell activation, BCR expression, and antibody production (23), was upregulated, which suggests compromised activation and proliferation capacity of IgE PBs. Downregulated genes included LILRB4 (24), galectin 1(LGALS1), which supports plasma cell survival (25), and the S100 proteins S100A4, S100A6, and S100A10, which may indicate reduced proliferative and survival signaling (26, 27). One of the most significantly downregulated genes in IgE PBs was spleen associated tyrosine kinase (SYK), which plays an essential role in BCR signal transduction (28) and is necessary for na?ve differentiation into plasma cells and for memory B cell survival (29). Taken together, this gene expression program shows that the IgE PB cell state is immature relative to other PBs with weakened activation, proliferation, and survival capacity. It also provides a potential transcriptomic mechanism for the hypothesized short-lived IgE PB phenotype described in mouse models of allergy (15).

(395) B cell intrinsic factors also regulate IgE production in murine models via impaired memory formation (30, 31). Indeed, we found human IgE B cells belonging to the na?ve/memory subset were deficient in heavy chain membrane immunoglobulin exon splicing compared to other common isotypes. Furthermore, membrane exon splicing was detected at low levels in non-IgE PBs, but not in IgE PBs (FIGS. 3F and 3G). In fact, the absence of mIgE splicing rendered us unable to assess the relative utilization of the two splice variants of mIgE known to have distinct signaling characteristics (32, 33). The lack of mature mIgE transcripts could be explained by poor processing of pre-mRNA (34) and is consistent with low IgE surface protein we measured by FACS; indeed, mIgE surface protein levels on true IgE B cells did not exceed those of some non-IgE B cells presumably displaying surface IgE as a result of CD23-mediated capture (FIG. 8B). Together, these results suggest that the scarcity of circulating memory IgE B cells in vivo could result from impaired membrane IgE expression that compromises IgE B cell entry into the memory compartment and/or memory B cell survival. Murine studies support such a hypothesis, having shown IgE responses are reduced by removal or modification of mIgE domains, but augmented by the exchange of these domains for those of IgG1 (35).

(396) Characterization of Peanut-Specific IgE and IgG4 Antibodies

(397) Surprisingly, our clonal analysis produced one CF of cells belonging to multiple individuals (CF1, FIGS. 2F and 2G), which contained three IgE PBs from individual PA12 and three IgE PBs from individual PA13. The antibodies produced by these six cells were highly similar as all utilized the IGHV3-30*18 and IGHJ6*02 heavy chain genes as well as the IGKV3-20*01 and IGKJ2*01 light chain genes, with pairwise CDR3 amino acid sequence identity ranging from 65% to 94% for the heavy chain and 70% to 100% for the light chain. These antibodies were also highly mutated and enriched in replacement mutations within the complementarity determining regions of both chains (FIG. 4A). In fact, compared to all other class switched antibodies, these were amongst the most mutated: the heavy chains were in the 76th percentile or above for mutation frequency, while all of the light chains were in the 96th percentile or above (FIG. 4B).

(398) We recombinantly expressed the six IgE antibodies belonging to this convergent clonal family in order to assess whether they bind the natural forms of the major allergenic peanut (Arachis hypogaea) proteins Ara h 1, Ara h 2, or Ara h 3. Of all characterized peanut allergens, Ara h 2 is the most commonly recognized by allergic individuals and is the most clinically relevant both in terms of immunological response (36) and discriminating allergic status (37, 38). Using an indirect ELISA as a semi-quantitative screen for binding, we found these six antibodies bound strongly to Ara h 2, moderately to Ara h 3, and very weakly to Ara h 1 (FIGS. 12A-12H). We then used biolayer interferometry to determine dissociation constants of each antibody for Ara h 2 and Ara h 3, with resulting affinities of 17 picomolar (pM) to sub-pM for Ara h 2 and micromolar to sub-nanomolar for Ara h 3 (FIG. 4C and FIGS. 12A-12G). These affinities are comparable to some of the highest affinity native human antibodies discovered for pathogens such as HIV, influenza, and malaria (39-43). Additionally, high affinity to multiple peanut allergens should be advantageous if such antibodies or variants thereof were to be used therapeutically as blocking antibodies intended to outcompete endogenous IgE for allergenic protein, an approach recently shown to be efficacious for treatment of cat allergy (44).

(399) To investigate the degree to which each chain and the mutations therein affect the binding properties, we recombinantly expressed eight variants of antibody PA13P1H08, each with one or more regions in the heavy and/or light chain reverted to the inferred na?ve rearrangement. Reversion of the heavy chain CDR3 was performed based on the aforementioned heavy chain V and J gene segements as well as the IGHD4-11.01 D gene and inferred nontemplated nucleotides TYCT between the V and D genes. Reversion of the light chain CDR3 was performed based on the aforementioned light chain V and J genes. Retaining the native heavy chain while swapping the light chain with another kappa light chain abrogated binding to both allergenic proteins, while reverting both chains eliminated Ara h 3 specificity and dramatically reduced Ara h 2 affinity (FIG. 4C). Reverting only the heavy or light chain reduced the affinity to Ara h 2 and Ara h 3, but disproportionately; light chain mutations contributed more to Ara h 3 affinity than did heavy chain mutations. We also found a synergistic contribution of heavy chain mutations to affinity as independent reversion of the CDR1, CDR2, CDR3 or framework region(s) each caused minor decreases in affinity. Interestingly, reversion of the heavy chain CDR2 increased Ara h 3 affinity, while only marginally decreasing Ara h 2 affinity. These results indicate that the naively recombined antibody sequence is capable of binding the most clinically relevant peanut allergen Ara h 2, but mutations, especially in the light chain, are necessary for generating high affinity antibodies which are cross-reactive towards Ara h 3. More broadly, this shows that two unrelated individuals produced an identically rearranged naive B cell that bound Ara h 2 and underwent class switching, affinity maturation, differentiation, and clonal expansion, eventually resulting in the presence of multiple circulating IgE PBs secreting high affinity antibodies with cross-reactivity towards Ara h 3.

(400) We also expressed antibodies from two other CFs. CF2 contained three IgE PBs from individual PA16 (two of which were identical), but their recombinantly expressed antibodies did not bind Ara h 1, 2, or 3, which was unsurprising given this individual had low plasma peanut-specific IgE levels as well as IgE specific to other allergens (FIGS. 7A-7C). On the other hand, CF3 contained an IgE PB (PA15P1D05) and IgG4 PB (PA1SP1D12), the recombinantly expressed antibodies from which did not bind Ara h 1, but bound Ara h 3 with nanomolar affinity and Ara h 2 with sub-nanomolar affinity (FIGS. 12A-12H). Interestingly, these two antibodies utilize the same light chain V gene and a highly similar heavy chain V gene (IGHV3-30-3*01) as the six convergent antibodies of CF1, which provides additional support for the importance of these V genes in Ara h 2 binding. Moreover, the presence of peanut-specific IgE and IgG4 in the same CF within an allergic individual provides a unique example of antagonist cell fate given the roles of IgE and IgG4 in allergic reactivity and potentially decreased sensitization, respectively.

(401) Polarized Germ/Me Transcription and Class Switch Priming

(402) Tailored responses of the adaptive immune system are possible in part due to the ability of activation-induced cytidine deaminase (AID) to initiate class switch recombination (CSR) in B cells, leading to the production of antibodies with specific effector functions. CSR is preceded by cytokine-induced germline transcription, where nonproductive germline transcripts (GLTs) that contain an I-exon, switch (S) region, and heavy chain constant region exons guide AID to the S region (45). Importantly, GLT processing is necessary for CSR (46, 47) and canonically results in two species: an intronic S region lariat and a mature polyadenylated transcript consisting of the I exon spliced to the constant region exons (48). In our scRNA-seq data, we observe multiple splice isoforms of the latter, where the proximal constant region exon serves as the exclusive splice acceptor for multiple splice donors. IgE had the largest number of distinct GLTs at five (FIG. 5A and FIG. 14), which we confirmed through Sanger sequencing; these were expressed in numerous cells of varying isotypes and across all individuals, but at nonuniform frequencies (FIG. 5A). The I-exon was the most common splice donor site (FIG. 5A, GLT #1) and it is known that I-exons can provide multiple splice donors (49-51), but ?GLT splice donors within the switch region were also observed.

(403) We found independent evidence for multiple IgE GLT splice donors in a previously published scRNA-seq dataset from murine B cells harvested 24 h after simulation to class switch (52) (FIG. 15). We also assessed variation in the isotypes expressing ?GLTs. The IgG4 isotype had the highest proportion of cells expressing an ?GLT (FIG. 5B), while IgE B cells themselves also commonly expressed ?GLTs. The remainder of isotypes had fairly low expression of ?GLTs.

(404) GLT production is not limited to the IgE locus; we extended our analysis to all isotypes, enabling the construction of a global class switch priming state diagram (FIG. 5D) that illustrates the fraction of cells of each isotype that produce a GLT of their own (self) or another isotype. We observe that, in contrast to IgE, we find almost no IgG4 GLT expression in these allergic individuals. We also observe elevated IgG2 GLT production, which can be explained by splicing of the CH1 IgG2 exon to an upstream IincRNA. Interestingly, we observe that GLT expression arising from the alternate allele is common, as evidenced by common expression of IgM GLTs as well as GLTs of other isotypes upstream of a class switched isotype (signal below the diagonal in FIG. 5D). Mirroring the landscape of human class switching (53), we observe the trend for GLT production to be higher for proximal downstream isotypes rather than distant downstream isotypes. Unlike previous reports (54), we found that cells with GLT expression tend to be polarized towards the expression of a single GLT isotype, although we did not detect any non-self GLT production in most cells (FIG. 5E).

(405) The study of B lymphocyte transcriptomes at single cell resolution offers other advantages; for example, we discovered multiple instances of biallelic GLT expression though heavy chain constant region haplotype phasing in single B cells from in individuals who had heterozygous single nucleotide variants within these loci. An example of this process that demonstrates biallelic ?GLT expression is shown in FIG. 5C.

(406) Characterization of Tree Nut-Specific IgE and IgG4 Antibodies

(407) Given that some subjects had plasma IgE against other allergens in addition to peanut (FIG. 7A), we assessed whether recombinant monoclonal antibodies from subjects PA11, PA12, PA13, PA14, PA15, and PA16 bound to allergen extracts derived not only from peanut, but other allergens as well, including cashew, pistachio, latex, BSA, soy, sesame, milk, egg, almond, pine nuts, pecan, walnut, hazelnut, and macadamia. The results of an indirect ELISA are shown in FIG. 12H. A total of 89 antibodies were tested, although only those with any OD value above 0.25 are shown in FIG. 12H. Antibodies not depicted include: PA12P1D04, PA12P1G02, PA16P1B09, PA16P1E11, PA16P1E12, PA11P1C01, PA11P1C12, PA11P1C06, PA11P1C08, PA11P1D07, PA11P1E08, PA11P1F10, PA11P1F02, PA11P1G06, PA11P1G07, PA13P2H10, PA15P1CO3, PA15P1E01, PA15P1E02, PA13P1C01, PA13P1C09, PA13P1D02, PA13P1E06, PA14P1C10, PA14P1C12, PA14P1CO2, PA14P1C04, PA14P1C06, PA14P1C07, PA14P1C08, PA14P1D10, PA14P1D02, PA14P1D07, PA14P1D09, PA14P1E10, PA14P1E11, PA14P1E12, PA14P1E04, PA14P1E06, PA14P1E08, PA14P1E09, PA14P1F10, PA14P1F11, PA14P1F05, PA14P1F07, PA14P1G01, PA14P1G11, PA14P1G12, PA14P1G03, PA14P1H01, PA14P1H11, PA14P1H12, PA14P1H02, PA14P1H05, PA14P1H09, PA12P3CO5, PA12P3CO9, PA12P3D11, PA12P3D09, PA12P3E06, PA12P3EO7, PA12P3F02, PA12P3F07, PA13P3G04, PA14P3F10, PA14P3F02, PA14P3H10, PA14P3H12, PA12P4G03, and PA12P4G06.

(408) As shown in FIG. 12H, several antibodies exhibited specificity for multiple tree nut allergens. The antibody PA14P3H08 bound strongly to pecan, walnut, hazelnut, and macadamia allergens; the antibody PA11P1D11 bound to pecan, walnut, and macadamia allergens; the antibodies PA11P1E01, PA11P1C11, and PA11P1CO3 each strongly bound to cashew and pistachio allergens; and the antibody PA11P1C04 more weakly bound to cashew and pistachio allergens. Some antibodies exhibited specificity for both peanut and tree nut allergens. For example, the antibody PA11P1G10 strongly bound to both pecan and walnut allergens and also bound (albeit more weakly) to peanut allergen, while the antibody PA12P4DO2 strongly bound to peanut allergen and more weakly bound to walnut allergen while not binding natural peanut allergen Ara h 2. Other antibodies exhibited specificity for a single tree nut allergen. For example, antibody PA11P1G04 bound to pistachio allergen, PA11P1F03 bound to pecan allergen, and PA11P1D12 bound to macadamia allergen. Furthermore, additional peanut-specific antibodies were discovered during these experiments. Antibodies PA12P3EO9 and PA12P3E11 bound peanut extract with little to no binding to natural peanut allergen Ara h 2, while antibodies PA12P1D02, PA12P1G11, PA13P1H03, PA12P3C01, and PA12P3EO4 bound strongly to both peanut extract and natural peanut allergen Ara h 2.

Conclusion

(409) Using scRNA-seq, we provide the first transcriptomic characterization of circulating human IgE B cells and the antibodies they produce. Our data suggests two mechanisms underlying IgE regulation in humans: membrane immunoglobulin expression deficiency and an IgE PB gene expression program suggestive of weakened activation, proliferation, and survival capacity. These results are largely consistent with extensive studies of mIgE signaling and IgE memory in murine models of allergy, and provide evidence supporting the use of animal models for this disease. (55-59). Furthermore, the ability to capture GLT splice variant, polarization, and biallelic expression information within single B cells presents an exciting application of scRNA-seq for future mechanistic studies of GLT and CSR.

(410) Insight into convergent evolution of high affinity antibodies in unrelated individuals can guide vaccine design and lead to strategies for population-level passive immunity; it is also a process that has been argued to occur in response to a number of pathogens such as influenza (60), HIV (43), and Streptococcus pneumoniae (61). Here we found a striking case of convergence where two unrelated individuals produced high affinity, cross-reactive, peanut-specific antibodies comprised of identical gene rearrangements within respective heavy and light chains. A third individual has Ara h 2-specific antibodies that utilize a similar heavy V gene and the same light chain V gene. Although this is a small sample size, there is evidence supporting the importance of these genes within the peanut-allergic population more broadly: one independent dataset of IgE heavy chain sequences from peanut allergic individuals (62) contains IgE heavy chains that utilize identical V and J genes and share at least 70% CDR3 identity with one or more of the six convergent antibodies in our dataset (FIG. 16); another dataset (9) contains Ara h 2 specific antibodies belonging to IgG and IgM B cells that utilize similar IGHV3-30 genes.

(411) Cross-inhibition experiments with purified allergens and plasma IgE have shown that cross-reactivity of IgE antibodies may also be common within peanut allergic individuals (63) and the antibodies we have isolated here offer a clear example of these findings. Furthermore, the fact that these high affinity antibodies were being produced by secretory IgE PBs found in circulation contributes to an understanding of how minute amounts of allergen are capable of eliciting severe allergic reactions. We also expect that either these antibodies themselves or engineered variants of them may find application as therapeutics; recent clinical results have shown that engineered allergen-specific IgG antibodies can be administered to humans and provide effective treatment for cat-whisker allergies, perhaps by outcompeting the native IgE for antigen (44).

Methods

(412) Study Subjects

(413) All study subjects were consented and screened through the Stanford IRB approved-protocol. Participants were eligible if they had a peanut allergy confirmed by an oral food challenge and board certified allergist. Peanut allergic individuals with reported reactivity to peanut ranged in age from 8 to 17, and in some cases exhibited sensitivities to other food allergens (FIGS. 7A-7C).

(414) Plasma IgE Measurement and B Cell Isolation

(415) Both plasma and cellular fractions were extracted from up to 45 mL of fresh peripheral blood collected in K2 EDTA tubes. For plasma extraction, blood was transferred to 15 mL falcon tubes and spun at 1600 g for 10 min. The upper plasma layer was extracted, transferred to 2 mL Eppendorf protein LoBind tubes and spun again at 16000 g to further purify the plasma fraction. The resulting supernatant was moved to fresh tubes before being put on dry ice and later transferred to ?80? C. Allergen-specific plasma IgE measurements were performed by CLIA-licensed Johns Hopkins University Dermatology, Allergy, and Clinical Immunology (DACI) Reference Laboratory using the ImmunoCAP system. To purify B cells remaining after plasma extraction, RosetteSep human B cell enrichment cocktail (Stemcell Technologies), a negative selection antibody cocktail, was added after the plasma fraction was replaced with PBS+2% fetal bovine serum (FBS). After a 20 min incubation, the blood was then diluted two-fold with PBS+2% FBS before being transferred to Sepmate 50 mL tubes (Stemcell Technologies) containing 15 mL Ficoll-Plaque PLUS (GE Healthcare Life Sciences). An enriched B cell population was achieved after a 10 min, 1200 g spin with the brake on and transferred a fresh tube. Residual red blood cells were then removed using ACK lysis buffer (ThermoFisher) and cells were washed with stain buffer (BD Biosciences). Cells were stained on ice with the following BioLegend antibodies according to the manufacturer's instructions: PE anti-human IgE clone MHE-18, Brilliant Violent 421 anti-human CD19 clone HIB19, APC anti-human IgM clone MHM-88, and Alexa Fluor 488 anti-human IgG clone M1310G05. Cells were washed twice more prior to sorting.

(416) Flow Cytometry and Single Cell Sorting

(417) Single cell sorts were performed on a FACSAria II Special Order Research Product (BD Biosciences) with a 5 laser configuration (355, 405, 488, 561, and 640 nm excitation). Fluorophore compensation was performed prior to each sort using OneComp eBeads (ThermoFisher), although minimal compensation was required due to the fluorophore panel and laser configuration. Equivalent laser power settings were used for each sort. Cells were sorted using single cell purity mode into chilled 96 well plates (Biorad HSP9641) containing lysis buffer (11) and ERCC synthetic RNA spike-in mix (ThermoFisher). Plates were spun and put on dry ice immediately before storage at ?80? C.

(418) cDNA Generation, Library Preparation, and Sequencing

(419) A modified version of the SmartSeq2 protocol (64) was used as previously described (11). In total, 1165 cells were sequenced across 5 runs using 2?150 bp Illumina High Output kits on an Illumina NextSeq.

(420) Sequencing Read Alignment Gene Expression, and Splicing

(421) Sequencing reads were aligned to the genome in order to determine gene expression, identify splice variants, and assess read coverage. To produce the gene expression counts table, reads were first aligned to the GRCh38 human genome using STAR v2.5.3a (12) run in 2-pass mode. Gene counts were then determined using htseq-count (65) run in intersection-nonempty mode. The GTF annotation file supplied to both STAR and htseq-count was the Ensembl 90 release manually cleaned of erroneous Ig transcripts e.g. those annotated as either a V gene or constant region but containing both V gene and constant region exons. During STAR genome generation an additional splice junction file was provided that included splicing between all combinations of heavy chain CH1 exons and IGHJ genes to improve read mapping across these junctions. Gene expression was normalized using log2 counts per million after removing counts belonging to ERCCs. Cells with fewer than 950 expressed genes were excluded prior to analysis, as were putative basophils, identified by high FACS IgE, absent or poor quality antibody assemblies, and expression of histidine decarboxylase (HDC) and Charcot-Leyden crystal protein/Galectin-10 (CLC). Batch effects mostly affecting the naive/memory B cell subset were noted between sorts by clustering using PCA on the 500 most variable genes; this gene set was enriched in genes known to be affected by sample processing such as FOS, FOSB, JUN, JUNB, JUND, HSPA8 (66). PCA following the exclusion of genes differentially expressed between sort batches (Mann-Whitney test, p-value<0.01 after Bonferroni correction) yielded well-mixed populations within both the naive/memory and PB cell clusters not biased by sort batch, individual, or sequencing library (FIG. 9G). For differential expression analysis between IgE and non-IgE PBs, genes expressed in at least 10 PBs were analyzed by voom-limma (67) with sort batch and sequencing library were supplied as technical covariates. Constant region genes, such as IGHE and IGHA1, were excluded given these are differentially expressed by design of the comparison being made.

(422) Analysis of splicing, including GLT expression, relied upon splice junctions called by STAR. Junctions were discarded if they contained fewer than three unique reads and GLT splice donors were only considered if observed in at least three cells. Biallelic expression of GLTs was determined based on heterozygous expression of variants discovered within heavy chain constant regions using bcftools (68).

(423) Antibody Heavy and Light Chain Assembly

(424) In addition to alignment, sequencing reads were also independently assembled in order to reconstruct full length heavy and light chain transcripts. BASIC (69) was used as the primary assembler given its intended use for antibody reconstruction, while Bridger (70), a whole transcriptome assembler, was used as an alternative when BASIC did not assemble a functional heavy and/or light chain. The heavy chain isotype or light chain type (lambda or kappa) was determined using a BLAST (71) database of heavy and light chain constant regions constructed from IMGT sequences (72). Here it is important to note the necessity of isotype determination using heavy chain transcript presence rather than FACS immunoglobulin surface staining: only 30% of B cells in the IgE B cell sort gate were in fact producing IgE transcripts (FIG. 8B). This likely results from the presence of surface-bound IgE captured by CD23 on non-IgE B cells, and while acid-washing can remove IgE bound by CD23 (73), we avoided this harsh treatment in order minimize transcriptomic perturbations to the cells. Immunoglobulin variable domain gene segment assignment was performed using IgBLAST (74) v1.8.0 using a database of human germline gene segments from IMGT. IgBLAST output was parsed with Change-O and mutation frequency was called with SHazaM (75). Cells without a single productive heavy and single productive light chain, which were all members of the naive/memory cell cluster, were excluded, leaving a final total of 973 cells. The workflow engine Snakemake (76) was used to execute these analysis pipelines.

(425) Recombinant Antibody Expression

(426) Select antibodies were expressed recombinantly for specificity and affinity assays. All heavy chains were expressed as human IgG1, while light chains were expressed as either lambda or kappa as appropriate. Heavy and light chain sequences were synthesized by Genscript after codon optimization and were transiently transfected in HEK293-6E cells. Antibodies were purified with RoboColumn Eshmuno? A columns (EMD Millipore) and were confirmed under reducing and non-reducing conditions by SDS-PAGE and by western blots with goat anti-human IgG-HRP and goat anti-human kappa-HRP or goat anti-human lambda-HRP as appropriate.

(427) Functional Antibody Characterization

(428) ELISAs were performed one of two ways. For antibodies derived from CF1, CF2, or CF3, purified peanut allergens were used to semi-quantitatively assess peanut allergen binding. Purified natural Ara h 1 (NA-AH1-1), Ara h 2 (NA-AH2-1) and Ara h 3 (NA-AH3-1), purchased from Indoor Biotechnologies, were immobilized overnight at 4? C. using 50 ?L at a concentration of 2 ng/?L. Following 3 washes, wells were blocked with 100 ?L of PBST (ThermoFisher)+2% BSA for 2 hours. After two washes, 100 ?L of primary antibodies were incubated for 2 hours at a concentration of 2 ng/?L in blocking buffer. Following 4 washes, 100 ?L of rabbit anti-human HRP (abcam #ab6759) or rabbit anti-mouse HRP (abcam #ab6728) secondary antibodies were incubated for 2 hours at a dilution of 1/1000 in blocking buffer. After 5 washes, 150 ?L of 1-Step ABTS Substrate Solution (ThermoFisher) was added to the wells. Color development was measured at 405 nm on a plate reader after 8-20 min and reported OD values are after subtraction of signal from no-antibody wells. Negative controls included immobilized BSA as an antigen, as well as a human isotype control primary antibody (abcam #ab206195). One random IgM/IgK antibody we recombinantly expressed (PA12P4H3) also did not exhibit any binding. Positive controls consisted of monoclonal mouse antibodies 2C12, 1C4, and 1E8 (Indoor Biotechnologies) specific for Ara h 1, Ara h 2, and Ara h 3, respectively.

(429) For ELISAs testing recombinant antibodies against a broad panel of allergen extracts, the following was performed. First, the allergens were obtained. Raw nut allergens, sesame seeds, peanuts, non-fat dry milk, and soy flour were purchased at a local grocery market, while spray-dried whole egg was purchased from the National Institute of Standards and Technology (RM 8445), and liquid latex containing natural rubber centrifuged latex and water was obtained from Amazon. If necessary, a mortar and pestle was used to grind solid allergens, following which 100 mg was added to a 2 mL Eppendorf Protein LoBind tube along with a 5 mm stainless steel bead and 1.7 mL PBS. A TissueLyser system (Qiagen) was used to homogenize the sample at 30 Hz for 10 min. Subsequently, the samples were spun for 20 min at 20000 g and 4? C. The aqueous layer was then transferred to a fresh tube. The protein concentrations of these allergen extracts were then determined using the Pierce 660 nm protein assay kit (ThermoFisher) in microplate format according to the manufacturer's instructions. ELISAs were performed in 384 well format according to the following steps. First, 20 ?L of 15 allergens and BSA were incubated overnight at 4? C. at a concentration of 2 ng/?L each. The plate was then washed 3 times with 62.5 ?L of 1?PBST per well per wash using an Integra VIAFLO. Wells were then blocked for 2 hrs using 50 ?L of a blocking buffer consisting of 1?PBST and 2% BSA. Next, 20 ?L of recombinant antibodies were incubated at a concentration of 2 ng/?L in blocking buffer. Following 4 washes, 20 ?L of rabbit anti-human HRP (abcam #ab6759) diluted 1/1000 in blocking buffer was incubated for 2 hours. Following 5 washes, 40 ?L of ABTS was added and 405 nm plate absorbance was measured using the BioTek Neo2.

(430) Kinetic characterization of antibody interactions with natural purified allergenic peanut proteins was achieved using biolayer interferometry on a ForteBio Octet 96 using anti human IgG Fc capture (AHC) biosensors with 1?PBST as the assay buffer. The assay was run with the following protocol: up to 600s baseline, 120-150s antibody load, 120-300s baseline, associations of up to 300s, and variable length dissociations that lasted up to 30 min for high affinity antibody-antigen interactions. Biosensors were regenerated by cycling between buffer and pH 1.5 glycine following each experiment. Antibodies were loaded at a concentration of 10 nM, while optimal peanut protein concentrations were determined experimentally (FIGS. 12A-12H). Data were processed using ForteBio software using a 1:1 binding model and global fit after reference sensor (ligand, but no analyte) subtraction.

Example 2Consensus Ara h 2 Binding Motif for Monoclonal Antibody PA13P1H08

Methods

(431) Linear epitope mapping of the recombinant IgG1 PA13P1H08 antibody was performed against Ara h 2 and Ara h 3 sequences linked and elongated with neutral GSGSGSG (SEQ ID NO: 1017) linkers at the N- and C-termini to avoid truncated peptides. The linked antigen sequences were translated into linear 15 amino acid peptides with a peptide-peptide overlap of 14 amino acids. The resulting Ara h 2 and Ara h 3 peptide microarray contained 668 different peptides printed in duplicate (1,336 peptide spots) as well as 90 spots of influenza virus hemagglutinin (HA) peptide YPYDVPDYAG (SEQ ID NO: 1018) framing the microarray as internal quality controls.

(432) The microarray was first subjected to 15 min pre-swelling in washing buffer (PBS, pH 7.4 with 0.05% Tween 20), followed by 30 min in blocking buffer (Rockland blocking buffer MB-070). The microarray was incubated with the PA13P1H08 IgG1 antibody at a concentration of 1 ?g/ml in incubation buffer (washing buffer with 10% blocking buffer) for 16 h at 4? C. with shaking at 140 rpm. The microarray was then stained with secondary goat anti-human IgG (H+L) DyLight680 antibody (1:5000) and control mouse monoclonal anti-HA (12CA5) DyLight800 antibody (1:2000) for 45 min in incubation buffer at room temperature. Read-out was performed with the LI-COR Odyssey Imaging System with the following parameters: scanning offset 0.65 mm, resolution 21 ?m, scanning intensities of 7/7 (red=700 nm/green=800 nm). Quantification of spot intensities and peptide annotation were done with PepSlide? Analyzer.

(433) An identical copy of the peptide microarray was subjected to the above procedure without incubation of the PA13P1H08 antibody. This served as a control to analyze background interactions of the secondary and control antibodies with the 668 different peptides of both antigens.

Results

(434) To assess whether the PA13P1H08 antibody, and by extension antibodies similar to PA13P1H08, could be binding linear peanut allergen epitope(s), we synthesized a microarray containing 15 amino acid peptides from peanut allergens Ara h 2 and Ara h 3. We found secondary and control antibody staining of the Ara h 2 and Ara h 3 peptide microarray did not highlight any background interactions that could interfere with the main assay (FIG. 17A). In contrast, we observed a strong PA13P1H08 antibody response with high signal-to-noise ratios to the very similar consensus motifs DSYGRDPYSPS (SEO ID NO:705), YSPSQDPYSPS (SEO ID NO:706), and PDRRDPYSPS (SEO ID NO:707) of Ara h 2. The similar responses were found in a region with multiple repeat units with the common DPYSPS (SEQ ID NO:704) motif (FIGS. 17B and 17C). This motif occurs three times in the Ara h 2 isoform Ara h 2.0201 (SEQ ID NO:708; WHO/IUIS allergen nomenclature; Uniprot ID: Q6PSU2-1).

Example 3Aspergillus-Specific Antibodies Derived from Human IgE B Cells

(435) This example describes the generation and characterization of Aspergillus-specific antibodies derived from human IgE B cells. The methods of Example 1 were used to obtain Aspergillus-specific antibodies, with the following differences: the blood from which B cells were isolated originated from a subject (subject number 10033201) with allergic reactivity to Aspergillus, rather than a food allergy. Accordingly, the subject's plasma was tested for Aspergillus-specific IgE as well as for common food allergens and as shown in FIG. 18, plasma IgE levels indicate Aspergillus sensitization but no confounding food sensitizations.

(436) Functional assays (ELISAs) were performed as described in Example 1 to semi-quantitatively assess the obtained antibodies' specificity for statically grown, defatted, powdered, and dried Aspergillus species purchased from Stallergenes Greer as well as recombinant Aspergillus fumigatus antigen Asp f 1 purchased from Indoor Biotechnologies. As shown in FIG. 19, the monoclonal antibody clones 1003320101_D6, 1003320105_D6, and 1003320107_F8 each exhibited specific binding to Aspergillus fumigatus. Clone 1003320107_F3 exhibited specific binding to purified recombinant allergen Aspergillus fumigatus 1 (rAsp f 1). Furthermore, clone 1003320107_C5 specifically bound to each of the allergens Aspergillus fumigatus, Aspergillus niger, and Aspergillus nidulans and to rAsp F 1. These results demonstrate that the method disclosed herein for generating antibodies from single IgE- or IgG4-expressing human B cells is able to robustly isolate allergen-specific antibodies independent of the type of allergic disease.

Example 4Milk Allergen-Specific Antibodies Derived from Human IgE B Cells

(437) This example describes the generation and characterization of milk-specific antibodies derived from human IgE B cells. The methods of Example 1 were used to obtain milk-specific antibodies, with the following differences: the blood from which B cells were isolated originated from a subject (PA01) with allergic reactivity to cow's milk but not to other food allergens. The subject's plasma was tested for common food allergens, including milk. As shown in FIG. 18, plasma IgE levels from the subject indicate milk sensitization but no other confounding food sensitizations.

(438) Functional assays (ELISAs) were performed as described in Example 1 to semi-quantitatively assess the specificity of the obtained IgE and IgG4 antibodies. As shown in FIG. 20, the monoclonal antibody clones PA01P2DO9, PA01P2DO4, PA01P2B12, PA01P2B05, and PA01P2D10 each strongly bound to milk extract, while the antibody PA01P2EO8 bound moderately. These results demonstrate that the method disclosed herein for generating antibodies from single IgE- or IgG4-expressing human B cells is able to robustly isolate allergen-specific antibodies independent of the type of allergic disease.

REFERENCES

(439) 1. Fitzsimmons C M, Falcone F H, Dunne D W. Helminth Allergens, Parasite-Specific IgE, and Its Protective Role in Human Immunity. Front Immunol. 2014 Feb. 14; 5:61. 2. Eckl-Dorna J, Niederberger V. What is the source of serum allergen-specific IgE? Curr Allergy Asthma Rep. 2013 Jun.; 13(3):281-287. 3. Shreffler W G, Beyer K, Chu T-H T, Burks A W, Sampson H A. Microarray immunoassay: association of clinical history, in vitro IgE function, and heterogeneity of allergenic peanut epitopes. J Allergy Clin Immunol. 2004 April; 113(4):776-782. 4. Croote D, Quake S R. Food allergen detection by mass spectrometry: the role of systems biology. npj Syst Biol Appl. 2016 Sep. 29; 2:16022. 5. Heeringa J J, Rijvers L, Arends N J, Driessen G J, Pasmans S G, van Dongen J J M, et al. IgE-expressing memory B cells and plasmablasts are increased in blood of children with asthma, food allergy, and atopic dermatitis. Allergy. 2018 Jan. 30; 6. Berkowska M A, Heeringa J J, Hajdarbegovic E, van der Burg M, Thio H B, van Hagen P M, et al. Human IgE(+) B cells are derived from T cell-dependent and T cell-independent pathways. J Allergy Clin Immunol. 2014 September; 134(3):688-697.e6. 7. Looney T J, Lee J-Y, Roskin K M, Hoh R A, King J, Glanville J, et al. Human B-cell isotype switching origins of IgE. J Allergy Clin Immunol. 2016 February; 137(2):579-586.e7. 8. Patil S U, Ogunniyi A O, Calatroni A, Tadigotla V R, Ruiter B, Ma A, et al. Peanut oral immunotherapy transiently expands circulating Ara h 2-specific B cells with a homologous repertoire in unrelated subjects. J Allergy Clin Immunol. 2015 July; 136(1):125-134.e12. 9. Hoh R A, Joshi S A, Liu Y, Wang C, Roskin K M, Lee J-Y, et al. Single B-cell deconvolution of peanut-specific antibody responses in allergic patients. J Allergy Clin Immunol. 2016 Jan; 137(1):157-167. 10. Tordesillas L, Berin M C, Sampson H A. Immunology of food allergy. Immunity. 2017 Jul. 18; 47(1):32-50. 11. Darmanis S, Sloan S A, Croote D, Mignardi M, Chernikova S, Samghababi P. et al. Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma. Cell Rep. 2017 Oct. 31; 21(5):1399-1410. 12. Dobin A, Davis C A, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013 Jan. 1; 29(1):15-21. 13. Nutt S L, Hodgkin P D, Tarlinton D M, Corcoran L M. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015 Mar.; 15(3):160-171. 14. Xu H, Chaudhri V K, Wu Z, Biliouris K, Dienger-Stambaugh K, Rochman V. et al. Regulation of bifurcating B cell trajectories by mutual antagonism between transcription factors IRF4 and IRF8. Nat Immunol. 2015 Dec.; 16(12):1274-1281. 15. Erazo A, Kutchukhidze N, Leung M, Christ A P G, Urban J F, Curotto de Lafaille M A, et al. Unique maturation program of the IgE response in vivo. Immunity. 2007 Feb. 8; 26(2):191-203. 16. Horst A, Hunzelmann N, Arce S, Herber M, Manz R A, Radbruch A, et al. Detection and characterization of plasma cells in peripheral blood: correlation of IgE+ plasma cell frequency with IgE serum titre. Clin Exp Immunol. 2002 December; 130(3):370-378. 17. Manz R, L?hning M, Cassese G, Thiel A, Radbruch A. Survival of long-lived plasma cells is independent of antigen. Int Immunol. 1998 Nov. 1; 10(11):1703-1711. 18. Medina F, Segundo C, Campos-Caro A, Gonz?lez-Garc?a I, Brieva J A. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood. 2002 Mar. 15; 99(6):2154-2161. 19. Calame K L, Lin K-I, Tunyaplin C. Regulatory mechanisms that determine the development and function of plasma cells. Annu Rev Immunol. 2003; 21:205-230. 20. Gould H J, Sutton B J. IgE in allergy and asthma today. Nat Rev Immunol. 2008 Mar.; 8(3):205-217. 21. Cooper A M, Hobson P S, Jutton M R, Kao M W, Drung B, Schmidt B, et al. Soluble CD23 controls IgE synthesis and homeostasis in human B cells. J Immunol. 2012 Apr. 1; 188(7):3199 3207. 22. Weskamp G, Ford J W, Sturgill J, Martin S, Docherty A J P, Swendeman S, et al. ADAM10 is a principal sheddase of the low-affinity immunoglobulin E receptor CD23. Nat Immunol. 2006 Dec.; 7(12):1293-1298. 23. Ouchida R, Kurosaki T, Wang J-Y. A role for lysosomal-associated protein transmembrane 5 in the negative regulation of surface B cell receptor levels and B cell activation. J Immunol. 2010 Jul. 1; 185(1):294-301. 24. Cella M, D?hring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A, et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med. 1997 May 19; 185(10):1743-1751. 25. Anginot A, Espeli M, Chasson L, Mancini S J C, Schiff C. Galectin 1 modulates plasma cell homeostasis and regulates the humoral immune response. J Immunol. 2013 Jun. 1; 190(11):5526-5533. 26. Le?niak W, S?omnicki ? P, Filipek A. S100A6new facts and features. Biochem Biophys Res Commun. 2009 Dec. 25; 390(4):1087-1092. 27. Boye K, Maelandsmo G M. S100A4 and metastasis: a small actor playing many roles. Am J Pathol. 2010 February; 176(2):528-535. 28. Geahlen R L. Syk and pTyr'd: Signaling through the B cell antigen receptor. Biochim Biophys Acta. 2009 July; 1793(7):1115-1127. 29. Ackermann J A, Nys J, Schweighoffer E, McCleary S, Smithers N, Tybulewicz V U. Syk tyrosine kinase is critical for B cell antibody responses and memory B cell survival. J Immunol. 2015 May 15; 194(10):4650-4656. 30. Yang Z, Sullivan B M, Allen C D C. Fluorescent in vivo detection reveals that IgE(+) B cells are restrained by an intrinsic cell fate predisposition. Immunity. 2012 May 25; 36(5):857-872. 31. He J-S, Subramaniam S, Narang V, Srinivasan K, Saunders S P, Carbajo D, et al. IgG1 memory B cells keep the memory of IgE responses. Nat Commun. 2017 Sep. 21; 8(1):641. 32. Poggianella M, Bestagno M, Burrone O R. The extracellular membrane-proximal domain of human membrane IgE controls apoptotic signaling of the B cell receptor in the mature B cell line A20. J Immunol. 2006 Sep. 15; 177(6):3597-3605. 33. Batista F D, Anand S, Presani G, Efremov D G, Burrone O R. The two membrane isoforms of human IgE assemble into functionally distinct B cell antigen receptors. J Exp Med. 1996 Dec. 1; 184(6):2197-2205. 34. Karnowski A, Achatz-Straussberger G, Klockenbusch C, Achatz G, Lamers M C. Inefficient processing of mRNA for the membrane form of IgE is a genetic mechanism to limit recruitment of IgE-secreting cells. Eur J Immunol. 2006 July; 36(7):1917-1925. 35. Wu L C, Zarrin A A. The production and regulation of IgE by the immune system. Nat Rev Immunol. 2014 April; 14(4):247-259. 36. Koppelman S J, Wensing M, Ertmann M, Knulst A C, Knol E F. Relevance of Ara h1, Ara h2 and Ara h3 in peanut-allergic patients, as determined by immunoglobulin E Western blotting, basophil-histamine release and intracutaneous testing: Ara h2 is the most important peanut allergen. Clin Exp Allergy. 2004 April; 34(4):583-590. 37. Nicolaou N, Murray C, Belgrave D, Poorafshar M, Simpson A, Custovic A. Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy. Journal of Allergy and Clinical Immunology. 2011 March; 127(3):684-685. 38. Dang T D, Tang M, Choo S, Licciardi P V, Koplin J J, Martin P E, et al. Increasing the accuracy of peanut allergy diagnosis by using Ara h 2. J Allergy Clin Immunol. 2012 April; 129(4):1056-1063. 39. Wrammert J, Smith K, Miller J, Langley W A, Kokko K, Larsen C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008 May 29; 453(7195):667-671. 40. Murugan R, Buchauer L, Triller G, Kreschel C, Costa G, Pidelaserra Marti G, et al. Clonal selection drives protective memory B cell responses in controlled human malaria infection. Sci Immunol. 2018 Feb. 16; 3(20). 41. Kaur K, Zheng N Y, Smith K, Huang M, Li L, Pauli N T, et al. High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination. PLoS ONE. 2015 May 7; 10(5):e0125618. 42. Mouquet H, Klein F, Scheid J F, Warncke M, Pietzsch J, Oliveira T Y K, et al. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with Glade A and B viruses. PLoS ONE. 2011 Sep. 8; 6(9):e24078. 43. Scheid J F, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira T Y K, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011 Sep. 16; 333(6049):1633-1637. 44. Orengo J M, Radin A R, Kamat V, Badithe A, Ben L H, Bennett B L, et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat Commun. 2018 Apr. 12; 9(1):1421. 45. Yewdell W T, Chaudhuri J. A transcriptional serenAlD: the role of noncoding RNAs in class switch recombination. Int Immunol. 2017 Apr. 1; 29(4):183-196. 46. Hein K, Lorenz M G, Siebenkotten G, Petry K, Christine R, Radbruch A. Processing of switch transcripts is required for targeting of antibody class switch recombination. J Exp Med. 1998 Dec. 21; 188(12):2369-2374. 47. Lorenz M, Jung S, Radbruch A. Switch transcripts in immunoglobulin class switching. Science. 1995 Mar. 24; 267(5205):1825-1828. 48. Zheng S, Vuong B Q, Vaidyanathan B, Lin J-Y, Huang F-T, Chaudhuri J. Non-coding RNA Generated following Lariat Debranching Mediates Targeting of AID to DNA. Cell. 2015 May 7; 161(4):762-773. 49. Collins J T, Dunnick W A. Germline transcripts of the murine immunoglobuliny 2a gene: structure and induction by IFN-?. Int Immunol. 1993; 5(8):885-891. 50. Gaff C, Gerondakis S. RNA splicing generates alternate forms of germline immunoglobulin alpha heavy chain transcripts. Int Immunol. 1990; 2(12):1143-1148. 51. Gauchat J F, Lebman D A, Coffman R L, Gascan H, de Vries J E. Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production. J Exp Med. 1990 Aug. 1; 172(2):463-473. 52. Wu Y L, Stubbington M J T, Daly M, Teichmann S A, Rada C. Intrinsic transcriptional heterogeneity in B cells controls early class switching to IgE. J Exp Med. 2017 January; 214(1):183-196. 53. Horns F, Vollmers C, Croote D, Mackey S F, Swan G E, Dekker C L, et al. Lineage tracing of human B cells reveals the in vivo landscape of human antibody class switching. elife. 2016 Aug. 2; 5. 54. Fear D J, McCloskey N, O'Connor B, Felsenfeld G, Gould H J. Transcription of Ig germline genes in single human B cells and the role of cytokines in isotype determination. J Immunol. 2004 Oct. 1; 173(7):4529-4538. 55. Laffleur B, Duchez S, Tarte K, Denis-Lagache N, P?ron S, Carrion C, et al. Self-Restrained B Cells Arise following Membrane IgE Expression. Cell Rep. 2015 Feb. 12; 56. Haniuda K, Fukao S, Kodama T, Hasegawa H, Kitamura D. Autonomous membrane IgE signaling prevents IgE-memory formation. Nat Immunol. 2016 Jul. 18; 17(9):1109-1117. 57. Tong P, Granato A, Zuo T, Chaudhary N, Zuiani A, Han S S, et al. IgH isotype-specific B cell receptor expression influences B cell fate. Proc Natl Acad Sci USA. 2017 Oct. 3; 114(40):E8411-E8420. 58. Yang Z, Robinson M J, Chen X, Smith G A, Taunton J, Liu W, et al. Regulation of B cell fate by chronic activity of the IgE B cell receptor. elife. 2016 Dec. 9; 5. 59. Laffleur B, Debeaupuis O, Dalloul Z, Cogn? M. B cell intrinsic mechanisms constraining ige memory. Front Immunol. 2017 Nov. 13; 8:1277. 60. Jackson K J L, Liu V. Roskin K M, Glanville J, Hoh R A, Seo K, et al. Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. Cell Host Microbe. 2014 Jul. 9; 16(1):105-114. 61. Zhou J, Lottenbach K R, Barenkamp S J, Lucas A H, Reason D C. Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F. Infect Immun. 2002 August; 70(8):4083-4091. 62. Kiyotani K, Mai T H, Yamaguchi R, Yew P Y, Kulis M, Orgel K, et al. Characterization of the B-cell receptor repertoires in peanut allergic subjects undergoing oral immunotherapy. J Hum Genet. 2018 February; 63(2):239-248. 63. Bublin M, Kostadinova M, Radauer C, Hafner C, Sz?pfalusi Z, Varga E-M, et al. IgE cross-reactivity between the major peanut allergen Ara h 2 and the nonhomologous allergens Ara h 1 and Ara h 3. J Allergy Clin Immunol. 2013 July; 132(1):118-124. 64. Picelli S, Faridani O R, Bj?rklund AK, Winberg G, Sagasser S, Sandberg R. Full-length RNA-seq from single cells using Smart-seg2. Nat Protoc. 2014 Jan. 2; 9(1):171-181. 65. Anders S, Pyl P T, Huber W. HTSeqa Python framework to work with high-throughput sequencing data. Bioinformatics. 2015 Jan. 15; 31(2):166-169. 66. Van den Brink S C, Sage F, V?rtesy ?, Spanjaard B, Peterson-Maduro J, Baron C S, et al. Single-cell sequencing reveals dissociation-induced gene expression in tissue subpopulations. Nat Methods. 2017 Sep. 29; 14(10):935-936. 67. Ritchie M E, Phipson B, Wu D, Hu Y, Law C W, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015 Apr. 20; 43(7):e47. 68. Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics. 2011 Nov. 1; 27(21):2987-2993. 69. Canzar S, Neu K E, Tang Q, Wilson P C, Khan A A. BASIC: BCR assembly from single cells. Bioinformatics. 2017 Feb. 1; 33(3):425-427. 70. Chang Z, Li G, Liu J, Zhang Y, Ashby C, Liu D, et al. Bridger: a new framework for de novo transcriptome assembly using RNA-seq data. Genome Biol. 2015 Feb. 11; 16:30. 71. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al. BLAST+: architecture and applications. BMC Bioinformatics. 2009 Dec. 15; 10:421. 72. Lefranc M-P, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2009 Jan; 37(Database issue):D1006-12. 73. Katona I M, Urban J F, Scher I, Kanellopoulos-Langevin C, Finkelman F D. Induction of an IgE response in mice by Nippostrongylus brasiliensis: characterization of lymphoid cells with intracytoplasmic or surface IgE. J Immunol. 1983 January; 130(1):350-356. 74. Ye J, Ma N, Madden T L, Ostell J M. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res. 2013 July; 41(Web Server issue):W34-40. 75. Gupta N T, Vander Heiden J A, Uduman M, Gadala-Maria D, Yaari G, Kleinstein S H. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. Bioinformatics. 2015 Oct. 15; 31(20):3356-3358. 76. K?ster J, Rahmann S. Snakemakea scalable bioinformatics workflow engine. Bioinformatics. 2012 Oct. 1; 28(19):2520-2522.

(440) TABLE-US-00003 TABLE1 SequenceListing SEQ ID NO Sequence Description 1 QVQLVNSGGGVVQPGRSLRLSCVASGFTFSTFGIHWVRQAPGKGLEWVAVISNDGEKSESA Heavychainvariableregionfor DSVKGRFTPSRDNSKNTVYLQMNNLRVEDTAVYYCAKVLDYSRYSYYYGMDVWGQGTTVI clonePA13P1H08andN-Rvariant VSS ofPA13P1H08 2 GFTFSTFG CDR-H1forclonePA13P1H08and PA13P1H08variantsN-R,rCDR2-N, rCDR3-N,rFWRs-N 3 ISNDGEKS CDR-H2forclonePA13P1H08and forPA13P1H08variantsN-R, rCDR1-N,rCDR3-N 4 AKVLDYSRYSYYYGMDV CDR-H3forclonePA13P1H08and PA13P1H08variantsN-R,rCDR1-N, rCDR2-N 5 EIVLTQSPGTLSLSPGGRGTLSCRTSQTINNAHLAWYQHKPGQAPRLLIYGSSERATGVPDRF Lightchainvariableregionfor SGSGSGSDFTLTISSLEAEDFAVYYCQHYGRSPPYTFGPGTKLDIK clonePA13P1H08andPA13P1H08 variantsR-N,rCDR1-N,rCDR2-N, rCDR3-N,rFWRs-N 6 QTINNAH CDR-L1forclonePA13P1H08and PA13P1H08variantsR-N,rCDR1-N, rCDR2-N,rCDR3-N,rFWRs-N 7 GSS CDR-L2forclonePA13P1H08and PA13P1H08variantsR-N,rCDR1-N, rCDR2-N,rCDR3-N,rFWRs-N 8 QHYGRSPPYT CDR-L3forclonePA13P1H08and PA13P1H08variantsR-N,rCDR1-N, rCDR2-N,rCDR3-N,rFWRs-N 9 QVQLVDSGGGVVQPGKSLRLSCVGSGFTFRTFGIHWVRQAPGKGLEWVAVISNDGGNSAS ClonePA13P1E10-Heavychain ADSVKGRFTTSRDNSKNTVYLQINSLRPEDTAIYYCAKVLDYSAFSYYYGMDVWGQGTTVIVSS variableregion 10 GFTFRTFG ClonePA13P1E10-CDR-H1 11 ISNDGGNS ClonePA13P1E10-CDR-H2 12 AKVLDYSAFSYYYGMDV ClonePA13P1E10-CDR-H3 13 EIVLTQSPGTLSLSPGERGTLSCRTSQPISRAHLAWYQHKAGQAPRLLIYGSTERAAGIPERFS ClonePA13P1E10-lightchain GGGSGSDFTLTISSLEAEDFAVYYCQHYGRSPPYTFGQGTKVEIK variableregion 14 QPISRAH ClonePA13P1E10-CDR-L1 15 GST ClonePA13P1E10-CDR-L2 8 QHYGRSPPYT ClonePA13P1E10-CDR-L3 16 QVQLVESGGGVVQPGGSLTLSCVGSGFTFSHYAIHWVRQAPGKGLEWVAVISNVGTTRDY ClonePA12P3F10-Heavychain ADSLKGRLTISRENSQSTVFLQMNSLRADDTAIYYCAKVLDYSEFHYYYGLDVWGQGTAVAV variableregion SS 17 GFTFSHYA ClonePA12P3F10-CDR-H1 18 ISNVGTTR ClonePA12P3F10-CDR-H2 19 AKVLDYSEFHYYYGLDV ClonePA12P3F10-CDR-H3 20 EIVLTQSPGTLSLSPGQRVTLSCRVSQAIPTMYVAWYQQRPGQAPRLLIYGTSSRATGIPDRFS ClonePA12P3F10-lightchain GGGSGTDFTLTINRLEPEDIAVYYCQHYSNSPPYTFGPGTKLEIK variableregion 21 QAIPTMY ClonePA12P3F10-CDR-L1 22 GTS ClonePA12P3F10-CDR-L2 23 QHYSNSPPYT ClonePA12P3F10-CDR-L3 24 QEQLVESGGGVVHPGGSLRLSCVASAFTFNRFGMHWVRQAPGKGLEWVAVISNDGRSQDY ClonePA13P3G09-Heavychain ADSVKGRFIISRDNSKNTLYLQLNSLRFEDTAVYYCAKVLDYSIFYYYFGLDVWGQGTTVTVSS variableregion 25 AFTFNRFG ClonePA13P3G09-CDR-H1 26 ISNDGRSQ ClonePA13P3G09-CDR-H2 27 AKVLDYSIFYYYFGLDV ClonePA13P3G09-CDR-H3 28 EVVLTQSPGSLSLSPGERATLSCRAGQSLSSKFLAWYQHKPGQAPRLLIYGASTRATGVPDRF ClonePA13P3G09-lightchain SGSGSGTDFSLIISRVEPEDFAVYYCQHYGDSPPYTFGQGTKVEMK variableregion 29 QSLSSKF ClonePA13P3G09-CDR-L1 30 GAS CDR-L2forclonePA13P3G09and PA13P1H08variantsR-R,N-R 31 QHYGDSPPYT ClonePA13P3G09-CDR-L3 32 QVQLVESGGGVVQPGKSLRLSCAASAFTFRRFAMHWVRQAPGKGLEWVAVISDNGLREDY ClonePA12P3D08-Heavychain EDSVKGRFTISRDNSQNTLYLQMNGLRAEDTAVYYCAKVLDYNEYSLYFGMDVWGQGTTV variableregion TVSS 33 AFTFRRFA ClonePA12P3D08-CDR-H1 34 ISDNGLRE ClonePA12P3D08-CDR-H2 35 AKVLDYNEYSLYFGMDV ClonePA12P3D08-CDR-H3 36 EVVLTQSPATLSLSPGERATLSCRTSQAISNNFLAWYQQRPGQPPRLLIYASSRRATDTPDRFT ClonePA12P3D08-lightchain GSGSGTDFTLTITRLEPEDFAVYFCQYYSDSPPYTFGPGTKLEIK variableregion 37 QAISNNF ClonePA12P3D08-CDR-L1 38 ASS ClonePA12P3D08-CDR-L2 39 QYYSDSPPYT ClonePA12P3D08-CDR-L3 40 QVQLEESGGGVVQPGKSLRLSCVASAFTFKRFAMHWVRQAPGKGLEWVAVISDNGLREDY ClonePA12P1C07-Heavychain EDSVKGRFTISRDNSKDTLYLQMNSLRPEDTAIYYCAKVLDYSEYSLYFGMDVWGQGTTVLV variableregion SS 41 AFTFKRFA ClonePA12P1C07-CDR-H1 34 ISDNGLRE ClonePA12P1C07-CDR-H2 42 AKVLDYSEYSLYFGMDV ClonePA12P1C07-CDR-H3 43 EIVLTQSPAILSLSPGDRATLSCRTSQTVNSNFLAWYQQKPGQAPRLLIYGASRRAIDIPDRFT ClonePA12P1C07-lightchain GSGSGTEFTLTIARLEPEDFAVYSCQHYSDSPPYTFGQGTKLEIK variableregion 44 QTVNSNF ClonePA12P1C07-CDR-L1 30 GAS ClonePA12P1C07-CDR-L2 45 QHYSDSPPYT ClonePA12P1C07-CDR-L3 46 QVHLVESGGGVVQPGRSLGLSCAASGFTFNYYAIHWVRQAPGKGLEWVAVVSFDGNIIYYA ClonePA15P1D12-Heavychain DSVKGRFNISRDNSKNTVNLQMNSLRADDTAVYYCVRDGEYCSGGNCYWGDFDYWGQGT variableregion LVTVSP 47 GFTFNYYA ClonePA15P1D12-CDR-H1 48 VSFDGNII ClonePA15P1D12-CDR-H2 49 VRDGEYCSGGNCYWGDFDY ClonePA15P1D12-CDR-H3 50 EIVLTQSPGTLSLSPGERATLSCRASQSISSEYLTWFQQKPGQAPRLLIYGAFNRATGIPDRFS ClonePA15P1D12-lightchain GSGSGTDFTLTISSLEPEDFAVYYCQQYANWWTFGQGTKVEIK variableregion 51 QSISSEY ClonePA15P1D12-CDR-L1 52 GAF ClonePA15P1D12-CDR-L2 53 QQYANWWT ClonePA15P1D12-CDR-L3 54 QVHLVESGGGVVQPGRSLGLSCVASGFTFNYYAIHWVRQAPGKGLEWVAVVSFDGNIIYYA ClonePA15P1D05-Heavychain DSVKGRFNISRDNSKNTVNLQMNSLRPDDTAVYYCVRDGEYCSGGNCYWGDFDHWGQGS variableregion LVTVSP 47 GFTFNYYA ClonePA15P1D05-CDR-H1 48 VSFDGNII ClonePA15P1D05-CDR-H2 55 VRDGEYCSGGNCYWGDFDH ClonePA15P1D05-CDR-H3 56 EIVLTQSPATLSLSPGERATLSCRASQSISSEYLTWFQQKPGQAPRLLIYGAFNRATGIPDRFS ClonePA15P1D05-lightchain GSGSGTDFTLTISSLEPEDFAVYYCQQYANWWTFGQGTKVEIK variableregion 51 QSISSEY ClonePA15P1D05-CDR-L1 52 GAF ClonePA15P1D05-CDR-L2 53 QQYANWWT ClonePA15P1D05-CDR-L3 57 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY HeavychainvariableregionforR-R ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVLDYSNYYYYYGMDVWGQGTTVT andR-NvariantsofPA13P1H08 VSS 58 GFTFSSYG CDR-H1forPA13P1H08variantsR- R,R-N,rCDR1-N 59 ISYDGSNK CDR-H2forPA13P1H08variantsR- R,R-N,rCDR2-N 60 AKVLDYSNYYYYYGMDV CDR-H3forPA13P1H08variantsR- R,R-N,rCDR3-N 61 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFS LightchainvariableforregionR-R GSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTKLEIK andN-RvariantsofPA13P1H08 62 QSVSSSY CDR-L1forPA13P1H08variantsR- R,N-R 63 QQYGSSPPYT CDR-L3forPA13P1H08variantsR- R,N-R 64 QVQLVNSGGGVVQPGRSLRLSCVASGFTFSSYGIHWVRQAPGKGLEWVAVISNDGEKSESA Heavychainvariableregionfor DSVKGRFTPSRDNSKNTVYLQMNNLRVEDTAVYYCAKVLDYSRYSYYYGMDVWGQGTTVI PA13P1H08variantrCDR1-N VSS 65 QVQLVNSGGGVVQPGRSLRLSCVASGFTFSTFGIHWVRQAPGKGLEWVAVISYDGSNKESA Heavychainvariableregionfor DSVKGRFTPSRDNSKNTVYLQMNNLRVEDTAVYYCAKVLDYSRYSYYYGMDVWGQGTTVI PA13P1H08variantrCDR2-N VSS 66 QVQLVNSGGGVVQPGRSLRLSCVASGFTFSTFGIHWVRQAPGKGLEWVAVISNDGEKSESA Heavychainvariableregionfor DSVKGRFTPSRDNSKNTVYLQMNNLRVEDTAVYYCAKVLDYSNYYYYYGMDVWGQGTTVI PA13P1H08variantrCDR3-N VSS 67 QVQLVESGGGVVQPGRSLRLSCAASGFTFSTFGMHWVRQAPGKGLEWVAVISNDGEKSYY Heavychainvariableregionfor ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVLDYSRYSYYYGMDVWGQGTTVT PA13P1H08variantrFWRs-N VSS 68 GCCTCCACACAGAGCCCATCCGTCTTCCCCTTGACCCGCTGCTGCAAAAACATTCCCTCCA NucleotidesequenceforIgEheavy ATGCCACCTCCGTGACTCTGGGCTGCCTGGCCACGGGCTACTTCCCGGAGCCGGTGATG chainconstantregion GTGACCTGGGACACAGGCTCCCTCAACGGGACAACTATGACCTTACCAGCCACCACCCTC ACGCTCTCTGGTCACTATGCCACCATCAGCTTGCTGACCGTCTCGGGTGCGTGGGCCAAG CAGATGTTCACCTGCCGTGTGGCACACACTCCATCGTCCACAGACTGGGTCGACAACAAA ACCTTCAGCGTCTGCTCCAGGGACTTCACCCCGCCCACCGTGAAGATCTTACAGTCGTCCT GCGACGGCGGCGGGCACTTCCCCCCGACCATCCAGCTCCTGTGCCTCGTCTCTGGGTACA CCCCAGGGACTATCAACATCACCTGGCTGGAGGACGGGCAGGTCATGGACGTGGACTTG TCCACCGCCTCTACCACGCAGGAGGGTGAGCTGGCCTCCACACAAAGCGAGCTCACCCTC AGCCAGAAGCACTGGCTGTCAGACCGCACCTACACCTGCCAGGTCACCTATCAAGGTCAC ACCTTTGAGGACAGCACCAAGAAGTGTGCAGATTCCAACCCGAGAGGGGTGAGCGCCTA CCTAAGCCGGCCCAGCCCGTTCGACCTGTTCATCCGCAAGTCGCCCACGATCACCTGTCT GGTGGTGGACCTGGCACCCAGCAAGGGGACCGTGAACCTGACCTGGTCCCGGGCCAGT GGGAAGCCTGTGAACCACTCCACCAGAAAGGAGGAGAAGCAGCGCAATGGCACGTTAA CCGTCACGTCCACCCTGCCGGTGGGCACCCGAGACTGGATCGAGGGGGAGACCTACCAG TGCAGGGTGACCCACCCCCACCTGCCCAGGGCCCTCATGCGGTCCACGACCAAGACCAG CGGCCCGCGTGCTGCCCCGGAAGTCTATGCGTTTGCGACGCCGGAGTGGCCGGGGAGC CGGGACAAGCGCACCCTCGCCTGCCTGATCCAGAACTTCATGCCTGAGGACATCTCGGTG CAGTGGCTGCACAACGAGGTGCAGCTCCCGGACGCCCGGCACAGCACGACGCAGCCCC GCAAGACCAAGGGCTCCGGCTTCTTCGTCTTCAGCCGCCTGGAGGTGACCAGGGCCGAA TGGGAGCAGAAAGATGAGTTCATCTGCCGTGCAGTCCATGAGGCAGCGAGCCCCTCACA GACCGTCCAGCGAGCGGTGTCTGTAAATCCCGGTAAA 69 ASTQSPSVFPLTRCCKNIPSNATSVTLGCLATGYFPEPVMVTWDTGSLNGTTMTLPATTLTLS AminoacidsequenceforIgEheavy GHYATISLLTVSGAWAKQMFTCRVAHTPSSTDWVDNKTFSVCSRDFTPPTVKILQSSCDGG chainconstantregion GHFPPTIQLLCLVSGYTPGTINITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLS DRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTV NLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMR STTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTT QPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGK 70 GCTTCCACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAG NucleotidesequenceforIgG4 AGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTC heavychainconstantregion GTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTC AGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGA CCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG TCCAAATATGGTCCCCCATGCCCATCATGCCCAGCACCTGAGTTCCTGGGGGGACCATCA GTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCA CGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGT GGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGC ACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGA GTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAA AGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAG ATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATC GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCG TGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGT GGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC ACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAA 71 ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS AminoacidsequenceforIgG4 LSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPK heavychainconstantregion DTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL HNHYTQKSLSLSLGK 72 QVQLVESGGGVVQPGRSLRLSCAASGFTFDTYGMHWVRQAPGKGPEWVAVIWYDGTRED ClonePA14P1E12-Heavychain YADSVKGRFTVSRDNSKSTLFLQMNSLRADDTAVYYCAKEHNTYFSDHIGRVGGMDVWGQ variableregion GTTVIVSS 73 GFTFDTYG ClonePA14P1E12-CDR-H1 74 IWYDGTRE ClonePA14P1E12-CDR-H2 75 AKEHNTYFSDHIGRVGGMDV ClonePA14P1E12-CDR-H3 76 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGV ClonePA14P1E12-lightchain PDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQVLQTPPWTFGQGTQVEIK variableregion 77 QSLLHSNGYNY ClonePA14P1E12-CDR-L1 78 LGS ClonePA14P1E12-CDR-L2 79 MQVLQTPPWT ClonePA14P1E12-CDR-L3 80 QVQLVESGGGVVQPGRSLRLSCAGSGFTFNAYGLHWVRQAPGKGLEWVAGIYYDGSNKYY ClonePA14P1E10-Heavychain ADSVKGRFAISRDNSQNTLYLEMNSLRVEDTAVYYCAKAGPIASIGTRHTFDHWGQGTLVTV variableregion SS 81 GFTFNAYG ClonePA14P1E10-CDR-H1 82 IYYDGSNK ClonePA14P1E10-CDR-H2 83 AKAGPIASIGTRHTFDH ClonePA14P1E10-CDR-H3 84 DIVMTQSPDSLAVSLGERATINCKSSQSLLLNSNNKNYLAWYQQKPGQPPKLLIYWASTRES ClonePA14P1E10-lightchain GVPGRFSGNGSVTDFTLTISGLQAEDVAVYYCHQYYTTSYTFGQGTKLEIK variableregion 85 QSLLLNSNNKNY ClonePA14P1E10-CDR-L1 86 WAS ClonePA14P1E10-CDR-L2 87 HQYYTTSYT ClonePA14P1E10-CDR-L3 88 QVQLVQSGAEVKKPGASVKISCKAVGYTFTSYYLHWVRQAPGQGLEWVGIIDPSRGHRNYA ClonePA14P1E11-Heavychain QGFQGRVTMTSDTSTSTVYMDLGSLRSEDTAVYYCARAPARDHFDNWGQGTPVTVSP variableregion 89 GYTFTSYY ClonePA14P1E11-CDR-H1 90 IDPSRGHR ClonePA14P1E11-CDR-H2 91 ARAPARDHFDN ClonePA14P1E11-CDR-H3 92 DIQMTQSPSSLAASVGDRVTINCQASQDIRNCLNWYQQQPGKAPKLLIYDASILETGVPSRFS ClonePA14P1E11-lightchain GSGSGTDFTFSISSLQPEDIATYYCQQCEDLPLTFGPGSKVDIK variableregion 93 QDIRNC ClonePA14P1E11-CDR-L1 94 DAS ClonePA14P1E11-CDR-L2 95 QQCEDLPLT ClonePA14P1E11-CDR-L3 96 QVQLVQSGAEVKQPGSSVKVSCKASGGTFRNSALSWVRQAPGQGLEWMGGIIPIFDTTNY ClonePA13P1C01-Heavychain AQEFQGRVTITADKSTTTAYMELSSLKSEDTAVYYCARGEGLPWLTYHYYGMDVWGQGTTV variableregion TVSS 97 GGTFRNSA ClonePA13P1C01-CDR-H1 98 IIPIFDTT ClonePA13P1C01-CDR-H2 99 ARGEGLPWLTYHYYGMDV ClonePA13P1C01-CDR-H3 100 QAVLTQPSSLSASPGASASLTCTLRSGINIGTDRIYWFQQKPGSPPQYLLTYKSDSDEQRGSG ClonePA13P1C01-lightchain VPSRFSGSKDVSANAGILLISGLQSEDEADYYCMIWHSSAWVFGGGTKLTVL variableregion 101 SGINIGTDR ClonePA13P1C01-CDR-L1 102 YKSDSDE ClonePA13P1C01-CDR-L2 103 MIWHSSAWV ClonePA13P1C01-CDR-L3 104 QVQLQQWGAGLLKPSETLSLTCAVYGGSLSGYHWSWIRQPPGKGLQWIGEISHSGNAKYN ClonePA14P1F11-Heavychain PSLKSRVSISVHMSKNEFYLNLTSVTAADTAVYYCARGYCSGGSCYYKFWGQGTLVTVSS variableregion 105 GGSLSGYH ClonePA14P1F11-CDR-H1 106 ISHSGNA ClonePA14P1F11-CDR-H2 107 ARGYCSGGSCYYKF ClonePA14P1F11-CDR-H3 108 QSVLTQPPSVSAAPGQKVTISCSGNSSNIGNNYVSWFQQLPGTAPKLLIYDNNKRPSGIPDRF ClonePA14P1F11-lightchain SGSKSGTSATLGITGLQTGDEADYFCGTWDSSLRTGVFGGGTKLTVL variableregion 109 SSNIGNNY ClonePA14P1F11-CDR-L1 110 DNN ClonePA14P1F11-CDR-L2 111 GTWDSSLRTGV ClonePA14P1F11-CDR-L3 112 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSLIYSGGSRTSYPD ClonePA14P1F10-Heavychain SVKGRFTISRDNSNSTLFLQMNSLRVEDTAVYYCAKGGSSWLKMDYWGQGTLVIVSS variableregion 113 GFTFSSYA ClonePA14P1F10-CDR-H1 114 IYSGGSRT ClonePA14P1F10-CDR-H2 115 AKGGSSWLKMDY ClonePA14P1F10-CDR-H3 116 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVQWYQHLPGTAPKLLIFANTNRPSGVPD ClonePA14P1F10-lightchain RFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL variableregion 117 SSNIGAGYD ClonePA14P1F10-CDR-L1 118 ANT ClonePA14P1F10-CDR-L2 119 QSYDSSLSGSV ClonePA14P1F10-CDR-L3 120 QVQLVQSGAEVKKPGASVRVSCSSSGYTFTGYYIHWVRQAPGQGLEYMGRINPHSGGTNY ClonePA13P1C09-Heavychain AQKFQGRVTMTRDTSTSTVYMELSSLRSDDTAVYYCAKEGTTAHIFNWFDPWGQGTLVTVSS variableregion 121 GYTFTGYY ClonePA13P1C09-CDR-H1 122 INPHSGGT ClonePA13P1C09-CDR-H2 123 AKEGTTAHIFNWFDP ClonePA13P1C09-CDR-H3 124 DIQMTQSPSSLSASVGDRVTITCRASQSINSYLNWYQQKPGKAPNLLIYTASSLQSGVPSRFS ClonePA13P1C09-lightchain GSGSGTDFTLTISSLQPEDFATYYCQQSYTSLFTFGQGTKLEIK variableregion 125 QSINSY ClonePA13P1C09-CDR-L1 126 TAS ClonePA13P1C09-CDR-L2 127 QQSYTSLFT ClonePA13P1C09-CDR-L3 128 QLQLQESGPGLVKPSETLSLTCTVSGVSINSTSYYWGWMRQPPGKGLEWIGNIYYTGTTYYN ClonePA13P1D02-Heavychain PSLNRRVSISGDTSKNQFSLSLTSVTAADTAVYYCAGPRRVTVFGILLMESFDVWSQGTMVT variableregion VSS 129 GVSINSTSYY ClonePA13P1D02-CDR-H1 130 IYYTGTT ClonePA13P1D02-CDR-H2 131 AGPRRVTVFGILLMESFDV ClonePA13P1D02-CDR-H3 132 AIQMTQSPSSLSASVGDRVTITCRASQAIRDDLGWFQQKPGKAPKLLIYTASTLQSGVPSRFS ClonePA13P1D02-lightchain GGGSGTEFILTISSLQPEDIGTYYCLQDYGYPWTFGQGTKVEIK variableregion 133 QAIRDD ClonePA13P1D02-CDR-L1 126 TAS ClonePA13P1D02-CDR-L2 134 LQDYGYPWT ClonePA13P1D02-CDR-L3 135 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYALSWVRQAPGKGLEWVSAISGRDASTYYAD ClonePA14P1E04-Heavychain SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTLFDYDSSGYFDFDYWGQGTLVTVSS variableregion 136 GFTFSNYA ClonePA14P1E04-CDR-H1 137 ISGRDAST ClonePA14P1E04-CDR-H2 138 TLFDYDSSGYFDFDY ClonePA14P1E04-CDR-H3 139 QSALTQPRSVSGSPGQSVTISCTGTGSDVGGYNYVSWYQHHPGKAPKLIIFDVTKRPSGVPD ClonePA14P1E04-lightchain RFSGSKSGYTASLTISGLQAEDEAVYYCCSYANSYTGVFGTGTKVTVL variableregion 140 GSDVGGYNY ClonePA14P1E04-CDR-L1 141 DVT ClonePA14P1E04-CDR-L2 142 CSYANSYTGV ClonePA14P1E04-CDR-L3 143 QVQLVESGGGVVQPGGSLRLSCAASGFTFSSHVMHWVRQAPGKGLEWVALISLDGDDKYY ClonePA14P1E06-Heavychain ADSVNGRVAISRDNSKNTLYLQVNSLRSDDTCVYYCARGGRWDYALDVWGQGTTVTVSS variableregion 144 GFTFSSHV ClonePA14P1E06-CDR-H1 145 ISLDGDDK ClonePA14P1E06-CDR-H2 146 ARGGRWDYALDV ClonePA14P1E06-CDR-H3 147 EIVMTQSPATLSVSPGERATLSCRVSQSISNSLAWYQQKPGQVPRLLIYAASTRATGIPARFSG ClonePA14P1E06-lightchain SGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRALTFGGGTKVEIK variableregion 148 QSISNS ClonePA14P1E06-CDR-L1 149 AAS ClonePA14P1E06-CDR-L2 150 QQYNNWPRALT ClonePA14P1E06-CDR-L3 151 QVQLVESGGGVVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGPEWVAVISYDGTNEY ClonePA11P1G06-Heavychain YMGSVKGRFTISRDNSKNMVNLQMNSLRPEDTAVYYCARDLAAWSRELLVFDQWGQGTL variableregion VTVSS 152 GFTFNDYA ClonePA11P1G06-CDR-H1 153 ISYDGTNE ClonePA11P1G06-CDR-H2 154 ARDLAAWSRELLVFDQ ClonePA11P1G06-CDR-H3 155 ENVLTQSPGTLSLSPGEGATLSCRASQSVPNTYLAWYQQKPGQAPRLLIYGASSRAAGIPDRF ClonePA11P1G06-lightchain SGSGSGTDFTLTISRLEPEDFAVYYCQQYGRSPGTFGQGTKVEIK variableregion 156 QSVPNTY ClonePA11P1G06-CDR-L1 30 GAS ClonePA11P1G06-CDR-L2 157 QQYGRSPGT ClonePA11P1G06-CDR-L3 158 QAQVVESGGGVVQPGTSLRLSCEPSGFTLSDYGIHWVRQPPGKGLEWVAVIWHDGDRINY ClonePA11P1G07-Heavychain ADSVKGRFTISRDESDKKVHLQMESLRTEDTAVYYCARGTLPRNCRGMRCYGEFDHYYYLDV variableregion WGTGTTVTVSS 159 GFTLSDYG ClonePA11P1G07-CDR-H1 160 IWHDGDRI ClonePA11P1G07-CDR-H2 161 ARGTLPRNCRGMRCYGEFDHYYYLDV ClonePA11P1G07-CDR-H3 162 QSVLTQPPSVSGAPGQRVTISCTGHSSNIGANSDVHWYQQLPLRAPKLLIFGTINRASGVPD ClonePA11P1G07-lightchain RFSGSRSGTSASLVISGLQPDDEADYYCQSYDRGLSAYVFGSGTRVDVL variableregion 163 SSNIGANSD ClonePA11P1G07-CDR-L1 164 GTI ClonePA11P1G07-CDR-L2 165 QSYDRGLSAYV ClonePA11P1G07-CDR-L3 166 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGSEKDY ClonePA11P1G04-Heavychain VDSVKGRFTISRDNAKNSLYLQLNSLRAEDTAVYYCARERSTQSSSWYVSSYYSYYGMDVWG variableregion QGTTVTVSS 167 GFTFSSYW ClonePA11P1G04-CDR-H1 168 IKQDGSEK ClonePA11P1G04-CDR-H2 169 ARERSTQSSSWYVSSYYSYYGMDV ClonePA11P1G04-CDR-H3 170 SSELTQDPAVSVALGQTVTITCQGDSLRSFYASWYQQKPGQAPVFVIYGKYNRPSGIPDRFSG ClonePA11P1G04-lightchain SSSGNTASLTITGAQAEDEADYYCNSRDSSDNHLGVFGGGTKLTVL variableregion 171 SLRSFY ClonePA11P1G04-CDR-L1 172 GKY ClonePA11P1G04-CDR-L2 173 NSRDSSDNHLGV ClonePA11P1G04-CDR-L3 174 QVQLVQSGSELRKPGASVKLSCRTSGYTFIHFAMNWLRQAPGQGLEWLGWINTHSGNPTY ClonePA11P1C11-Heavychain AQGFTGRFVFSLDVSAGTAYLEISGLKAEDTAVYYCARERYFDFWGQGALVAVSS variableregion 175 GYTFIHFA ClonePA11P1C11-CDR-H1 176 INTHSGNP ClonePA11P1C11-CDR-H2 177 ARERYFDF ClonePA11P1C11-CDR-H3 178 QSVLTQPPSASGTPGQRVTISCSGTSSNIGKNFLYWYQQVPGTAPKLLIYSSNQRPSGVPDRF ClonePA11P1C11-lightchain SGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGWVFGGGTKVTVL variableregion 179 SSNIGKNF ClonePA11P1C11-CDR-L1 180 SSN ClonePA11P1C11-CDR-L2 181 AAWDDSLSGWV ClonePA11P1C11-CDR-L3 182 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNYWMNWVRQPPGKGLVWVSRISGDGTGTSY ClonePA11P1C12-Heavychain ADSVRGRFTISRDNAKSTLYLQVNSLSAEDTAVYYCTRDGGRDHPTPDAFDIWGQGTMVTV variableregion SS 183 GFTFSNYW ClonePA11P1C12-CDR-H1 184 ISGDGTGT ClonePA11P1C12-CDR-H2 185 TRDGGRDHPTPDAFDI ClonePA11P1C12-CDR-H3 186 DVVMAQSPLSLPVTLGQPASISCRSSQSLVHSDGNTYLNWFQQRPGQSPRRLIYKISNRDSG ClonePA11P1C12-lightchain VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPRTFGQGTKLEIK variableregion 187 QSLVHSDGNTY ClonePA11P1C12-CDR-L1 188 KIS ClonePA11P1C12-CDR-L2 189 MQGTHWPRT ClonePA11P1C12-CDR-L3 190 QVQLQQWGAGLLKPSETLSLTCVVSGGSFSTHYWNWIRQSPGKGLEWIGEINHSGNTNYN ClonePA15P1G05-Heavychain PSLTGRATISVATSKTQFSLRLNSVTAADTAVYFCARGPRLRYTAGRPLFDTWGQGTLVTVSS variableregion 191 GGSFSTHY ClonePA15P1G05-CDR-H1 192 INHSGNT ClonePA15P1G05-CDR-H2 193 ARGPRLRYTAGRPLFDT ClonePA15P1G05-CDR-H3 194 DIQMTQSPSTLSASVGDRVTITCRASQSISAFLAWYQQKPGKAPNLVIYKASSLDSGVPSTFS ClonePA15P1G05-lightchain GSGSGTEYTLTISSLQPDDFATYYCQQYFSSPPTFGQGTKVEMK variableregion 195 QSISAF ClonePA15P1G05-CDR-L1 196 KAS ClonePA15P1G05-CDR-L2 197 QQYFSSPPT ClonePA15P1G05-CDR-L3 198 QVQLQESGPGLVKPSQTLSLTCAVSGGSISSGGYYWSWIRQLPGKGLEWIGYIYYSGSTSYNP ClonePA14P1F05-Heavychain SLKSRVTISVDTSKNQLSLNLSSVTAADTAVYNCARGRRISISGVVTPLFDYWGQGTLVTVSS variableregion 199 GGSISSGGYY ClonePA14P1F05-CDR-H1 200 IYYSGST ClonePA14P1F05-CDR-H2 201 ARGRRISISGVVTPLFDY ClonePA14P1F05-CDR-H3 202 DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQLKPGKAPKLLIYAASSLQSGVPSRFS ClonePA14P1F05-lightchain GSGSGTDFTLTISSLQPEDFATYYCQQANSVPLTFGGGTKVEIK variableregion 203 QGISSW ClonePA14P1F05-CDR-L1 149 AAS ClonePA14P1F05-CDR-L2 204 QQANSVPLT ClonePA14P1F05-CDR-L3 205 EVQLVESGGGLVKPGGSLRLSCAASGFTFSHYYLNWVRQAPGKGLEWVACISDRSENVYYA ClonePA14P1F07-Heavychain DSVKGRFTISRDNAKNSLFLQMNNLRAEDTAIYYCARDMRELRPSADYWGQGTLVTVSS variableregion 206 GFTFSHYY ClonePA14P1F07-CDR-H1 207 ISDRSENV ClonePA14P1F07-CDR-H2 208 ARDMRELRPSADY ClonePA14P1F07-CDR-H3 209 EIVLTQSPGTLSLSPGDRATLSCRASQSVDGNSLAWYQQKPGQAPRLLISGASTRATGIPDRF ClonePA14P1F07-lightchain SGSGSGTDFTLTISRLEPEDFVLYHCQLYTVSPRYTFGQGTKLEIK variableregion 210 QSVDGNS ClonePA14P1F07-CDR-L1 30 GAS ClonePA14P1F07-CDR-L2 211 QLYTVSPRYT ClonePA14P1F07-CDR-L3 212 QLQLQESGPGLVKPSETLSLTCTVSGGSISSDNYYWGWIRQPPGKGPLWIGTIFYNGDTYYN ClonePA14P3H12-Heavychain PSLKSQLNISVDPSKNQFSLKLTSVTAADTAIYYCTRHDSYSRGWYVTHWGQGTLVTVSS variableregion 213 GGSISSDNYY ClonePA14P3H12-CDR-H1 214 IFYNGDT ClonePA14P3H12-CDR-H2 215 TRHDSYSRGWYVTH ClonePA14P3H12-CDR-H3 216 EIVLTQSPATLSLFPGERATLSCRASQSVTSYLAWYQQKPGQAPRLLIYDASKRATGIPARFSG ClonePA14P3H12-lightchain SGSGTDFTLTISSLEPEDFATYYCQQRSARQLFGGGTKVEIK variableregion 217 QSVTSY ClonePA14P3H12-CDR-L1 94 DAS ClonePA14P3H12-CDR-L2 218 QQRSARQL ClonePA14P3H12-CDR-L3 219 EVQLVESGGGLVKPGGSLRLSCVASGLTFRNAWMTWVRQAPGKGLEWVGRIKSNVNGGT ClonePA14P3H10-Heavychain TDYAAPVRGRFTISRDDSRDTLYLQMNSLETEDTAMYYCTKDPPYTGGGYCQHWGLGTLVT variableregion VSS 220 GLTFRNAW ClonePA14P3H10-CDR-H1 221 IKSNVNGGTT ClonePA14P3H10-CDR-H2 222 TKDPPYTGGGYCQH ClonePA14P3H10-CDR-H3 223 EIVLTQSPATLSLSPGESATLSCRASQSVSSCLAWYQQKPGQAPRLLIYDASTRAPGIPGRFSG ClonePA14P3H10-lightchain SGSGTDFTLAISSLEPEDFAVYYCQQCSNWPLTFGRGTRLEIK variableregion 224 QSVSSC ClonePA14P3H10-CDR-L1 94 DAS ClonePA14P3H10-CDR-L2 225 QQCSNWPLT CloneP?14P3H10-CDR-L3 226 QVQLQESGPGLVKPSQTLSLTCTVSGGSINTGAYYWSWIRQHPGKGLEWIGYIYYSGSTYYN ClonePA11P1G10-Heavychain PSLKSRVTISKDTSKNQFSLRLTSVTAADTAVYYCVREKLTGAPDNWGQGTLVAVSS variableregion 227 GGSINTGAYY ClonePA11P1G10-CDR-H1 200 IYYSGST ClonePA11P1G10-CDR-H2 228 VREKLTGAPDN ClonePA11P1G10-CDR-H3 229 DIQMTQSPSSLSASVGDRVTITCRASQGVSNYLAWFHQKPGKAPKSLIYAASTLHDGVPSSFS ClonePA11P1G10-lightchain GSGSGTEFTLTISDLQPEHFGTYYCEQYNSYPFTFGPGTTVDFK variableregion 230 QGVSNY ClonePA11P1G10-CDR-L1 149 AAS ClonePA11P1G10-CDR-L2 231 EQYNSYPFT ClonePA11P1G10-CDR-L3 232 QVQLVQSGAEVKKPGSSVKVSCKASGGPLSSYNFIWVRQAPGQGLEWMGGILPVFDTTNY ClonePA13P2H10-Heavychain AQKFQGRVTITADKATSTSYMELSSLTSEDTAVYYCARAVGGTHYYYYGLDVWGQGTTVAV variableregion SS 233 GGPLSSYN ClonePA13P2H10-CDR-H1 234 ILPVFDTT ClonePA13P2H10-CDR-H2 235 ARAVGGTHYYYYGLDV ClonePA13P2H10-CDR-H3 236 EIVMTQSPLSLPVTPGEPASISCRSSQSLLHGNGYNYVDWYLQRPGQPPQLLIYLGSRRASGV ClonePA13P2H10-lightchain PDRFSGSGSGTDFTLKISRVEADDLGVYYCMQALQTRVTFGPGTKVDIK variableregion 237 QSLLHGNGYNY ClonePA13P2H10-CDR-L1 78 LGS ClonePA13P2H10-CDR-L2 238 MQALQTRVT ClonePA13P2H10-CDR-L3 239 EVQLVQSGAEVKKPGESLKISCKGSGYSFMSYWIGWVRQKPGKGLEWMGIIFPGDSDTRYS ClonePA14P1H02-Heavychain PSFQGHVTISADKSITTAYLQWNSLEASDTAIYYCATLDGDYWGRGTLVTVSS variableregion 240 GYSFMSYW ClonePA14P1H02-CDR-H1 241 IFPGDSDT ClonePA14P1H02-CDR-H2 242 ATLDGDY ClonePA14P1H02-CDR-H3 243 DIVMTQSPDSLAVSLGERATINCRSSQSVLSSSSNKNYLGWYQQKPGQPPKLLIHWASTRAA ClonePA14P1H02-lightchain GVPDRFSGSGTGTDFTLNISSLQAEDVAVYYCQQYHTTLPTFGQGTKLEIK variableregion 244 QSVLSSSSNKNY ClonePA14P1H02-CDR-L1 86 WAS ClonePA14P1H02-CDR-L2 245 QQYHTTLPT ClonePA14P1H02-CDR-L3 246 EVQLLESGGGLVQPGGSLRLSCAASGFTFRDSAMTWVRQAPGKGLEWVSTISGNGDTTYYA ClonePA14P1H01-Heavychain DSVKGRFSIFRDNSRNTLYVQMNSLRAEDTAVYYCARYGDHKGWFDSWGQGTLVTVSS variableregion 247 GFTFRDSA ClonePA14P1H01-CDR-H1 248 ISGNGDTT ClonePA14P1H01-CDR-H2 249 ARYGDHKGWFDS ClonePA14P1H01-CDR-H3 250 ELVMTQSPASLSVSPGEGATVSCRASQSVGSNLAWYQQKPGQGPRLLIYGASTRATGVPAR ClonePA14P1H01-lightchain FSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKVEIK variableregion 251 QSVGSN ClonePA14P1H01-CDR-L1 30 GAS ClonePA14P1H01-CDR-L2 252 QQYNNWPRT ClonePA14P1H01-CDR-L3 253 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSDGSKTY ClonePA14P1H09-Heavychain AQKFQGRVTLTRDTSTSTVYMELSSLRSEDTAVYYCARGNGYSSSWYVNDYWGQGTLVTVSS variableregion 89 GYTFTSYY ClonePA14P1H09-CDR-H1 254 INPSDGSK ClonePA14P1H09-CDR-H2 255 ARGNGYSSSWYVNDY ClonePA14P1H09-CDR-H3 256 DIVLTQSPGTLSLSPGERATLSCRASQSLTNSNFAWYQQIPGQAPRLLIYGASSRATGIPDRFS ClonePA14P1H09-lightchain GSGSGTDFTLTISRLEPEDFVVYYCQQYGRSPITFGQGTRLEIK variableregion 257 QSLTNSN ClonePA14P1H09-CDR-L1 30 GAS ClonePA14P1H09-CDR-L2 258 QQYGRSPIT ClonePA14P1H09-CDR-L3 259 QVQLVESGGGVVQPGRSLRLSCAASGFTFTKYGMHWVRQAPGKGLEWVALISYDGNNKYY ClonePA12P3D11-Heavychain ADSVRGRVTISRDNSKNTLYLQMDSLRAEDTAVYYCARGQDYPFWSGSTFEYWGQGTLVTV variableregion SS 260 GFTFTKYG ClonePA12P3D11-CDR-H1 261 ISYDGNNK ClonePA12P3D11-CDR-H2 262 ARGQDYPFWSGSTFEY ClonePA12P3D11-CDR-H3 263 QAVVTQEPSLTVSPGGTVTLTCGSTTGAVTGGHFPYWIQQKPGQAPRTLIYDATNRHSWTP ClonePA12P3D11-lightchain ARFSGSLLGGKAALTLSGAQPEDEADYYCLLSYSSATFLIFGGGTKLTVL variableregion 264 TGAVTGGHF ClonePA12P3D11-CDR-L1 265 DAT ClonePA12P3D11-CDR-L2 266 LLSYSSATFLI ClonePA12P3D11-CDR-L3 267 QVQLQESGPGLVKPSETLSLTCTVSGDSLSSGSYFWSWIRQPPGKGLEWIGYISFRGDTNYNP ClonePA12P3F02-Heavychain SLKSRVIISLDKSKNQFSLRLSSMTPADTAVYYCARSPWIQSWSYYFDYWGQGTLVTVSS variableregion 268 GDSLSSGSYF ClonePA12P3F02-CDR-H1 269 ISFRGDT ClonePA12P3F02-CDR-H2 270 ARSPWIQSWSYYFDY ClonePA12P3F02-CDR-H3 271 DIQMTQSPSTVSASVGDRVTITCRASQRISSWLAWYQQKPGKAPKLLIYKASSLEGGVPSRFS ClonePA12P3F02-lightchain GSGSGTEFTLTISSLQPDDFAIYYCQQYNGYPWTFGQGTKVEIK variableregion 272 QRISSW ClonePA12P3F02-CDR-L1 196 KAS ClonePA12P3F02-CDR-L2 273 QQYNGYPWT ClonePA12P3F02-CDR-L3 274 QVQLQESGPGLVKPSGTLSLTCAVSGGSISTDNWWSWVRQPPNKGLEWIGAIFQSGSTIYN ClonePA12P3F07-Heavychain PSLMSRVTISLDRSNNRFSLQLISVTAADTALYYCARASFHYGSGNYFEYLGQGTLVTVSS variableregion 275 GGSISTDNW ClonePA12P3F07-CDR-H1 276 IFQSGST ClonePA12P3F07-CDR-H2 277 ARASFHYGSGNYFEY ClonePA12P3F07-CDR-H3 278 QSVLTQPPSVSAAPGQKVTISCSGSSSNVGTHHVSWYQQLPGTAPKLLIYENDKRPSGIPNRF ClonePA12P3F07-lightchain SGSKSGTSATLAIIGLQTGDEADYYCGSWDSSLSAFWVFGGGTKLTVL variableregion 279 SSNVGTHH ClonePA12P3F07-CDR-L1 280 END ClonePA12P3F07-CDR-L2 281 GSWDSSLSAFWV ClonePA12P3F07-CDR-L3 282 QVQLVQSGAEVKKPGASVKVACKASGYTFTRYAMHWVRQAPGQRLEWMGWINAGNGN ClonePA14P1G03-Heavychain TKDSQKFQGRVTITRDTSASTVYMELSSLRSEDTAVYYCARGVPWGLGSYNFDYWGQGTLV variableregion SISS 283 GYTFTRYA ClonePA14P1G03-CDR-H1 284 INAGNGNT ClonePA14P1G03-CDR-H2 285 ARGVPWGLGSYNFDY ClonePA14P1G03-CDR-H3 286 QTVVTQEPSLTVSPGGTVTLSCASNTGAVTSGYYPYWFQQKPGQAPRTLIYETSNKHPWTP ClonePA14P1G03-lightchain ARFSGSLLGGKAALTLSGVQPEDEAEYCCLLYYGGTWVFGGGTKLTVL variableregion 287 TGAVTSGYY ClonePA14P1G03-CDR-L1 288 ETS ClonePA14P1G03-CDR-L2 289 LLYYGGTWV ClonePA14P1G03-CDR-L3 290 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYALSWVRQAPGKGLEWVSAISGRDGNTYYAD ClonePA14P1G01-Heavychain SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTLYDYDSSGYFDFDYWGQGTLVTVSS variableregion 113 GFTFSSYA ClonePA14P1G01-CDR-H1 291 ISGRDGNT ClonePA14P1G01-CDR-H2 292 TLYDYDSSGYFDFDY ClonePA14P1G01-CDR-H3 293 QSALTQPRSVSGSPGQSVTISCTGTSSDVGGFNYVSWYQQHPGKAPKLMIFDVTQRPSGVP ClonePA14P1G01-lightchain DRFSGSKSGNTASLTISGLQAEDEADYHCCSYANYYTGVFGTGTRVTVL variableregion 294 SSDVGGFNY ClonePA14P1G01-CDR-L1 141 DVT ClonePA14P1G01-CDR-L2 295 CSYANYYTGV ClonePA14P1G01-CDR-L3 296 EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMHWVRQAPGKGLVWVSRINSDGSNIRF ClonePA16P1F09-Heavychain ADSVKGRFTFSRDNANNTLYLQMNSLRAEDTAVYYCARASRTVYGDSPLSYGIDVWGQGTT variableregion VTVSS 183 GFTFSNYW ClonePA16P1F09-CDR-H1 297 INSDGSNI ClonePA16P1F09-CDR-H2 298 ARASRTVYGDSPLSYGIDV ClonePA16P1F09-CDR-H3 299 SYALTQPPSVSVSPGQTASITCSGDKLGNKFACWYQQKPGRSPVLVIYQDSQRPTGIPERFSG ClonePA16P1F09-lightchain SNSGNTATLTISGTQAMDEADYYCQAWDSNTHVLFGGGTKLTVL variableregion 300 KLGNKF ClonePA16P1F09-CDR-L1 301 QDS ClonePA16P1F09-CDR-L2 302 QAWDSNTHVL ClonePA16P1F09-CDR-L3 303 QVQLVESGGGVVQPGGSLRLSCAASGFTFSGYGMHWVRQAPGKGLEWVAFFSFDGSNTD ClonePA14P1G12-Heavychain YVDSVKGRFTISGDNSKNTLYLQMNSLRAEDTAVYYCVRDILVLPAAVSVFSGYYYGMDVW variableregion GQGTTVTVSS 304 GFTFSGYG ClonePA14P1G12-CDR-H1 305 FSFDGSNT ClonePA14P1G12-CDR-H2 306 VRDILVLPAAVSVFSGYYYGMDV ClonePA14P1G12-CDR-H3 307 EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSG ClonePA14P1G12-lightchain SGSGTDFTLTISSLEPEDFAVYYCQHRSNWPITFGQGTRLEIK variableregion 308 QSVRSY ClonePA14P1G12-CDR-L1 94 DAS ClonePA14P1G12-CDR-L2 309 QHRSNWPIT ClonePA14P1G12-CDR-L3 310 QVQLRVSGPGLVNPSETLSLTCIVSGDSLRDYYWSWIRQSPGKGLEWIGYVTESGGAHYNPS ClonePA11P1D12-Heavychain LESRVTISVDASKTQFSLNLKSVTAADTAVYYCARDAYSSTWYTVGWFDPWGPGSLVTVSS variableregion 311 GDSLRDYY ClonePA11P1D12-CDR-H1 312 VTESGGA ClonePA11P1D12-CDR-H2 313 ARDAYSSTWYTVGWFDP ClonePA11P1D12-CDR-H3 314 EIVLTQSPATLSLSPGERATLSCRASQDVGVYLAWYQQKPGQAPRLIIYDASDRVSGVPARFT ClonePA11P1D12-lightchain GSGSGTDFTLTITSLEPEDFAVYFCQQRTSGLTFGGGTTLEIK variableregion 315 QDVGVY ClonePA11P1D12-CDR-L1 94 DAS ClonePA11P1D12-CDR-L2 316 QQRTSGLT ClonePA11P1D12-CDR-L3 317 QVELVESGGGVVQPGRSLRLSCVASGFTFSDYGMHWVRQAPGKGLEWVAVIWFDGSSKYY ClonePA11P1D11-Heavychain ADSVKGRFTISRDDSKNTVFMQMNNVRVEDTAVYYCAREQWLGTEYFQNWGQGTLVTVSS variableregion 318 GFTFSDYG ClonePA11P1D11-CDR-H1 319 IWFDGSSK ClonePA11P1D11-CDR-H2 320 AREQWLGTEYFQN ClonePA11P1D11-CDR-H3 321 EIVMTQSPATLSLFPGERATLSCRASQSVAGNLAWYQQKPGQAPRLLIYEASTRATDIPARFS ClonePA11P1D11-lightchain GSGSETEFTLTISSLQSEDFAVYYCQQYKKWLITFGQGTRLEIK variableregion 322 QSVAGN ClonePA11P1D11-CDR-L1 323 EAS ClonePA11P1D11-CDR-L2 324 QQYKKWLIT ClonePA11P1D11-CDR-L3 325 QLQLQQWGAGLVKPSETLSLTCTVSGGSLSGHFWSWIRQSPEKGLEWIGEINHSGRKNYNP ClonePA12P1D02-Heavychain SLMIRVDISIDTSKNQFSMRMTSLTAADSAVYYCARVGRNIVDTDDAFDVWGRGTLVTVSS variableregion 326 GGSLSGHF ClonePA12P1D02-CDR-H1 327 INHSGRK ClonePA12P1D02-CDR-H2 328 ARVGRNIVDTDDAFDV ClonePA12P1D02-CDR-H3 329 EIVLTQSPGTLSLSPGDTVTLSCRASQTIDSIYLAWYQQRPGQAPRLLIYGASTRATGTPDRFS ClonePA12P1D02-lightchain GGGSGTDFTLTITRLEPEDFAVYFCQQYGTSPPITFGRGTRLEIK variableregion 330 QTIDSIY ClonePA12P1D02-CDR-L1 30 GAS ClonePA12P1D02-CDR-L2 331 QQYGTSPPIT ClonePA12P1D02-CDR-L3 332 QVQLLQSGAEVKKPGASVKVSCKASGYTFTSYNIHWVRQAPGQSFEWMGWIHVGNGETK ClonePA12P1D04-Heavychain YSQNFQDRVAITRDTSANTVYMELSPLRSEDTALYYCVRDHVTAIVVGLFDPWGQGTLVTVSS variableregion 333 GYTFTSYN ClonePA12P1D04-CDR-H1 334 IHVGNGET ClonePA12P1D04-CDR-H2 335 VRDHVTAIVVGLFDP ClonePA12P1D04-CDR-H3 336 QSALTQPASVSGSPGQSITISCSGTSTDVGAYKYVSWYQHHPGRSPKVILYEVDNRPSGVSIR ClonePA12P1D04-lightchain FSGSKSGNTASLTISGLRAEDEADYYCSSFTSSSTWVFGGGTKVTVL variableregion 337 STDVGAYKY ClonePA12P1D04-CDR-L1 338 EVD ClonePA12P1D04-CDR-L2 339 SSFTSSSTWV ClonePA12P1D04-CDR-L3 340 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYSISWVRQAPGQGLEWMGGIIPIFGSGSYA ClonePA12P3E09-Heavychain QKFQGRVTITADKSTSTAYMELSSLSSDDTAVYYCARGESPSNFVYYGMDVWGQGTTVTVSS variableregion 341 GGTFSSYS ClonePA12P3E09-CDR-H1 342 IPIFGSG ClonePA12P3E09-CDR-H2 343 ARGESPSNFVYYGMDV ClonePA12P3E09-CDR-H3 344 DIVLTQSPLSLPVTPGEPASISCRSSHSLLHSNGYNHLDWYLQKPGQSPQLLIYLGSNRASGVP ClonePA12P3E09-lightchain DRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALLVTFGPGTKVDIK variableregion 345 HSLLHSNGYNH ClonePA12P3E09-CDR-L1 78 LGS ClonePA12P3E09-CDR-L2 346 MQALLVT ClonePA12P3E09-CDR-L3 347 EVKVVESGGGLVQPGGSLRLSCAASEFTFTYYWMSWIRQAPGKGLEWVANVNGDATEKYY ClonePA12P3E04-Heavychain VDSVKGRFTISRDNPKKTVYLQMNSLRVEDTAVYYCARVGTTVVNDGFDLWGLGTMVTVSS variableregion 348 EFTFTYYW ClonePA12P3E04-CDR-H1 349 VNGDATEK ClonePA12P3E04-CDR-H2 350 ARVGTTVVNDGFDL ClonePA12P3E04-CDR-H3 351 SYVLTQSHSVSVAPGQTARITCGGENIGGKGVHWYQQKPGQAPLLVVSSDTGRRSVTPDRF ClonePA12P3E04-lightchain SGSNSGDTATLIISRVEAGDEADYYCQVWDPTSEYVFGSGTKVTVL variableregion 352 NIGGKG ClonePA12P3E04-CDR-L1 353 SDT ClonePA12P3E04-CDR-L2 354 QVWDPTSEYV ClonePA12P3E04-CDR-L3 355 QLQLQESGSGLVKPSQTLSLTCAVSGGSISSGDYSWSWIRQPPGKGLEWIGFRYYSGTTFYNP ClonePA12P3E07-Heavychain SLESRLTISIDRSTNQFSLQLTSVTAADTAVYFCASFRPLLRFLDPEGLFEYWGQGILVTVSS variableregion 356 GGSISSGDYS ClonePA12P3E07-CDR-H1 357 RYYSGTT ClonePA12P3E07-CDR-H2 358 ASFRPLLRFLDPEGLFEY ClonePA12P3E07-CDR-H3 359 ELVMTQSPATLSVSPGARATLSCRASPGANSHLAWYQQKPGQAPRLLIYGASTRATGIPARF ClonePA12P3E07-lightchain SGSGSGTEFTLTISSLQSEDFAVYYCQQYNDWPYTFGQGTKLEIK variableregion 360 PGANSH ClonePA12P3E07-CDR-L1 30 GAS ClonePA12P3E07-CDR-L2 361 QQYNDWPYT ClonePA12P3E07-CDR-L3 362 QVQLVQSGAAVKKPGASVRISCEASGYTFTGYNIHWVRQAPGQGLEWMGWVNPNNGGT ClonePA12P3E06-Heavychain KFAQKFEGWVTMTVATSINTVYMELTGLKSGDTAVYFCARDHGDSFDQWGQGTLVTVSS variableregion 363 GYTFTGYN ClonePA12P3E06-CDR-H1 364 VNPNNGGT ClonePA12P3E06-CDR-H2 365 ARDHGDSFDQ ClonePA12P3E06-CDR-H3 366 EIVLTQSPDTLSLSPGDRATLSCRASHSLNNDYLAWYQHRPGQAPRLLIYGTSHGATGIPDRF ClonePA12P3E06-lightchain SGSGSGTDFTLTISRLETEDFAVYYCHHYGKSLFPFGPGTKVDIK variableregion 367 HSLNNDY ClonePA12P3E06-CDR-L1 22 GTS ClonePA12P3E06-CDR-L2 368 HHYGKSLFP ClonePA12P3E06-CDR-L3 369 EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSAMHWVRQASGKGLEWVGRIRSKANTYAT ClonePA14P1E08-Heavychain AYAASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRKHTSGWYDRGGDVWGQGTTV variableregion TVSS 370 GFTFSGSA ClonePA14P1E08-CDR-H1 371 IRSKANTYAT ClonePA14P1E08-CDR-H2 372 TRKHTSGWYDRGGDV ClonePA14P1E08-CDR-H3 373 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFS ClonePA14P1E08-lightchain GSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGGGTKVEIK variableregion 374 QDISNY ClonePA14P1E08-CDR-L1 94 DAS ClonePA14P1E08-CDR-L2 375 QQYDNLPLT ClonePA14P1E08-CDR-L3 376 EVQLLESGGGLVQPGGSLRLSCAASGFTVSNYAMSWVRQAPGKGLEWVSAISGSGGSTYYA ClonePA14P1E09-Heavychain DSVKGRFTISRDTSKNTLYLQMNSLRAEDTAVYYCAIDCTVTDAPLSYWGQGTLVTVSS variableregion 377 GFTVSNYA ClonePA14P1E09-CDR-H1 378 ISGSGGST ClonePA14P1E09-CDR-H2 379 AIDCTVTDAPLSY ClonePA14P1E09-CDR-H3 380 AIQMTQSPSSLSPSVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFS ClonePA14P1E09-lightchain GGGSGTDFTLTISSLQPEDFATYYCLQDYNYPRTFGQGTKVEIK variableregion 381 QGIRND ClonePA14P1E09-CDR-L1 149 AAS ClonePA14P1E09-CDR-L2 382 LQDYNYPRT ClonePA14P1809-CDR-L3 383 QVQLEQSGAEVRKPGSSVKVSCKASGTTFSNHAMSWVRQAPGQGLEWMGGIIPLVDKSM ClonePA14P1H05-Heavychain YALKFQGRVTITADESRNTVYMELSSLGSEDTAVYYCARSFADITTFGFVVNFHYYYTLDVWG variableregion QGTPVTVSS 384 GTTFSNHA ClonePA14P1H05-CDR-H1 385 IPLVDKS ClonePA14P1H05-CDR-H2 386 ARSFADITTFGFVVNFHYYYTLDV ClonePA14P1H05-CDR-H3 387 NFMLTQPHSVSESPGKTVTISCTRSSGSIADNYVQWFQQRPGSAPTTLIYEDNRRPSGVPDR ClonePA14P1H05-lightchain FSGSVDSSSNSASLTISGLKPEDEADYYCQSYDTTQRVFGGGTKLTVL variableregion 388 SGSIADNY ClonePA14P1H05-CDR-L1 389 EDN ClonePA14P1H05-CDR-L2 390 QSYDTTQRV ClonePA14P1H05-CDR-L3 391 QLQLQESGSRLVKPSQTLSLTCAVSGGSINSGGYSWSWIRQPPGKGLEWIGNIYHGETTHYN ClonePA12P3C09-Heavychain PSLKSRVTISIDKSKNQFSLKLTSVTAADTAVYYCARAPLGNYYDTSGYLQPFDYWGPGALVTV variableregion SS 392 GGSINSGGYS ClonePA12P3C09-CDR-H1 393 IYHGETT ClonePA12P3C09-CDR-H2 394 ARAPLGNYYDTSGYLQPFDY ClonePA12P3C09-CDR-H3 395 DIQMTQSPSSLSASVGDRVTITCRASQGIINDLGWYQQRPGRAPTRLIYAASSLQSGVPSRFS ClonePA12P3C09-lightchain GSGSGTEFTLTINSLQPADFATYFCLQYNSYPPTFGQGTKVEIK variableregion 396 QGIIND ClonePA12P3C09-CDR-L1 149 AAS ClonePA12P3C09-CDR-L2 397 LQYNSYPPT ClonePA12P3C09-CDR-L3 398 EVQLVESGGGVVRPGGSLRLSCAASGFIFRDHGMSWVRQAPGKGLEWVSGINWNGANTG ClonePA12P3C05-Heavychain YADSVKGRSTISRDNAKNSLYLQMSSLRADDTALYHCVSHDYYYGLDVWGPGTTVIVSS variableregion 399 GFIFRDHG ClonePA12P3C05-CDR-H1 400 INWNGANT ClonePA12P3C05-CDR-H2 401 VSHDYYYGLDV ClonePA12P3C05-CDR-H3 402 QSALTQPRSVSGSPGQSVTISCTGTSSDVGGDNYVSWYQQHPGKVPKLIIHDVSERPSGVPD ClonePA12P3C05-lightchain RFSGSKSANTASLTISGLQADDEADYYCCSYAGTYTFGGGTRLTVL variableregion 403 SSDVGGDNY ClonePA12P3C05-CDR-L1 404 DVS ClonePA12P3C05-CDR-L2 405 CSYAGTYT ClonePA12P3C05-CDR-L3 406 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQLPGKGLEWIGYIYYSGSTSYNP ClonePA14P1G11-Heavychain SLKSRVTISVDTSKNQLSLNLSSVTAADTAVYYCARGRRISISGVVTPLFDYWGQGTLVTVSS variableregion 199 GGSISSGGYY ClonePA14P1G11-CDR-H1 200 IYYSGST ClonePA14P1G11-CDR-H2 201 ARGRRISISGVVTPLFDY ClonePA14P1G11-CDR-H3 407 DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFS ClonePA14P1G11-lightchain GSGSGTDFTLTISSLQPEDFATYYCQQANSVPLTFGGGTKVEIK variableregion 203 QGISSW ClonePA14P1G11-CDR-L1 149 AAS ClonePA14P1G11-CDR-L2 204 QQANSVPLT ClonePA14P1G11-CDR-L3 408 QVQLVQSGAEVKKPGASVKVSCQASGYTFTRYDINWVRQATGQGLEWMGWLNPKSGDT ClonePA12P3C01-Heavychain GYAQKFQGRVTMTRDTSISTAYMELTSLTSDDTAVYYCARGVDANHWGQGSLVTVSS variableregion 409 GYTFTRYD ClonePA12P3C01-CDR-H1 410 LNPKSGDT ClonePA12P3C01-CDR-H2 411 ARGVDANH ClonePA12P3C01-CDR-H3 412 DIVVTQSPDSLAVSLGERATINCKSSQSIFDTSSNKNYLAWFRQRPGQPPQLLIYWASTRESG ClonePA12P3C01-lightchain VPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSLPHAFGQGTKLEIK variableregion 413 QSIFDTSSNKNY ClonePA12P3C01-CDR-L1 86 WAS ClonePA12P3C01-CDR-L2 414 HQYYSLPHA ClonePA12P3C01-CDR-L3 415 EAQLVESGGGLVQPGGSLRLSCAASGFTFSSYYIHWVRQAPGKGLVWVSRINSDGSSTRYAD ClonePA16P1H09-Heavychain SVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYFCARASRTVYGDSPLSNGMDVWGQGTKV variableregion TVSS 416 GFTFSSYY ClonePA16P1H09-CDR-H1 417 INSDGSST ClonePA16P1H09-CDR-H2 418 ARASRTVYGDSPLSNGMDV ClonePA16P1H09-CDR-H3 419 SYELTQPPSVSVSPGQTASITCSGDKLGDKFACWYQQKPGHSPVLVIYQDDKRPSGIPERFSG ClonePA16P1H09-lightchain SNSGNTATLTISGTQAMDEADYYCQAWDSSTHVVFGGGTKLTVL variableregion 420 KLGDKF ClonePA16P1H09-CDR-L1 421 QDD ClonePA16P1H09-CDR-L2 422 QAWDSSTHVV ClonePA16P1H09-CDR-L3 423 EVQLVESGGGLVQPGGSLRLSCAASGFSFNTYNMNWVRQAPGKGLEWISDITSSGSMRSYA ClonePA12P3D09-Heavychain DAVKGRFTISRDNAKNSLHLQMNSLRVEDTAVYYCTRGWHDDLWSGYSYGLDVWGQGTT variableregion VTVSS 424 GFSFNTYN ClonePA12P3D09-CDR-H1 425 ITSSGSMR ClonePA12P3D09-CDR-H2 426 TRGWHDDLWSGYSYGLDV ClonePA12P3D09-CDR-H3 427 DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQRPGKAPRCLIYGASSLQSGVPSRF ClonePA12P3D09-lightchain SGSGSGTEFTLTISNLQAEDFATYYCLQHKSYPLTFGPGTKVDIK variableregion 381 QGIRND ClonePA12P3D09-CDR-L1 30 GAS ClonePA12P3D09-CDR-L2 428 LQHKSYPLT ClonePA12P3D09-CDR-L3 429 QLLLLGPGPGVVRPSETLSLTCNVSGHSITDSPYYWGWIRQAPGKGLEWIGHFYYSDYTYYN ClonePA13P3G04-Heavychain PSLKSRVNVSVDTSKNHLFLALTSVTAADTAVYYCARGFGGYDSPIWAIWGQGTLVTVSS variableregion 430 GHSITDSPYY ClonePA13P3G04-CDR-H1 431 FYYSDYT ClonePA13P3G04-CDR-H2 432 ARGFGGYDSPIWAI ClonePA13P3G04-CDR-H3 433 SHAVTQPPSVSVAPGQTASLTCAGDDIEENTVHWYQQKPGQAPVLVIYYTTDRPSAIPERFF ClonePA13P3G04-lightchain GSKSGNTATLSIARVEAGDEADYYCQVSDRVFGGGTKLTVL variableregion 434 DIEENT ClonePA13P3G04-CDR-L1 435 YTT ClonePA13P3G04-CDR-L2 436 QVSDRV ClonePA13P3G04-CDR-L3 437 EVQLVQSGGGLVKPGGSLRLSCAASGSTLTNYNINWVRQAPGKGLQWVSSISGTRDYTYYA ClonePA11P1C03-Heavychain DSVVGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCARGREVGGDYDSYDWGQGTLVTVSS variableregion 438 GSTLTNYN ClonePA11P1C03-CDR-H1 439 ISGTRDYT ClonePA11P1C03-CDR-H2 440 ARGREVGGDYDSYD ClonePA11P1C03-CDR-H3 441 DIQMTQSPSSLSASVGDRVTITCQASQDISTFLHWYQQKPGKAPSVLIYGASDLKTGVPSRFS ClonePA11P1C03-lightchain GSGSGTHFTLTISSLQPEDIATYYCQQYDHLPLTFGGGTKVEIK variableregion 442 QDISTF ClonePA11P1C03-CDR-L1 30 GAS ClonePA11P1C03-CDR-L2 443 QQYDHLPLT ClonePA11P1C03-CDR-L3 444 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYAD ClonePA11P1C01-Heavychain SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSRLGWAYDAFDIWGQGTMVTVSS variableregion 445 GFTVSSNY ClonePA11P1C01-CDR-H1 446 IYSGGST ClonePA11P1C01-CDR-H2 447 ARDSRLGWAYDAFDI ClonePA11P1C01-CDR-H3 448 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGV ClonePA11P1C01-lightchain PDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQDGTFGQGTKVEIK variableregion 77 QSLLHSNGYNY ClonePA11P1C01-CDR-L1 78 LGS ClonePA11P1C01-CDR-L2 449 MQDGT ClonePA11P1C01-CDR-L3 450 QVQLVQSGSELKKPGASVKASCKASGYTFSNYAVNWVRQAPGQGLEWMGWINTKTGNPT ClonePA11P1C06-Heavychain YGQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARAADYGEPYYYGMDVWGQGTTVT variableregion VSS 451 GYTFSNYA ClonePA11P1C06-CDR-H1 452 INTKTGNP ClonePA11P1C06-CDR-H2 453 ARAADYGEPYYYGMDV ClonePA11P1C06-CDR-H3 454 QSALTQPASVSGSPGQSITISCTGTNSDVGSYNLVSWYQQHPGKAPKFMIYEGTKRPSGVSN ClonePA11P1C06-lightchain RFSGSKSGHTASLTISGLQAEDEADYYCCSYAGTSTLVFGGGTKLTVL variableregion 455 NSDVGSYNL ClonePA11P1C06-CDR-L1 456 EGT ClonePA11P1C06-CDR-L2 457 CSYAGTSTLV ClonePA11P1C06-CDR-L3 458 EVQLVESGGGLVQPGGSLRLSCAASGFTFRNYWMNWVRQAPGKGLVWVSRINSEGSSTSY ClonePA13P1H03-Heavychain ADPVKGRFTISRDNAKDTLYLQMDSLRAEDSAVYYCARIFNGYIHVGRDYWGQGTRVTVSS variableregion 459 GFTFRNYW ClonePA13P1H03-CDR-H1 460 INSEGSST ClonePA13P1H03-CDR-H2 461 ARIFNGYIHVGRDY ClonePA13P1H03-CDR-H3 462 DIQMTQSPSTLSASIGDRVTITCRASESISNWLAWFQQKPGKAPKLLIYKASNLESGVPSRFSG ClonePA13P1H03-lightchain SGSGTEFTLTISSLQPDDFATYYCQQYNSNSQTFGQGTKLDLK variableregion 463 ESISNW ClonePA13P1H03-CDR-L1 196 KAS ClonePA13P1H03-CDR-L2 464 QQYNSNSQT ClonePA13P1H03-CDR-L3 465 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWNWIRQPPGKGLEWIGYIYYSGSTNYNPSL ClonePA11P1C04-Heavychain KSRATISVDTSKNQFSLKLSSVTAADTAVYYCARANLFGVALRRVLGPFDYWGQGTLVTVSS variableregion 466 GGSISSYY ClonePA11P1C04-CDR-H1 200 IYYSGST ClonePA11P1C04-CDR-H2 467 ARANLFGVALRRVLGPFDY ClonePA11P1C04-CDR-H3 468 DIQMTQSPSSLSASVGDRVTIACRASQSIANYLNWYQQKPGKAPKLLIYAASNLQSGVPSRFS ClonePA11P1C04-lightchain GSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK variableregion 469 QSIANY ClonePA11P1C04-CDR-L1 149 AAS ClonePA11P1C04-CDR-L2 470 QQSYSTPYT ClonePA11P1C04-CDR-L3 471 QVQLVESGGGVVQPGRSLRLSCAASGFSFRSYGMHWVRQAPGKGLEWVAVISYDGSNKYY ClonePA14P1D10-Heavychain VDSVKGRFTISRDNSKNTLYVQMNSLTDEDTAVYYCARDRGVTTRQFSYYYYGMDVWGQG variableregion TTVTVSS 472 GFSFRSYG ClonePA14P1D10-CDR-H1 59 ISYDGSNK ClonePA14P1D10-CDR-H2 473 ARDRGVTTRQFSYYYYGMDV ClonePA14P1D10-CDR-H3 474 AIRMTQSPSSFSASTGDRVTITCRASQSITSYLAWYQQKPGKAPKLLIYAASTLQSGLPSRFSG ClonePA14P1D10-lightchain SGSGTDFTLTISGLQSEDFATYYCQQYYNYPQTFGQGTRVEIK variableregion 475 QSITSY ClonePA14P1D10-CDR-L1 149 AAS ClonePA14P1D10-CDR-L2 476 QQYYNYPQT ClonePA14P1D10-CDR-L3 477 EVQLLESGGQLVQPGGSLRLSCGAFGFTFGDAAMTWVRQAPGKGLEWVSTISGRGDETFS ClonePA14P1C10-Heavychain ADSVKGRFTISRDNFKNMLYVQMNSLRAEDTATYYCARLGHLRGWFDSWGQGTLVTVSS variableregion 478 GFTFGDAA ClonePA14P1C10-CDR-H1 479 ISGRGDET ClonePA14P1C10-CDR-H2 480 ARLGHLRGWFDS ClonePA14P1C10-CDR-H3 481 EIVMTQSPATLSVSPGERVTLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPAGFS ClonePA14P1C10-lightchain GSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKVEIK variableregion 482 QSVSSN ClonePA14P1C10-CDR-L1 30 GAS ClonePA14P1C10-CDR-L2 252 QQYNNWPRT ClonePA14P1C10-CDR-L3 483 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDAWMTWVRQAPGKGLEWVGRIKSKTDGGTT ClonePA11P1C08-Heavychain DYGAPVKGRFSISRDDSKNTLYLHMNSLKTEDTAVYYCTTKSPNSNWFPFYYYYYMDVWGK variableregion GTTVTVSS 484 GFTFSDAW ClonePA11P1C08-CDR-H1 485 IKSKTDGGTT ClonePA11P1C08-CDR-H2 486 TTKSPNSNWFPFYYYYYMDV ClonePA11P1C08-CDR-H3 487 QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNFVSWYQQHPGKAPQLMIYDVTKRPSGVP ClonePA11P1C08-lightchain DRFSGSKSGNTASLTISGLQAEDEGDYYCYSYAASSLYVFGTGTKVTVL variableregion 488 SSDVGGYNF ClonePA11P1C08-CDR-L1 141 DVT ClonePA11P1C08-CDR-L2 489 YSYAASSLYV ClonePA11P1C08-CDR-L3 490 QLQLQESGPGLVKPSETLSLICTVSGGAITSSTFYWAWIRQPPGRGLEWIGSMYYSGSTYYNL ClonePA14P3F10-Heavychain SLKSRVIISVNTSKNQFSLTLTSATATDMAVYYCVRHTLHDYGSGSFPDYSYGMDVWGQGTT variableregion VTVSS 491 GGAITSSTFY ClonePA14P3F10-CDR-H1 492 MYYSGST ClonePA14P3F10-CDR-H2 493 VRHTLHDYGSGSFPDYSYGMDV ClonePA14P3F10-CDR-H3 494 EIVLTQSPATLSLFPGERGTLSCRASQSVSSHLIWYQQKPGQAPRVLIFDATNRATGIPARFSG ClonePA14P3F10-lightchain SGSGTDFTLTISNLEPEDYGVYYCQQRSNWPLTFGGGTKVEIK variableregion 495 QSVSSH ClonePA14P3F10-CDR-L1 265 DAT ClonePA14P3F10-CDR-L2 496 QQRSNWPLT ClonePA14P3F10-CDR-L3 497 EVQLLESGGGLVQPGGSLKLSCVASGFTFSSYAMMWVRQAPGKGLEWISSISSSGGSTYYAD ClonePA14P1D11-Heavychain SVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCAKSHCSTTSCPRAFYYYGMDVWGQGTT variableregion VTVSS 113 GFTFSSYA ClonePA14P1D11-CDR-H1 498 ISSSGGST ClonePA14P1D11-CDR-H2 499 AKSHCSTTSCPRAFYYYGMDV ClonePA14P1D11-CDR-H3 500 DIQMTQSPSSLSASVGDRVTITCRASQTITTYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSG ClonePA14P1D11-lightchain SGSGTDFTLSLSSLQPEDSATYYCQQSYSTLGAFGGGTKVEIK variableregion 501 QTITTY ClonePA14P1D11-CDR-L1 149 AAS ClonePA14P1D11-CDR-L2 502 QQSYSTLGA ClonePA14P1D11-CDR-L3 503 QVHLQESGPGLVKPSGTLSLTCTVSGGSISTYYWSWIRQPPGKGLEWIGYIYYGGTTNYNPSL ClonePA14P3F02-Heavychain KSRVTISVDTSKNQFSLRLRSVTAADTAVYYCAREIDSRMDRWGQGTLVTVSS variableregion 504 GGSISTYY ClonePA14P3F02-CDR-H1 505 IYYGGTT ClonePA14P3F02-CDR-H2 506 AREIDSRMDR ClonePA14P3F02-CDR-H3 507 SYALTQPPSVSVAPGKTARITCGGDNIGSKTVHWYHQKPGQAPVLVIYYDSNRPSGISERFSG ClonePA14P3F02-lightchain SNSGNTATLTISRVEAGDEADYYCQVWDSNSDHRIFGGGTKLTVL variableregion 508 NIGSKT ClonePA14P3F02-CDR-L1 509 YDS ClonePA14P3F02-CDR-L2 510 QVWDSNSDHRI ClonePA14P3F02-CDR-L3 511 QVQLVQSGAEVRKPGSSVKVSCKASGGTFSNNPITWVRQAPGQGLEWMGWIIPIFNTTNY ClonePA12P1G11-Heavychain AQKFQGRVTITADESTSTAYMELSSLKSEDTALFYCARDRAHAYCNNGVCYTTDAFDVWGQ variableregion GTLVTVSS 512 GGTFSNNP ClonePA12P1G11-CDR-H1 513 IIPIFNTT ClonePA12P1G11-CDR-H2 514 ARDRAHAYCNNGVCYTTDAFDV ClonePA12P1G11-CDR-H3 515 ETVLTQSPATLSLSPGERATLSCRASQSVGRYLAWYQHKPGQAPRLLIYDASNRATGIPARFS ClonePA12P1G11-lightchain GSGSGTDFTLTISSLEPEDSAVYYCQQGTDWLTFGGGTKVEIK variableregion 516 QSVGRY ClonePA12P1G11-CDR-L1 94 DAS ClonePA12P1G11-CDR-L2 517 QQGTDWLT ClonePA12P1G11-CDR-L3 518 QVQLVESGGGLVKPGGSLRLSCAASGITFSDNYMTWIRQAPGKGLEWVSYISSSGTNIFYAD ClonePA13P1E06-Heavychain SLKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARTLMTGSSLYFDYWGQGTQVTVSS variableregion 519 GITFSDNY ClonePA13P1E06-CDR-H1 520 ISSSGTNI ClonePA13P1E06-CDR-H2 521 ARTLMTGSSLYFDY ClonePA13P1E06-CDR-H3 522 SYELTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSG ClonePA13P1E06-lightchain SSSGTTVTLAISGVQAEDEADYYCQSADIRVTESVLFGGGTKLTVL variableregion 523 ALPKQY ClonePA13P1E06-CDR-L1 524 KDS ClonePA13P1E06-CDR-L2 525 QSADIRVTESVL ClonePA13P1E06-CDR-L3 526 EVHLLESGGHLVQPGGSLRLACAVSGFTFSDSAMTWVRQAPGKGLEWVSTISGRGDETFFA ClonePA14P1C12-Heavychain DSVKGRFSIFRDNSNSVLYVQMNSLRAEDTATYYCARYGHHKGWFDSWGQGTLVTVSS variableregion 527 GFTFSDSA ClonePA14P1C12-CDR-H1 479 ISGRGDET ClonePA14P1C12-CDR-H2 528 ARYGHHKGWFDS ClonePA14P1C12-CDR-H3 529 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRAIGIPAGFS ClonePA14P1C12-lightchain GSGSGTEFTLTISSLQSEDSAVYYCQQYNNWPRTFGQGTKVEIK variableregion 482 QSVSSN ClonePA14P1C12-CDR-L1 30 GAS ClonePA14P1C12-CDR-L2 252 QQYNNWPRT ClonePA14P1C12-CDR-L3 530 QVQLVQSGTEVKKPGASVKVSCKASGYTFSSFGITWVRQAPGQGLEWMGWISAYNGNTKY ClonePA11P1D07-Heavychain AQAVQGRVTLTTDTSTTTAYMELRSLRSNDTAVYFCAREGIEHLVVEGRGPGGDCWGQGTL variableregion VIVSS 531 GYTFSSFG ClonePA11P1D07-CDR-H1 532 ISAYNGNT ClonePA11P1D07-CDR-H2 533 AREGIEHLVVEGRGPGGDC ClonePA11P1D07-CDR-H3 534 SYELTQPPSVSVSPGQTARITCSGDALPKEYTSWYQQKSGQAPVLVIYEDIKRPSGIPERFSGS ClonePA11P1D07-lightchain SSGTMASLTISGAQVDDEADYYCYSTDTSGDHKVFGGGTKLTVL variableregion 535 ALPKEY ClonePA11P1D07-CDR-L1 536 EDI ClonePA11P1D07-CDR-L2 537 YSTDTSGDHKV ClonePA11P1D07-CDR-L3 538 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGREWVAALSYDGSSTYY ClonePA12P4D02-Heavychain ADSVKGRLTISRDNSKNTLYLQMNSLRAEDTAVYFCTRVPYGEGRAANDYWGQGTLVTVSS variableregion 113 GFTFSSYA ClonePA12P4D02-CDR-H1 539 LSYDGSST ClonePA12P4D02-CDR-H2 540 TRVPYGEGRAANDY ClonePA12P4D02-CDR-H3 541 DIQMTQSPSTLSASVGDRVTITCRASQSIGSWLAWYQQKPGKAPKLLIYKASNIESGVPSRFS ClonePA12P4D02-lightchain GSGSGTEFTLTISSLQPDDFATYYCQHYNTYSRSFGGGTEVAIK variableregion 542 QSIGSW ClonePA12P4D02-CDR-L1 196 KAS ClonePA12P4D02-CDR-L2 543 QHYNTYSRS ClonePA12P4D02-CDR-L3 544 QVQLVQSGAEVKTPGSSVKVSCTASGDSFSRYAINWVRQAPGQGLEWVGKIVPVFGAASYA ClonePA15P1C03-heavychain QKFQGRVTITADESTSTVYMELSSLRSEDTAVYYCARGIVKLSTMPPVYWGQGTLVTVSS variableregion 545 GDSFSRYA ClonePA15P1C03-CDR-H1 546 IVPVFGAA ClonePA15P1C03-CDR-H2 547 ARGIVKLSTMPPVY ClonePA15P1C03-CDR-H3 548 DIVMTQTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQKPGQSPQLLISEVSSRFSGVP ClonePA15P1C03-lightchain DRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGIHHLTFGPGTKVDIK variableregion 549 QSLLHSDGKTY ClonePA15P1C03-CDR-L1 550 EVS ClonePA15P1C03-CDR-L2 551 MQGIHHLT ClonePA15P1C03-CDR-L3 552 QVQLQESGPGLVKPSETLSLTCSVSGGSVSDSAYYWSWIRQPPGGGLEFIGYVYNSGSTNYN ClonePA12P4G06-heavychain PSLKSRVTISVDTSKNQFSLSLSSLTAADTAVYYCARYCSSTSCYVRSSDVNWFDPWGQGTLVI variableregion VSS 553 GGSVSDSAYY ClonePA12P4G06-CDR-H1 554 VYNSGST ClonePA12P4G06-CDR-H2 555 ARYCSSTSCYVRSSDVNWFDP ClonePA12P4G06-CDR-H3 556 EIVLTQSPGTLSSSPGESATLSCRASQSLGTYLAWYQQKPGQAPRLLIYDASKRATGIPARFSG ClonePA12P4G06-lightchain SGSGTDFTLTISSLEPEDFAVYYCHQRSHWLTFGGGTKVEIK variableregion 557 QSLGTY ClonePA12P4G06-CDR-L1 94 DAS ClonePA12P4G06-CDR-L2 558 HQRSHWLT ClonePA12P4G06-CDR-L3 559 EAQLLESGGGLVQPGGSLRLSCAASGFNFSNYAMTWVRQAPGKGLEWVSAISSGGGTTYYA ClonePA16P1809-heavychain DSVKGRFTISRDNSKNTVYLQMNSLKDADSALYYCAKPGRAVVVRLSYFDSWGQGTLVTVSS variableregion 560 GFNFSNYA ClonePA16P1B09-CDR-H1 561 ISSGGGTT ClonePA16P1B09-CDR-H2 562 AKPGRAVVVRLSYFDS ClonePA16P1809-CDR-H3 563 QSVLTQPPSVSAAPGQKVSISCSGSGSNIANHYVSWYQHLPGTAPKLLIYDNNKRPSGIPDRF ClonePA16P1B09-lightchain SGSKSGTSATLGITGLQTGDEADYYCGTWDSSLTVVVFGGGTKLTVL variableregion 564 GSNIANHY ClonePA16P1B09-CDR-L1 110 DNN ClonePA16P1B09-CDR-L2 565 GTWDSSLTVVV ClonePA16P1B09-CDR-L3 566 QITLKESGPTLVKPTETLTLTCTFSGFSLTTSGVAVGWVRQPPGKALEWLALIYWDDDERYTP ClonePA12P4G03-heavychain SLKSRLTITKDTSKSQVVLTMTNMDPVDTATYFCVHCEGPDILLVPAAYFFDFWGQGTLVTV variableregion SS 567 GFSLTTSGVA ClonePA12P4G03-CDR-H1 568 IYWDDDE ClonePA12P4G03-CDR-H2 569 VHCEGPDILLVPAAYFFDF ClonePA12P4G03-CDR-H3 570 EIVLTQSPGTLSLSPGDRATLSCRASQSVSRRYLAWYQQSPGQAPRLLISGASSRATGIPDRFS ClonePA12P4G03-lightchain GSGSGTDFTLTISRLEPEDFAMYYCQQYGSSTGTFGQGTKVEMK variableregion 571 QSVSRRY ClonePA12P4G03-CDR-L1 30 GAS ClonePA12P4G03-CDR-L2 572 QQYGSSTGT ClonePA12P4G03-CDR-L3 573 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSSGYYWSWIRQHPGKGLEWIGYINYIGGTYYNP ClonePA11P1F10-heavychain SLRSRVTMSVDTSKNQFSLRLSSVSAADTAVYYCASTHSYGDYSRDYYYGVDVWGQGTTVTI variableregion SS 574 GGSISSSGYY ClonePA11P1F10-CDR-H1 575 INYIGGT ClonePA11P1F10-CDR-H2 576 ASTHSYGDYSRDYYYGVDV ClonePA11P1F10-CDR-H3 577 EIVLTQSPATLSLSPGDRATLSCRTSQSVSSSYLAWYQQKPGQAPRLLIYAASSRATGIPDRFS ClonePA11P1F10-lightchain GSGSGTDFTLTISRLEPEDFAVYYCQQCAGSPFTFGPGTKVDLK variableregion 62 QSVSSSY ClonePA11P1F10-CDR-L1 149 AAS ClonePA11P1F10-CDR-L2 578 QQCAGSPFT ClonePA11P1F10-CDR-L3 579 QVQLVESGGGVVQPGRSLRLSCAASGFTFSDYAMHWVRQAPGKGLEWVAVISYDGNHRY ClonePA12P1G02-heavychain YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHPGLSIAVAGPFDYWGQGTLVTV variableregion SS 580 GFTFSDYA ClonePA12P1G02-CDR-H1 581 ISYDGNHR ClonePA12P1G02-CDR-H2 582 ARHPGLSIAVAGPFDY ClonePA12P1G02-CDR-H3 583 EIVMTQSPATLSVSPGERATLSCGASQSVSSNLAWYQQKPGQAPRLLFYGASTRATGIPARFS ClonePA12P1G02-lightchain GSGSGTEFTLTISSLQSEDFALYYCQQYNNWPWTFGQGTKVDIK variableregion 482 QSVSSN ClonePA12P1G02-CDR-L1 30 GAS ClonePA12P1G02-CDR-L2 584 QQYNNWPWT ClonePA12P1G02-CDR-L3 585 QVQLVQSGAEVKKPGASVKVSCKASGYTFNRDGITWVRQAPGQGLEWMGWISANNDFT ClonePA16P1E12-heavychain DYAQKFQGRLTMTTDTSTNTAYMELRSLRSDDTAVYYCARQVITVLQYSYGMDVWGQGTT variableregion VTVSS 586 GYTFNRDG ClonePA16P1E12-CDR-H1 587 ISANNDFT ClonePA16P1E12-CDR-H2 588 ARQVITVLQYSYGMDV ClonePA16P1E12-CDR-H3 589 DIQMTQFPSSLSASVGDRVTITCRASQSISRYLNWYQQTPGKAPKLLIYGASSLQSGVPSRFSG ClonePA16P1E12-lightchain SGSGTDFTLTISSLQPEDFATYYCQQSDTAPLTFGGGTRVEIK variableregion 590 QSISRY ClonePA16P1E12-CDR-L1 30 GAS ClonePA16P1E12-CDR-L2 591 QQSDTAPLT ClonePA16P1E12-CDR-L3 415 EAQLVESGGGLVQPGGSLRLSCAASGFTFSSYYIHWVRQAPGKGLVWVSRINSDGSSTRYAD ClonePA16P1E11-heavychain SVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYFCARASRTVYGDSPLSNGMDVWGQGTKV variableregion TVSS 416 GFTFSSYY ClonePA16P1E11-CDR-H1 417 INSDGSST ClonePA16P1E11-CDR-H2 418 ARASRTVYGDSPLSNGMDV ClonePA16P1E11-CDR-H3 419 SYELTQPPSVSVSPGQTASITCSGDKLGDKFACWYQQKPGHSPVLVIYQDDKRPSGIPERFSG ClonePA16P1E11-lightchain SNSGNTATLTISGTQAMDEADYYCQAWDSSTHVVFGGGTKLTVL variableregion 420 KLGDKF ClonePA16P1E11-CDR-L1 421 QDD ClonePA16P1E11-CDR-L2 422 QAWDSSTHVV ClonePA16P1E11-CDR-L3 592 QVQLVESGGGLVTPGGSLRLSCTVSGFTLSDYYMSWIRQAPGKGLDWLSYISGSGDNKNYA ClonePA12P3E11-heavychain DSVRGRFTISRDNSKNSLYLQMNSLRAEDTAVYYCAREFPSGGYSPGVVLWGQGTLVTVSS variableregion 593 GFTLSDYY ClonePA12P3E11-CDR-H1 594 ISGSGDNK ClonePA12P3E11-CDR-H2 595 AREFPSGGYSPGVVL ClonePA12P3E11-CDR-H3 596 NFVLTQPHSVSESPGKTVTISCARSSGSIAGSFVQWYQQRPGSSPTTVIYEDTRRPSGVPDRF ClonePA12P3E11-lightchain SGSIDSSSNSASLTISGLKTEDEADYYCQSYDSTNPWVFGGGTKLTVL variableregion 597 SGSIAGSF ClonePA12P3E11-CDR-L1 598 EDT ClonePA12P3E11-CDR-L2 599 QSYDSTNPWV ClonePA12P3E11-CDR-L3 600 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVIYSGGSRTYYA ClonePA14P1C06-heavychain DSAKGRFTISRDNSKNMLYLQMNSLRAEDTAVYYCTKNDYDSSGYFDFDNWGQGTLVTVSS variableregion 113 GFTFSSYA ClonePA14P1C06-CDR-H1 114 IYSGGSRT ClonePA14P1C06-CDR-H2 601 TKNDYDSSGYFDFDN ClonePA14P1C06-CDR-H3 602 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSN ClonePA14P1C06-lightchain RFSGSKSGNTASLTISGLQAEDEADYHCSSYTSSSTWVFGGGTKLTVL variableregion 603 SSDVGGYNY ClonePA14P1C06-CDR-L1 404 DVS ClonePA14P1C06-CDR-L2 604 SSYTSSSTWV ClonePA14P1C06-CDR-L3 605 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVVYSGGSGTYYA ClonePA14P1C07-heavychain DSVKGRFTISRDDSTNTLYLQMNSLRAEDTAVYYCAKDRDSFGELDLDSWGQGTLVSVSS variableregion 113 GFTFSSYA ClonePA14P1C07-CDR-H1 606 VYSGGSGT ClonePA14P1C07-CDR-H2 607 AKDRDSFGELDLDS ClonePA14P1C07-CDR-H3 608 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSKNKNYLAWYQQRPGQPPKLLIYWASTRES ClonePA14P1C07-lightchain GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCLQYYNIPRTFGQGTKLEIK variableregion 609 QSVLYSSKNKNY ClonePA14P1C07-CDR-L1 86 WAS ClonePA14P1C07-CDR-L2 610 LQYYNIPRT ClonePA14P1C07-CDR-L3 611 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYALSWVRQPPGKGLEWVSVIYSGGSRTYYAD ClonePA14P1C04-heavychain AAKGRFTISRDNSKNMLYLQMNSLRAEDTAVYYCTKHDYDSSGYFDFDNWGQGTLVTVSS variableregion 113 GFTFSSYA ClonePA14P1C04-CDR-H1 114 IYSGGSRT ClonePA14P1C04-CDR-H2 612 TKHDYDSSGYFDFDN ClonePA14P1C04-CDR-H3 602 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSN ClonePA14P1C04-lightchain RFSGSKSGNTASLTISGLQAEDEADYHCSSYTSSSTWVFGGGTKLTVL variableregion 603 SSDVGGYNY ClonePA14P1C04-CDR-L1 404 DVS ClonePA14P1C04-CDR-L2 604 SSYTSSSTWV ClonePA14P1C04-CDR-L3 613 EVQLVESGGGVARPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWNGGSTN ClonePA14P1C02-heavychain YADSVKGRFIISRDNGKNSLYLQMNSLRAEDTAFYHCARRGNFYYYGMDVWGQGTTVTVSS variableregion 614 GFTFDDYG ClonePA14P1C02-CDR-H1 615 INWNGGST ClonePA14P1C02-CDR-H2 616 ARRGNFYYYGMDV ClonePA14P1C02-CDR-H3 617 DIQMTQSPSSVSASVGDRVTITCRASQGNSTWLAWYQQKPGKAPELLIFDASNLQSGVPSR ClonePA14P1C02-lightchain FSGSGSGTDFTLTISSLQPEDFATYYCQQAQRFPLTFGGGTKVEIK variableregion 618 QGNSTW ClonePA14P1C02-CDR-L1 94 DAS ClonePA14P1C02-CDR-L2 619 QQAQRFPLT ClonePA14P1C02-CDR-L3 620 QVQLVQSGSELRRPGASVKVSCKTSGYAFTHFAMNWLRQAPGQGLEWLGWINTHSGNPT ClonePA11P1E01-heavychain YAQGFTGRIVFSLDTSAGTAYLEISSLKAEDTAVYYCARERYFDFWGQGTLVAVSS variableregion 621 GYAFTHFA ClonePA11P1E01-CDR-H1 176 INTHSGNP ClonePA11P1E01-CDR-H2 177 ARERYFDF ClonePA11P1E01-CDR-H3 622 QSVLTQPPSASGTPGQRVTISCSGTNSNIGKNFLYWYQQLPGTAPKLLIFSSNQRPSGVPDRF ClonePA11P1E01-lightchain SGSKSGTSASLAISGLRSEDEADYYCAAWDDNLSGWVFGGGTKVTVL variableregion 623 NSNIGKNF ClonePA11P1E01-CDR-L1 180 SSN ClonePA11P1E01-CDR-L2 624 AAWDDNLSGWV ClonePA11P1E01-CDR-L3 625 QVQLQESGPGLVKPSEALSLTCSVSDGSVSSGSYYWTWIRQPPGKGLEWIGCIHYSGRTNYN ClonePA11P1E08-heavychain PSLKSRVTISIDTSKNQFSLQLSSVTAVDTAVYYCARDRGEYDFWRVRYYGMDVWGQGTTV variableregion TVSS 626 DGSVSSGSYY ClonePA11P1E08-CDR-H1 627 IHYSGRT ClonePA11P1E08-CDR-H2 628 ARDRGEYDFWRVRYYGMDV ClonePA11P1E08-CDR-H3 629 QSALTQPASVSGSPGQSITISCTGTSSDVGDYNYVSWYQQHPGKAPKLLIYDFSNRPSGVSDR ClonePA11P1E08-lightchain FSGSKSGNTASLTISGLRAEDESDYYCTSYTNTNTRLFGGGTKLTVL variableregion 630 SSDVGDYNY ClonePA11P1E08-CDR-L1 631 DFS ClonePA11P1E08-CDR-L2 632 TSYTNTNTRL ClonePA11P1E08-CDR-L3 633 QVQLVQSGAEVKKPGASVKVSCKASGYTFISYGLHWVRQAPGQRPEWMGWINAGNGNR ClonePA14P1C08-heavychain KYSERFQARVTFTRDTSATTAYMELSSLRSEDTAVYYCARDRLTAAAHFDYWGQGTQVTVSS variableregion 634 GYTFISYG ClonePA14P1C08-CDR-H1 635 INAGNGNR ClonePA14P1C08-CDR-H2 636 ARDRLTAAAHFDY ClonePA14P1C08-CDR-H3 637 EIVMTQSPATLSVSLGERATLSCRASQSVSSDLAWYQQKPGQAPRLLMYGASTRATGFPARF ClonePA14P1C08-lightchain TGSGSGPEFTLTISSLQSEDFAVYYCQQYNNWPFTFGGGTKVEIK variableregion 638 QSVSSD ClonePA14P1C08-CDR-L1 30 GAS ClonePA14P1C08-CDR-L2 639 QQYNNWPFT ClonePA14P1C08-CDR-L3 640 QITLKESGPTLVKPTQTLTLTCTFSGFSLTSSAVGVGWIRQPPGKALEWLALIYGDDDKRYSPS ClonePA14P1H12-heavychain LKRRLTITKDTSKNQVVLTMTDVDPVDTATYYCAHRRLTIPLLMVAADAFDIWGPGTMVIVSS variableregion 641 GFSLTSSAVG ClonePA14P1H12-CDR-H1 642 IYGDDDK ClonePA14P1H12-CDR-H2 643 AHRRLTIPLLMVAADAFDI ClonePA14P1H12-CDR-H3 644 DIQMTQSPSTLSASVGDRVTITCRASQSVSRWLAWYQQKPGKAPKLLIYRASSLQSGVPSRFS ClonePA14P1H12-lightchain GSGSGTEFTLTISSLQPDDFATYYCQQYSSFHTFGQGTKLEIK variableregion 645 QSVSRW ClonePA14P1H12-CDR-L1 646 RAS ClonePA14P1H12-CDR-L2 647 QQYSSFHT ClonePA14P1H12-CDR-L3 648 EVQLVESGGGLVQPGGSLRLSCAASGFIFSTYSMNWVRQAPGKGLEWVSYISSSSNTIYYAD ClonePA14P1H11-heavychain SVKGRFTISRDNAKNSLYLQMNSLRDADTAVYYCARDGGRSGYFDDYWGQGTLVTVSS variableregion 649 GFIFSTYS ClonePA14P1H11-CDR-H1 650 ISSSSNTI ClonePA14P1H11-CDR-H2 651 ARDGGRSGYFDDY ClonePA14P1H11-CDR-H3 652 QLVLTQSPSASASLGASVKLTCTLSNGHINYAIAWHQQQPDKGPRYLLNLKSDGSHSKGDGI ClonePA14P1H11-lightchain PDRFSGSSSGAERYLTISGLQSEDEADYYCQTWGTGIQVFGGGTKLTVL variableregion 653 NGHINYA ClonePA14P1H11-CDR-L1 654 LKSDGSH ClonePA14P1H11-CDR-L2 655 QTWGTGIQV ClonePA14P1H11-CDR-L3 656 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNP ClonePA14P1D02-heavychain SLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGRGVWFGELFPFDYWGQGTLGTVSS variableregion 657 GGSFSGYY ClonePA14P1D02-CDR-H1 658 INHSGST ClonePA14P1D02-CDR-H2 659 ARGRGVWFGELFPFDY ClonePA14P1D02-CDR-H3 660 QGGLTQPPSVSKGLRQTATLTCTGNSNNVGNQGAAWLQQHQGHPPKLLSYRNNNRPSGIS ClonePA14P1D02-lightchain ERFSASRSGNTASLTITGLQPEDEADYYCSAWDSSLSAVVFGGGTKLTVL variableregion 661 SNNVGNQG ClonePA14P1D02-CDR-L1 662 RNN ClonePA14P1D02-CDR-L2 663 SAWDSSLSAVV ClonePA14P1D02-CDR-L3 664 QVQLQQWGAGLLKPSETLSLNCTVYHGSLSTSYWSWIRQPPGRGLEWIGEINDSGATNYNP ClonePA11P1F03-heavychain SLKSRVIISVDTSKDQFSLKLTSVTAADTAMYYCARAPLLWVGESFFYYFDSWGQGILVTVSS variableregion 665 HGSLSTSY ClonePA11P1F03-CDR-H1 666 INDSGAT ClonePA11P1F03-CDR-H2 667 ARAPLLWVGESFFYYFDS ClonePA11P1F03-CDR-H3 668 DIQMTQSPSSLSASVGDRVSITCRAGQSIDTYLNWYQHKPGKAPDLLIYTTSTLHSGVPSRFS ClonePA11P1F03-lightchain GSGSGTDFTLTITSLQPEDFAIYYCQQSYKSPYTFGQGTKVEIK variableregion 669 QSIDTY ClonePA11P1F03-CDR-L1 670 TTS ClonePA11P1F03-CDR-L2 671 QQSYKSPYT ClonePA11P1F03-CDR-L3 672 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGTTSS ClonePA11P1F02-heavychain AQKFQGRVTMTRDTSTSTVYMELSSLRSEDTALYYCARDREQKVGGAPLHWGQGTLVTVSS variableregion 89 GYTFTSYY ClonePA11P1F02-CDR-H1 673 INPSGGTT ClonePA11P1F02-CDR-H2 674 ARDREQKVGGAPLH ClonePA11P1F02-CDR-H3 675 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFS ClonePA11P1F02-lightchain GSGSGTDFSFTISSLQPEDIATYYCQQYDNFALTFGGGTKVEIK variableregion 374 QDISNY ClonePA11P1F02-CDR-L1 94 DAS ClonePA11P1F02-CDR-L2 676 QQYDNFALT ClonePA11P1F02-CDR-L3 677 EVQLLESGGGLVQPGVSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVIYSGGNIIYYAD ClonePA14P1D07-heavychain SVKGRFTISRDNSKNTLYLQIDNLRAEDTALYYCAKHDYDSSGYFDFDYWGHGTLVTVSS variableregion 113 GFTFSSYA ClonePA14P1D07-CDR-H1 678 IYSGGNII ClonePA14P1D07-CDR-H2 679 AKHDYDSSGYFDFDY ClonePA14P1D07-CDR-H3 680 QSALTQPASVSGSPGQSITISCTGTSRDVGGYNYVSWYQQHPGKAPKLMIYDVNNRPSGVS ClonePA14P1D07-lightchain NRFSGSKSGNTASLTISGLQAEDEADYFCCSYTSSSTWVFGGGTKLTVL variableregion 681 SRDVGGYNY ClonePA14P1D07-CDR-L1 682 DVN ClonePA14P1D07-CDR-L2 683 CSYTSSSTWV ClonePA14P1D07-CDR-L3 684 QVQLQESGPGLVKPSGTLSLTCAVSGASISNSAWWNWVRQPPRGGLEWVGEIYPSGSTNY ClonePA14P1D09-heavychain TPSLKSRATILLDESRNEFSLKLNSVTAADTAVYYCARGRLEDCNGGVCYFFDNWGQGILVSV variableregion SS 685 GASISNSAW ClonePA14P1D09-CDR-H1 686 IYPSGST ClonePA14P1D09-CDR-H2 687 ARGRLEDCNGGVCYFFDN ClonePA14P1D09-CDR-H3 688 DIEMTQSPSTLSASVGDRVTITCRANYGIGAWLAWYQQKPGKAPKLLIYKASTLESGVPLRFS ClonePA14P1D09-lightchain GSGSGTEFTLSISGLQPDDFATYYCHQYSTYPITFGQGTRLEIK variableregion 689 YGIGAW ClonePA14P1D09-CDR-L1 196 KAS ClonePA14P1D09-CDR-L2 690 HQYSTYPIT ClonePA14P1D09-CDR-L3 691 QVQLVESGGGVVQPGRSLTLSCAASGFNFKTYGMHWVRQAPGKGLEWVAVIYHDGNDKF ClonePA14P3H08-heavychain YADSVKGRFTISRDNSKNTLYVQMSSLRADDTAIYYCAKGIFSSGYHYGMDVWGQGTAVIVSS variableregion 692 GFNFKTYG ClonePA14P3H08-CDR-H1 693 IYHDGNDK ClonePA14P3H08-CDR-H2 694 AKGIFSSGYHYGMDV ClonePA14P3H08-CDR-H3 695 DIQMTQSPSSLSASLGDSVTITCLASQGIKEFLSWFQQKPGQAPKLLIYDASSSHSGVPSRFSG ClonePA14P3H08-lightchain SGSATHFTLTISSLQPDDIATYYCQQYHQVPLTFGQGTRLEIK variableregion 696 QGIKEF ClonePA14P3H08-CDR-L1 94 DAS ClonePA14P3H08-CDR-L2 697 QQYHQVPLT ClonePA14P3H08-CDR-L3 190 QVQLQQWGAGLLKPSETLSLTCVVSGGSFSTHYWNWIRQSPGKGLEWIGEINHSGNTNYN ClonePA15P1E01-heavychain PSLTGRATISVATSKTQFSLRLNSVTAADTAVYFCARGPRLRYTAGRPLFDTWGQGTLVTVSS variableregion 191 GGSFSTHY ClonePA15P1E01-CDR-H1 192 INHSGNT ClonePA15P1E01-CDR-H2 193 ARGPRLRYTAGRPLFDT ClonePA15P1E01-CDR-H3 194 DIQMTQSPSTLSASVGDRVTITCRASQSISAFLAWYQQKPGKAPNLVIYKASSLDSGVPSTFS ClonePA15P1E01-lightchain GSGSGTEYTLTISSLQPDDFATYYCQQYFSSPPTFGQGTKVEMK variableregion 195 QSISAF ClonePA15P1E01-CDR-L1 196 KAS ClonePA15P1E01-CDR-L2 197 QQYFSSPPT ClonePA15P1E01-CDR-L3 698 EVRLVESGGGLIQPGGSLRLSCAASGFNVSSDYMNWVRQAPGKGLEWVSVLYSSGFTYYAD ClonePA15P1E02-heavychain SVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVALFGEPLVDSWGQGTLVTVSS variableregion 699 GFNVSSDY ClonePA15P1E02-CDR-H1 700 LYSSGFT ClonePA15P1E02-CDR-H2 701 ARVALFGEPLVDS ClonePA15P1E02-CDR-H3 702 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAISRATGIPARFS ClonePA15P1E02-lightchain GSGSGTEFTLTISSLQSEDFAIYYCQQYNNWPWTFGQGTKVEIK variableregion 482 QSVSSN ClonePA15P1E02-CDR-L1 703 GAI ClonePA15P1E02-CDR-L2 584 QQYNNWPWT ClonePA15P1E02-CDR-L3 704 DPYSPS Bindingmotifsequencefor PA13P1H08 705 DSYGRDPYSPS Bindingmotifsequencefor PA13P1H08 706 YSPSQDPYSPS Bindingmotifsequencefor PA13P1H08 707 PDRRDPYSPS Bindingmotifsequencefor PA13P1H08 708 RQQWELQGDRRCQSQLERANLRPCEQHLMQKIQRDEDSYGRDPYSPSQDPYSPSQDPDRR Arah2isoformArah2.0201 DPYSPSPYDRRGAGSSQHQERCCNELNEFENNQRCMCEALQQIMENQSDRLOGRQQEQQ (DPYSPSmotifunderlined) FKRELRNLPQQCGLRAPQRCDLEVESGGRDRY 709 EVQLVASGGGLIHPGGSLRLSCEASGFSFSRFWMYWVRQSPGEGLVWVARLSGDGTVTNY Clone1003320101_D6heavy ADSMEGRVTISRDNVKNTLFLEMNSLREGDTGIYYCARKDCPSLSCQLDYWGQGVQVTVSS chainvariableregionsequence 710 GFSFSRFW Clone1003320101_D6CDR-H1 711 LSGDGTVT Clone1003320101_D6CDR-H2 712 ARKDCPSLSCQLDY Clone1003320101_D6CDR-H3 713 QSVLTQPPSVSAAPGQKVTISCSGSTSNIGKNYVSWYQHFPGAAPKLLIFDNDKRPSGIPDRF Clone1003320101_D6lightchain SGSRSGTSATLDITGLQTGDEADYFCATWDSRLSADVFGSGTTVSVL variableregionsequence 714 TSNIGKNY Clone1003320101_D6CDR-L1 715 DND Clone1003320101_D6CDR-L2 716 ATWDSRLSADV Clone1003320101_D6CDR-L3 717 EVQLLESGGGLVQPGGSLRLSCAASGFNFSNFAVSWVRQTPGKGLEWVSAILGSRSVTYYAD Clone1003320105_D6heavychain SVKGRFTISRDKSKNALYLQMDSLRAEDTAIYYCAKLFFMPYSHDDSGDYWGQGTLVAVSS variableregionsequence 718 GFNFSNFA Clone1003320105_D6CDR-H1 719 ILGSRSVT Clone1003320105_D6CDR-H2 720 AKLFFMPYSHDDSGDY Clone1003320105_D6CDR-H3 721 QLVLTQSPSASASLGASVKLTCTLSSDHRSYAIAWHQQQPGKGPRYLMKVNRDGSHIKGDGI Clone1003320105_D6lightchain PHRFSGSSSVTERYLIISSLQSEDEADYYCQSWDTGIQVFGGGTRLTVV variableregionsequence 722 SDHRSYA Clone1003320105_D6CDR-L1 723 VNRDGSH Clone1003320105_D6CDR-L2 724 QSWDTGIQV Clone1003320105_D6CDR-L3 725 QVQLQESGLGLVKPSGTLSLTCAVSGGPMNSSYWWSWVRQSPGGGLEWIGQISHYTNTKY Clone1003320107_C5heavychain NPSFKNRVSISIDKSKNEFSLRLTYVTGADTGVYYCVGERDWKDPNWFDPWGQGRLVTVSS variableregionsequence 726 GGPMNSSYW Clone1003320107_C5CDR-H1 727 ISHYTNT Clone1003320107_C5CDR-H2 728 VGERDWKDPNWFDP Clone1003320107_C5CDR-H3 729 QSVLTQPPSVSGAPGQRVTISCTGSNSNIGAGQDVHWYQHFPGTAPKLVIYGNSNRPSGVP Clone1003320107_C5lightchain DRFSGSKSGTSASLAISGLQADDEADYYCQSYDKSLSSSLFGGGTKLTVL variableregion 730 NSNIGAGQD Clone1003320107_C5CDR-L1 731 GNS Clone1003320107_C5CDR-L2 732 QSYDKSLSSSL Clone1003320107_C5CDR-L3 733 QVQLQESGPGLVKPSETLSLSCNVSGGSIRGHYWSWIRQSPGKRLEWLGYIYQSGYTKYNPS Clone1003320107_F3heavychain LKSRVSISLDTSKNKFSLNLKSVTTADTAVYYCAGRVAERGGDQFDFWGQGTLVTVSS variableregionsequence 734 GGSIRGHY Clone1003320107_F3CDR-H1 735 IYQSGYT Clone1003320107_F3CDR-H2 736 AGRVAERGGDQFDF Clone1003320107_F3CDR-H3 737 SYELTQSPSLSVSPGQTASITCSGENLGEKHASWYQQKSGQSPVLVIYQDTKRPAGIPERFSGS Clone1003320107_F3lightchain NSGSTATLTISGTQPMDEADYFCQAWDANTANVIFGGGTMLTVL variableregionsequence 738 NLGEKH Clone1003320107_F3CDR-L1 739 QDT Clone1003320107_F3CDR-L2 740 QAWDANTANVI Clone1003320107_F3CDR-L3 741 EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSTIHWVRQTSGKGLEWVGRIGSKATSYATAY Clone1003320107_F8heavychain AASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYFCTRRYYDTTKSVLVVSDSWGQGTLVTV variableregionsequence SS 742 GFTFSGST Clone1003320107_F8CDR-H1 743 IGSKATSYAT Clone1003320107_F8CDR-H2 744 TRRYYDTTKSVLVVSDS Clone1003320107_F8CDR-H3 745 SYELTQPPSMSVSPGQTARITCSGDVLAKQFAYWYQQKPGQAPVLVIYKDSERPSGIPERFSG Clone1003320107_F8lightchain SSSGTIITLTISGVQAEDEADYYCQSADSSGTSWVFGGGTKLTVL variableregionsequence 746 VLAKQF Clone1003320107_F8CDR-L1 747 KDS Clone1003320107_F8CDR-L2 748 QSADSSGTSWV Clone1003320107_F8CDR-L3 749 QLLLQESGPGLVKPSETLSLSCTVSAGSITSINYSWGWIRQPPGKGLEWIASVYFSGSIYYNPS ClonePA01P2C05heavychain LKSRVAISVDTSKNTFSLNLTSVTAADTAVYYCARLRLDTGRDSSGLSYREHFDYWAQGTLVTV variableregionsequence SS 750 AGSITSINYS ClonePA01P2C05CDR-H1 751 VYFSGSI ClonePA01P2C05CDR-H2 752 ARLRLDTGRDSSGLSYREHFDY ClonePA01P2C05CDR-H3 753 DIQMTQSPSTLSASVGDRVTITCRASQSIGMWLAWFQQKPGKAPKLLIYKASTLESGVPSRFS ClonePA01P2C05lightchain GSGSGTEFTLTINSLQPDDFATYYCQQYNSYLFTFGPGTKVDIK variableregionsequence 754 QSIGMW ClonePA01P2C05CDR-L1 196 KAS ClonePA01P2C05CDR-L2 755 QQYNSYLFT ClonePA01P2C05CDR-L3 756 EVQLVQSGAEVKKPGESLKISCKGSGYNFTSSWIGWVRQMPGKGLEWMGIIHPGDSDTRYS ClonePA01P2B03heavychain PSFQGQVTISADKSLTTAFLQWSSLKTSDTAIYYCARHGSTMLWGDAFDIWGQGTMVTVSS variableregionsequence 757 GYNFTSSW ClonePA01P2B03CDR-H1 758 IHPGDSDT ClonePA01P2803CDR-H2 759 ARHGSTMLWGDAFDI ClonePA01P2B03CDR-H3 760 SYELTQPPSVSLSPGQTARITCSGDALPKHYAYWYQQKPGQAPVLVIYKDTERPSGIPERFSGS ClonePA01P2B03lightchain SSGTTVTLTISGVQAEDEADYYCQSSDSTGEVFGGGTKLTVL variableregionsequence 761 ALPKHY ClonePA01P2B03CDR-L1 762 KDT ClonePA01P2B03CDR-L2 763 QSSDSTGEV ClonePA01P2B03CDR-L3 764 QVQLVQSGAEVKKPGASVMLSCKASGYIFTNSDINWVRQAPGQGPEWMGWMNPKSGNT ClonePA01P2A12heavychain GYEQKFQGRVTMTTNTSISTAYMELSRLRSEDTAVYYCARSTGAVAGNFDYWGQGTPVTVSS variableregionsequence 765 GYIFTNSD ClonePA01P2A12CDR-H1 766 MNPKSGNT ClonePA01P2A12CDR-H2 767 ARSTGAVAGNFDY ClonePA01P2A12CDR-H3 768 EIVMTQSPATLSVSLGDRATLSCRASQSISRNLAWYQQKPGQAPRLLIYGASIRITDIPARFSG ClonePA01P2A12lightchain SGSGTEFTLTISSLQSEDFAIYFCQQYNNWRTFGQGTRVELK variableregionsequence 769 QSISRN ClonePA01P2A12CDR-L1 30 GAS ClonePA01P2A12CDR-L2 770 QQYNNWRT ClonePA01P2A12CDR-L3 771 HVQLQESGPGLVKSSETLSLTCNVSSDSFSDHYWSWVRQPAGKGLQWLGRIYNTGTTTYNP ClonePA01P2C12heavychain SLNRRITMSVDTSKNQFSLRLTSVTAADTAVYYCAARHYHYDKTIWGQGTLVTVSS variableregionsequence 772 SDSFSDHY ClonePA01P2C12CDR-H1 773 IYNTGTT ClonePA01P2C12CDR-H2 774 AARHYHYDKTI ClonePA01P2C12CDR-H3 775 NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSPPTTVIYEDNQRPSGVPDR ClonePA01P2C12lightchain FSGSIDSSSNSASLTISGLKPEDEADFYCQSYDSDDREVFGGGTRLTVL variableregionsequence 776 SGSIASNY ClonePA01P2C12CDR-L1 389 EDN ClonePA01P2C12CDR-L2 777 QSYDSDDREV ClonePA01P2C12CDR-L3 778 QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYGISWVRQAPGQGLEWMGWISAYNGNTT ClonePA01P2E10heavychain YAQNFHARVTMTTDTSTSTAYMELRSLRSDDTAVYFCARTSARTITIFGVLIPAGLNLDYWGQ variableregionsequence GTLVTVSS 779 GYTFTTYG ClonePA01P2E10CDR-H1 532 ISAYNGNT ClonePA01P2E10CDR-H2 780 ARTSARTITIFGVLIPAGLNLDY ClonePA01P2E10CDR-H3 781 QSALTQPASVSGSPGQSITISCTGTGSDVGRYNYVSWYQQHPGKAPKFMIYDVSNRPSGVS ClonePA01P2E10lightchain NRFSASKSGNTASLTISGLQAEDEADYYCSSYTSTSTLVFGGGTKLTVL variableregionsequence 782 GSDVGRYNY ClonePA01P2E10CDR-L1 404 DVS ClonePA01P2E10CDR-L2 783 SSYTSTSTLV ClonePA01P2E10CDR-L3 784 QVDLVESGGGYVKSGGSLRLSCAASGFRFSDYYMSWVRQAPGKGLEWLSHISSDSSDTNYA ClonePA01P2C09heavychain DSVKGRFSISRDNAKNSVFLQMNTLRAEDTAVYYCARNALTNAYDMSGFRNWGQGILVTV variableregionsequence SS 785 GFRFSDYY ClonePA01P2C09CDR-H1 786 ISSDSSDT ClonePA01P2C09CDR-H2 787 ARNALTNAYDMSGFRN ClonePA01P2C09CDR-H3 788 NFMLTQPHSVSESPGKTVILSCTRSSGSIATNYVRWYQQRPGSAPTTVIYEDSRRPSSVPDRFS ClonePA01P2C09lightchain GSIDSSSNSASLTISGLRTEDEADYYCQSFDTSSRKVVFGGGTKLTVL variableregionsequence 789 SGSIATNY ClonePA01P2C09CDR-L1 790 EDS ClonePA01P2C09CDR-L2 791 QSFDTSSRKVV ClonePA01P2C09CDR-L3 792 QVTLRESGPALVEVTQTVTLTCNFSGFSLHTRGMYVNWIRQPPGKALEWLAVINWDDDKYY ClonePA01P1D06heavychain TPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARTDYGGYGPEGFDYWGQGTLVTVSS variableregionsequence 793 GFSLHTRGMY ClonePA01P1D06CDR-H1 794 INWDDDK ClonePA01P1D06CDR-H2 795 ARTDYGGYGPEGFDY ClonePA01P1D06CDR-H3 796 EIVMTQSPATLSVSPGESATLSCRASQSVRSNLAWYQQKPGQAPRLLIYGASTRAPGVPARF ClonePA01P1D06lightchain TGSESGREFTLTISSLQSEDFAVYYCQQYNNWPPYTFGQGTKLEIK variableregionsequence 797 QSVRSN ClonePA01P1D06CDR-L1 30 GAS ClonePA01P1D06CDR-L2 798 QQYNNWPPYT ClonePA01P1D06CDR-L3 799 QVQLVESGGGVVQPGRSLRLSCVASGFDLNAYGMHWVRQAPGKGLDWVAATSRGGTKKY ClonePA01P2E08heavychain YADSVKGRFTISRDVSKNTLYLQMGSLRTGDTAIYYCGVGMEDVFDIWGQGTMVTVSP variableregionsequence 800 GFDLNAYG ClonePA01P2E08CDR-H1 801 TSRGGTKK ClonePA01P2E08CDR-H2 802 GVGMEDVFDI ClonePA01P2E08CDR-H3 803 QSVLTQPPSVSAAPGQKVTISCSENNSNIGNRNVSWYQQLPGKAPKLFIYDNNERPSGIPAR ClonePA01P2E08lightchain FSGSKSGTSATLVITGLQTGDEADYYCGTWDRSLSVWVFGGGTKLTVL variableregionsequence 804 NSNIGNRN ClonePA01P2E08CDR-L1 110 DNN ClonePA01P2E08CDR-L2 805 GTWDRSLSVWV ClonePA01P2E08CDR-L3 806 QVQLQESGPGLVKPSQTLSLTCTVSGGSMRSGDYYWSWIRQPPGKGLEWIGYIYFTGSSYYN ClonePA01P2A05heavychain PSLKSRATISVDTSKNQFSLKLNSVTAADTAVYFCARGVDVDLTFFDCWGHGTLVTVSS variableregionsequence 807 GGSMRSGDYY ClonePA01P2A05CDR-H1 808 IYFTGSS ClonePA01P2A05CDR-H2 809 ARGVDVDLTFFDC ClonePA01P2A05CDR-H3 810 SYVLTQPPSVSLAPGKTARITCGGNNIGNKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSG ClonePA01P2A05lightchain SNSGNTATLTINRVEAGDEADYHCQVWDSSTDHRVFGEGTKLTVL variableregionsequence 811 NIGNKS ClonePA01P2A05CDR-L1 509 YDS ClonePA01P2A05CDR-L2 812 QVWDSSTDHRV ClonePA01P2A05CDR-L3 813 QVQLQQWGAGLLKPSETLSLTCTVIGTSFSNYYWSWIRQPPGKGLQWIGEITHSDSANYNPS ClonePA01P2B04heavychain LKSRVIISIDSSKNQLSLNLSSVTAADTAVYYCARGSKDYYDRSTFSWFDPWGQGTLVTVSS variableregionsequence 814 GTSFSNYY ClonePA01P2B04CDR-H1 815 ITHSDSA ClonePA01P2B04CDR-H2 816 ARGSKDYYDRSTFSWFDP ClonePA01P2B04CDR-H3 817 EIVMTQSPATLSVSPGERATLSCRASQNISNKLAWYQQKPGQAPRLLIYDASTRATGVPARFS ClonePA01P2B04lightchain CSVSGTAFTLTINRLQSEDFAVYYCQQYYYWPPPYTFGHGTKLEIK variableregionsequence 818 QNISNK ClonePA01P2B04CDR-L1 94 DAS ClonePA01P2B04CDR-L2 819 QQYYYWPPPYT ClonePA01P2B04CDR-L3 820 QVQLVESGGGFVKPGGSLRLSCAVSGFTFSDYYMSWVRQAPGKGLEWLSHISSDGSDTNYA ClonePA01P2E05heavychain DSVKGRFSISRDNAKNSVFLQMNTLRVEDTAVYYCARNALTNAYDMSGFRNWGQGTLVTV variableregionsequence SS 821 GFTFSDYY ClonePA01P2E05CDR-H1 822 ISSDGSDT ClonePA01P2E05CDR-H2 787 ARNALTNAYDMSGFRN ClonePA01P2E05CDR-H3 823 NFMLTQPHSVSESPGKTVILSCTRSSGSIASNYVRWYQQRPGSAPTTVIYEDSRRPSSVPDRFS ClonePA01P2E05lightchain GSIDSSSNSASLTISGLKTEDEADYYCQSFDSSSRKVVFGGGTKLTVL variableregionsequence 776 SGSIASNY ClonePA01P2E05CDR-L1 790 EDS ClonePA01P2E05CDR-L2 824 QSFDSSSRKVV ClonePA01P2E05CDR-L3 825 QVQLLQSGPEVKQPGASVQVSCQTSGYTFTGYYIHWVRQAPGQGLEWVGWINPNRGHTN ClonePA01P2D04heavychain YGPAFQGRLTLTADTSSSTAYLELTRLRSDDTAVYYCARDRLTGGRDAFEIWGQGTMLIVSS variableregionsequence 121 GYTFTGYY ClonePA01P2D04CDR-H1 826 INPNRGHT ClonePA01P2D04CDR-H2 827 ARDRLTGGRDAFEI ClonePA01P2D04CDR-H3 828 DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLISVASSLQDGVPPRFSG ClonePA01P2D04lightchain SRSGTEFTLTISSLQPEDFAIYYCQQSYSLSWTFGQGTKVEIK variableregionsequence 829 QSISSY ClonePA01P2D04CDR-L1 830 VAS ClonePA01P2D04CDR-L2 831 QQSYSLSWT ClonePA01P2D04CDR-L3 832 QVQLVQSGAEVKQPGASVQVACQTSGYIFTAYYIHWLRQAPGQGLEWVGWINPNRGHTN ClonePA01P2B12heavychain YAPGFQGRLTLTADTSSSTAYLALTRLASDDTAVYYCARDRLTGGRDAFEIWGQGTMLIVSS variableregionsequence 833 GYIFTAYY ClonePA01P2B12CDR-H1 826 INPNRGHT ClonePA01P2B12CDR-H2 827 ARDRLTGGRDAFEI ClonePA01P2B12CDR-H3 834 DIQLTQSPSSLSASVGDRVTITCRASQSVSSYLNWYQQKPGEAPKLLISAASSLQDGVPPRFSG ClonePA01P2B12lightchain SRSGTEFTLTISSLQPEDFAIYYCQQSYSLWWTFGQGTKVEIK variableregionsequence 835 QSVSSY ClonePA01P2B12CDR-L1 149 AAS ClonePA01P2B12CDR-L2 836 QQSYSLWWT ClonePA01P2B12CDR-L3 837 QLQLQESGSGLVKPSQTLSLTCDVSGDSMNDDVYTWSWIRQPPGRGLEWIGYISHTGNTFY ClonePA01P2D11heavychain NSSLQSRVTMSVDTSKNQFSLKLSSVTIADTAVYYCARLTFLFSAPFSSFNWFDPWGQGILVT variableregionsequence VSS 838 GDSMNDDVYT ClonePA01P2D11CDR-H1 839 ISHTGNT ClonePA01P2D11CDR-H2 840 ARLTFLFSAPFSSFNWFDP ClonePA01P2D11CDR-H3 841 QSVLTQPPSVSGAPGQTITISCTGTPSNFGADYDVHWYQQRPGTAPKLLIFADKHRPSGVPD ClonePA01P2D11lightchain RFSGSRSGTSASLAISGLQAEDEADYYCQSYDSGVVGLWVFGGGTKVTVL variableregionsequence 842 PSNFGADYD ClonePA01P2D11CDR-L1 843 ADK ClonePA01P2D11CDR-L2 844 QSYDSGVVGLWV ClonePA01P2D11CDR-L3 845 QVQLQQWGAGLLKPSETLSLTCGVHGGSLNNYYWSWIRQPPGKGLEWIGEVYHSGSINYN ClonePA01P2B10heavychain PSLKSRVTMSVDTSKNQFSFNLSSVTAADTAVYYCARGAYDSRGFWTLDAFNTWGQGTMV variableregionsequence IVSS 846 GGSLNNYY ClonePA01P2B10CDR-H1 847 VYHSGSI ClonePA01P2B10CDR-H2 848 ARGAYDSRGFWTLDAFNT ClonePA01P2B10CDR-H3 849 DIQMTQSPSALSASLGDRVTITCRASESINSWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSG ClonePA01P2B10lightchain SGSGTEFTLTISSLQPDDFATYYCHQYNRYSYTFGQGTKLDIK variableregionsequence 850 ESINSW ClonePA01P2B10CDR-L1 196 KAS ClonePA01P2B10CDR-L2 851 HQYNRYSYT ClonePA01P2B10CDR-L3 852 EVLLLESGGGLVHPGGTLRLSCAASGFTFRNSAMTWVRQAPGKGLEWVSSIGGSGAKSYYA ClonePA01P2D10heavychain DSVKGRFTISRDNSKNTLYLEMNTLRVDDTAIYYCAKDQLNCYDLWSGDYCWFDTWGQGT variableregionsequence LVTVSS 853 GFTFRNSA ClonePA01P2D10CDR-H1 854 IGGSGAKS ClonePA01P2D10CDR-H2 855 AKDQLNCYDLWSGDYCWFDT ClonePA01P2D10CDR-H3 856 QSVLIQPPSASGTPGQRVTISCSGSNSNIGSNYVCWYQHLPGGAPKLLIYRNNQRPSGVPDR ClonePA01P2D10lightchain FSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGSWVFGGGTKLTVL variableregionsequence 857 NSNIGSNY ClonePA01P2D10CDR-L1 662 RNN ClonePA01P2D10CDR-L2 858 AAWDDSLSGSWV ClonePA01P2D10CDR-L3 859 EVQLLESGGGLVQPGGSLRLSCAVSGLKFSSYAMSWVRQAPGKGLEWVSVVSGSSGSTFYA ClonePA01P2D09heavychain VSVEGRFSISRDNSNNMLYMDMHSLRVEDTAKYYCAKVVGWYYDRNGNRRPKGFRAFDV variableregionsequence WGQGTMVIVSS 860 GLKFSSYA ClonePA01P2D09CDR-H1 861 VSGSSGST ClonePA01P2D09CDR-H2 862 AKVVGWYYDRNGNRRPKGFRAFDV ClonePA01P2D09CDR-H3 863 QSVLTQPPSASGTPGQRITIACSGTTSNIGGNSVNWYQQFPGAAPRLLIFDYDQRPSGVPAR ClonePA01P2D09lightchain FSGSSSGSSGYLAISGLQSEDEADYYCSSWDDNLNGWVFGGGTKLTVL variableregionsequence 864 TSNIGGNS ClonePA01P2D09CDR-L1 865 DYD ClonePA01P2D09CDR-L2 866 SSWDDNLNGWV ClonePA01P2D09CDR-L3 867 EVQLLESGGGLVQPGGSLRLSCVASGFTFSGHAMSWVRQAPGKGLEWVSGISGSGGSTYYA ClonePA01P2B05heavychain DSVKGRFTISRDNSKKTVDLQMNNLRAEDTAIYYCAKDLHFDTSGYYYSMIFDYWGQGTLVP variableregionsequence VSS 868 GFTFSGHA ClonePA01P2805CDR-H1 378 ISGSGGST ClonePA01P2B05CDR-H2 869 AKDLHFDTSGYYYSMIFDY ClonePA01P2B05CDR-H3 870 QSALAQPASVSGSPGQSITISCTGTSSDISDYNYVSWYQQHPGKAPKLILYDVNNRPSGVSSR ClonePA01P2B05lightchain FSGSKSGDTASLTISGLQPEDEADYYCSSYTSTKIFGGGTKVTVL variableregionsequence 871 SSDISDYNY ClonePA01P2B05CDR-L1 682 DVN ClonePA01P2B05CDR-L2 872 SSYTSTKI ClonePA01P2B05CDR-L3 873 EVQLLESGGGLLQLGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVSLITGSGGNTYYAD ClonePA01P4C11heavychain SVKGRFTISRDNSKNTLFLQMNSLRVEDTAIYYCVKTDFYDSSGYYFHDAFHIWGQGTMVTV variableregionsequence SS 874 GFTFSSYV ClonePA01P4C11CDR-H1 875 ITGSGGNT ClonePA01P4C11CDR-H2 876 VKTDFYDSSGYYFHDAFHI ClonePA01P4C11CDR-H3 877 QTVVTQEPSLTVSPGGTVTLTCASSTGSVTSGYYPNWFQQKPGQAPRTLIYGTSNKHSWTPA ClonePA01P4C11lightchain RFSGSLLGGKAALTLSDVQPEDEAEYYCLLYYGGAYVFGTGTKVTVL variableregionsequence 878 TGSVTSGYY ClonePA01P4C11CDR-L1 22 GTS ClonePA01P4C11CDR-L2 879 LLYYGGAYV ClonePA01P4C11CDR-L3 880 QVQLVQSGAEVKKPGASVKVSCKASGYTFIRYDIHWVRQATGQGLEWMGWMNPNNGKS ClonePA01P3E08heavychain GFAQKFEGRVTLTRNTSVTSTYMQLSSLGLEDTAVYYCVRAGYSYGWGFDYWGQGSLVTVSS variableregionsequence 881 GYTFIRYD ClonePA01P3E08CDR-H1 882 MNPNNGKS ClonePA01P3E08CDR-H2 883 VRAGYSYGWGFDY ClonePA01P3E08CDR-H3 884 NFTLTQPHSVSGSPGKTVTISCTRSSGGIASSHVQWYQQRPASAPTTLIFEDDQRSSGVPDRF ClonePA01P3E08lightchain SGSIDTSSNSAYLTISGLEAEDEADYYCQSYDNSMWVFGGGSKVTVL variableregionsequence 885 SGGIASSH ClonePA01P3E08CDR-L1 886 EDD ClonePA01P3E08CDR-L2 887 QSYDNSMWV ClonePA01P3E08CDR-L3 888 HVQLVQSGADVKKPGSSVKVSCKFSGGTFNNDSINWVRQAPGQGLEWMGVIMPFFGATR ClonePA01P2E06heavychain FAPKFQGRVTLTADKFTSTGYMELGSLKSDDTAVYYCARDKPPDDKWADYGMDVWGQGT variableregionsequence TVTVSS 889 GGTFNNDS ClonePA01P2E06CDR-H1 890 IMPFFGAT ClonePA01P2E06CDR-H2 891 ARDKPPDDKWADYGMDV ClonePA01P2E06CDR-H3 892 SYELTQPPSVSVSPGQTARITCSGDALPKQYVYWYQQKTGQAPVLVIYKDTERPSGIPERFSG ClonePA01P2E06lightchain STSGTTVTLTISGVQADDEADYFCQSADRNANYRVFGGGTKLTVL variableregionsequence 523 ALPKQY ClonePA01P2E06CDR-L1 762 KDT ClonePA01P2E06CDR-L2 893 QSADRNANYRV ClonePA01P2E06CDR-L3 894 QLQLQESGSGLVKPSQTLSLTCAVSGGSITSGTYSWTWIRQSPEKGLEWIGYIYYTGSTYYNPS ClonePA01P2E07heavychain LGRRVTISGDTSNNEFSLNLKSVTAADTAVYYCARGIHRGGVLDFWGQGILVTVSS variableregionsequence 895 GGSITSGTYS ClonePA01P2E07CDR-H1 896 IYYTGST ClonePA01P2E07CDR-H2 897 ARGIHRGGVLDF ClonePA01P2E07CDR-H3 898 EIVLTQSPATLPLSPGERATLSCRASQSLDKYLAWYQQKPGQAPRLLIYDTSKRATGIPARFSG ClonePA01P2E07lightchain SGSGTDFTLTISSLEPEDFAVYFCQQRNNWPPYTFGQGTKVEMK variableregionsequence 899 QSLDKY ClonePA01P2E07CDR-L1 900 DTS ClonePA01P2E07CDR-L2 901 QQRNNWPPYT ClonePA01P2E07CDR-L3 902 QVLLVQSGSEVKNPGASIRVSCKTSGYMFTNNGIAWVREVPTQGLEWMGWISTYSGATHY ClonePA01P2G07heavychain APNLHGRITMTADTSASTAYMELRSLQSGDTGVYYCARLWFGKLGLDFWGQGTQVTVSS variableregionsequence 903 GYMFTNNG ClonePA01P2G07CDR-H1 904 ISTYSGAT ClonePA01P2G07CDR-H2 905 ARLWFGKLGLDF ClonePA01P2G07CDR-H3 906 QSVLTQPPSASGTPGQRVIISCSGSTSNIGTKTVNWYQHLPGTAPKLLIYNNNQRPSGVPDRF ClonePA01P2G07lightchain SGSKSGTSASLTISGLQSEDEADYYCAAWDDSLNGRGLFGPGTKVTVL variableregionsequence 907 TSNIGTKT ClonePA01P2G07CDR-L1 908 NNN ClonePA01P2G07CDR-L2 909 AAWDDSLNGRGL ClonePA01P2G07CDR-L3 910 QVEVVESGGGVVQPGKSLRLSCAASGFKFNVYGIHWVRQAPGKGLEWVAVVWYDGSNKY ClonePA01P2B09heavychain YADSVKGRFTISRDNSKNTTYLQMDSLRVDDTAVYYCARELQYSNYDYFYAMDVWGQGTT variableregionsequence VTVSS 911 GFKFNVYG ClonePA01P2B09CDR-H1 912 VWYDGSNK ClonePA01P2B09CDR-H2 913 ARELQYSNYDYFYAMDV ClonePA01P2B09CDR-H3 914 DIQMTQSPPSLSASVGDRVTITCRASQDIDNYLVWFQQKPGRAPKSLIYAASSLQSGVPSKFS ClonePA01P2B09lightchain GSGSGTEFTLTISSLQPEDFATYYCQQYNSFPYTFGQGTKLEIK variableregionsequence 915 QDIDNY ClonePA01P2B09CDR-L1 149 AAS ClonePA01P2B09CDR-L2 916 QQYNSFPYT ClonePA01P2B09CDR-L3 917 QVQLQESGPGLVKPSETLSLTCSVSGGSISSHYWSWIRQPPGRGLEWIAYISYSGRTKYNPSLK ClonePA01P2C04heavychain SRVTISEDTSKNQFSLKLSSVTPADTAVYYCARIYGDYGPFIDYWGQGTLVTVSS variableregionsequence 918 GGSISSHY ClonePA01P2C04CDR-H1 919 ISYSGRT ClonePA01P2C04CDR-H2 920 ARIYGDYGPFIDY ClonePA01P2C04CDR-H3 921 DIQMTQSPSSLSASVGDRVTITCRASQTISTYLNWYQQKPGTAPMLLIYGAYSLHSGVPSRFS ClonePA01P2C04lightchain GSGSGTDFTLTISSLQPEDFATYYCQQSSSLPLTFGGGTKVEIK variableregionsequence 922 QTISTY ClonePA01P2C04CDR-L1 923 GAY ClonePA01P2C04CDR-L2 924 QQSSSLPLT ClonePA01P2C04CDR-L3 925 QEQLQESGPGLVKPSQTLSLTCTVSGGSISSGDHYWSWLRQTPGKGLEWIGYIYYRGNTNYN ClonePA01P2H08heavychain PSLESRITMSVDTSKNQFSLKLSSVTAADTGVYYCARDRRLLFWFGQGPETFDIWGPGTMVT variableregionsequence VSS 926 GGSISSGDHY ClonePA01P2H08CDR-H1 927 IYYRGNT ClonePA01P2H08CDR-H2 928 ARDRRLLFWFGQGPETFDI ClonePA01P2H08CDR-H3 929 DIQMTQSPSILSASVGDRVTITCRASQNINHWLAWYQQKPGKAPKLLIYMASSLENGVPSRF ClonePA01P2H08lightchain SGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSGTFGHGTKVDIK variableregionsequence 930 QNINHW ClonePA01P2H08CDR-L1 931 MAS ClonePA01P2H08CDR-L2 932 QQYNSYSGT ClonePA01P2H08CDR-L3 933 TACTGTGCGAAAGTTCTTGACTACAGTGAATTTCATTACTATTACGGTTTGGACGTCTGG FIG.13APA12P3F10 GGCCAAGGGACCGCGGTCGCCGTCTCCTCAG 934 TACTGTGCGAAAGTTCTTGACTACAATGAGTACTCTCTCTACTTCGGTATGGACGTCTGG FIG.13APA12P3D08 GGCCAAGGGACCACGGTCACCGTCTCCTCAG 935 TACTGTGCGAAAGTTCTTGACTACAGTGAATACTCTCTCTACTTCGGTATGGACGTCTGG FIG.13APA12P1C07 GGCCAAGGGACCACGGTCCTTGTCTCCTCAG 936 TACTGTGCGAAGGTCCTTGACTACAGTAGGTACTCCTATTATTACGGGATGGACGTCTGG FIG.13APA13P1H08 GGCCAGGGGACCACGGTCATCGTCTCCTCAG 937 TACTGTGCTAAGGTCCTTGACTACAGTGCATTCTCCTATTATTATGGGATGGACGTCTGG FIG.13APA13P1E10 GGCCAGGGGACCACGGTCATCGTCTCCTCAG 938 TATTGTGCGAAAGTCCTTGACTACAGTATTTTCTATTACTATTTCGGCCTGGACGTCTGGG FIG.13APA13P3G09 GCCAAGGGACCACGGTCACCGTCTCCTCAG 939 TACTGTGCGAAAGA FIG.13AIGHV30-30*18 940 TYCT FIG.13ANontemplated(inferred) 941 TGACTACAGTAACTAC FIG.13AIGHD4-11*01 942 ATTACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCT FIG.13AIGHJ6*02 CAG 943 YCAK FIG.13ATranslated:V 944 VLDYSNY FIG.13ATranslated: Nontemplated+D 945 NYYYYYGMDVWGQGTTVTVSS FIG.13ATranslated:J 946 YCAKVLDYSNYYYYYGMDVWGQGTTVTVSS FIG.13AInferrednaive rearrangement 947 YCAKVLDYSEFHYYYGLDVWGQGTAVAVSS FIG.13ATranslated:PA12P3F10 948 YCAKVLDYNEYSLYFGMDVWGQGTTVTVSS FIG.13ATranslated:PA12P3D08 949 YCAKVLDYSEYSLYFGMDVWGQGTTVLVSS FIG.13ATranslated:PA12P1C07 950 YCAKVLDYSRYSYYYGMDVWGQGTTVIVSS FIG.13ATranslated:PA13P1H08 951 YCAKVLDYSAFSYYYGMDVWGQGTTVIVSS FIG.13ATranslated:PA13P1E10 952 YCAKVLDYSIFYYYFGLDVWGQGTTVTVSS FIG.13ATranslated:PA13P3G09 953 GCAGTGTATTACTGTCAGCATTACAGTAATTCACCCCCGTACACTTTTGGCCCGGGGACC FIG.13CPA12P3F10 AAGTTGGAGATCAAAC 954 GCAGTGTATTTCTGTCAGTACTATAGTGACTCACCTCCGTACACTTTTGGCCCGGGGACC FIG.13CPA12P3D08 AAGCTGGAGATCAAAC 955 GCAGTGTATTCCTGTCAACACTATAGTGACTCACCTCCTTACACTTTTGGCCAGGGGACCA FIG.13CPA12P1C07 AACTGGAGATCAAAC 956 GCAGTTTATTACTGTCAGCACTATGGTAGGTCACCTCCGTACACTTTTGGCCCGGGGACC FIG.13CPA13P1H08 AAGCTGGACATCAAAC 957 GCAGTATATTACTGTCAACACTATGGTAGGTCACCTCCATACACTTTTGGCCAGGGGACC FIG.13CPA13P1E10 AAAGTGGAGATCAAAC 958 GCAGTGTACTACTGTCAGCACTATGGAGACTCACCTCCGTACACCTTTGGCCAGGGGACG FIG.13CPA13P3G09 AAAGTGGAGATGAAAC 959 GCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCTCC FIG.13CIGKV3-20*01 960 TGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAAC FIG.13CIGKJ2*01 961 AVYYCQQYGSSP FIG.13CTranslated:V 962 PYTFGQGTKLEIK FIG.13CTranslated:J 963 AVYYCQQYGSSPPYTFGQGTKLEIK FIG.13CInferrednaive rearrangement 964 AVYYCQHYSNSPPYTFGPGTKLEIK FIG.13CTranslated:PA12P3F10 965 AVYFCQYYSDSPPYTFGPGTKLEIK FIG.13CTranslated:PA12P3D08 966 AVYSCQHYSDSPPYTFGQGTKLEIK FIG.13CTranslated:PA12P1C07 967 AVYYCQHYGRSPPYTFGPGTKLDIK FIG.13CTranslated:PA13P1H08 968 AVYYCQHYGRSPPYTFGQGTKVEIK FIG.13CTranslated:PA13P1E10 969 AVYYCQHYGDSPPYTFGQGTKVEMK FIG.13CTranslated:PA13P3G09 970 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSG FIG.13Eswap SGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPGFTFGPGTKVDIK 971 AKVMDYDIFKNYFGLDV FIG.16 972 AKVMDYDVFKNYYGLDV FIG.16 973 AKTLDYSQYMYYYGLDV FIG.16 974 QHYGRSPPYT FIG.12G 975 QHYGSSPPFT FIG.12G 976 QHYGSLPPFT FIG.12G 977 AAWDDTLVGV FIG.12G 978 AAWDDLVVGV FIG.12G 979 QSTDSSGDYVV FIG.12G 980 QSTDSSLRDVV FIG.12G 981 TSYAGRNIQV FIG.12G 982 SSYAGSNIAV FIG.12G 983 QSYDGSSPVI FIG.12G 984 QSYDTNIVV FIG.12G 985 QSYDSANVV FIG.12G 986 QSYDADNAV FIG.12G 987 SSYTRETALGGV FIG.12G 988 QQYYTTPRT FIG.12G 989 QQYYTTPYT FIG.12G 990 QQYLTTPYT FIG.12G 991 QQYDEWPPFT FIG.12G 992 QQYNHWPPYT FIG.12G 993 GSYKSGSTWV FIG.12G 994 SSYRSGSTWV FIG.12G 995 SSYTSGRTWV FIG.12G 996 SSYTTGRTWV FIG.12G 997 ASRYCTDSGCYLGSFDY FIG.12G 998 ASRYCTDDGCYLGSFDF FIG.12G 999 TRDHGYY FIG.12G 1000 ARDHGYY FIG.12G 1001 ARDPAAGTWWFDP FIG.12G 1002 ARPSAHYYDRGGYNDAFDM FIG.12G 1003 TTGYRTTTTYHGDDAFDI FIG.12G 1004 TTGYRTSTSYHGDDAFDI FIG.12G 1005 ARGPPAVQGYFYYMYV FIG.12G 1006 ARGPPGVHGYFYYTDV FIG.12G 1007 ARDVVRPGSGPRLGFDP FIG.12G 1008 ARDVVRPGRGPRLGFDP FIG.12G 1009 AKEGGSSTSWYSLYHEYEMDV FIG.12G 1010 AHKAAEPGSRDRWFDS FIG.12G 1011 AGGYNNSSFYFDS FIG.12G 1012 AVGYNNSWFYFDY FIG.12G 1013 ARLGHLRGWFDS FIG.12G 1014 VLSQYEFGSSWFYYYRMDV FIG.12G 1015 VLSKYEFGSSWFYYYRMDV FIG.12G 1016 VLSKYEFHSSWFYYYRMDV FIG.12G

(441) Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, one of skill in the art will appreciate that certain changes and modifications may be practiced within the scope of the appended claims. In addition, each reference provided herein is incorporated by reference in its entirety to the same extent as if each reference was individually incorporated by reference.